Propofol for the management of postoperative nausea and vomiting (PONV). by Gan, T.J.
Propofol for the Management of 
Postoperative Nausea and Vomiting (PONV)
Tong Joo Gan 
M.B., B.S., F.R.C.A., F.F.A.R.C.S. (I), Li. Ac.
University o f  London
Doctor in Medicine (M.D.)
UMI Number: U592612
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U592612
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
2The work presented in the thesis is original and my own.
(Tong Joo Gan)
3A B ST R A C T
Postoperative nausea and vomiting (PONV) is one o f the most common 
complications following surgery. Despite better anaesthetic techniques, and the availability 
o f newer generations o f antiemetics, the incidence o f PONV is still as high as 60-70%  in 
high-risk subjects. Patients rated symptoms o f nausea and vomiting as highly undesirable 
and are willing to pay out o f pocket a substantial amount for an effective antiemetic. PONV 
also has major economic implications, prolonging recovery room and hospital stay, and in 
some cases, increases patient morbidity.
Propofol is an intravenous anaesthetic which gained rapid popularity due to its 
favourable pharmacokinetic and pharmacodynamic profile. In particular, it is associated 
with rapid recovery, making it the intravenous anaesthetic agent o f choice especially in 
ambulatory anaesthesia. Previous studies have demonstrated that total intravenous 
anaesthesia with propofol is associated with a lower incidence o f PONV when compared 
with inhalational anaesthetic. However, it is unclear regarding the dose response o f propofol 
when used as an antiemetic, and how propofol should be administered in the perioperative 
period for its antiemetic effects.
The over arching goal o f this MD thesis is to examine the use o f propofol for its 
antiemetic properties. First, we assessed the extent o f clinical practice o f using propofol for 
its antiemetic effects among US anaesthesiologists. Next, we determine the dose response o f 
propofol for its antiemetic effects. We examined the efficacy o f propofol when used as
4antiemetic prophylaxis as well as for the treatment o f established PONV. Different regimens 
o f propofol administration were assessed for its prophylactic antiemetic effects. Treatment 
o f established PONV was assessed using a patient controlled antiemetic system. We also 
determined the use o f propofol in a multimodal PONV prevention strategy as well as its use 
in paediatric population.
The main objective o f these series o f  investigations was to systematically determine 
the antiemetic effects o f propofol and recommend how propofol should be used in clinical 
practice.
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CHAPTER 1
Postoperative Nausea and Vomiting 
Introduction
Postoperative nausea and vomiting (PONV) is one o f  the most common and 
distressing complications following surgery. Despite significant advances in the 
management o f PONV and the introduction o f new antiemetic agents, the overall incidence 
is currently estimated to be around 30 % }  In certain high-risk patients, this incidence may 
be as high as 70 %.2
Nausea and vomiting are also among the most unpleasant experiences associated 
with surgery and one o f  the most com mon reasons for poor patient satisfaction rating in the 
postoperative period.3 Macario et al. quantified patients’ preferences for postoperative 
outcomes. Postoperative nausea and vomiting were among the ten most undesirable 
outcomes following surgery. Indeed, patients allocated the highest amount (about $30) to 
avoid PONV out o f a total o f $100 they were allowed to spend to avoid all complications.4 
Gan and colleagues also reported that surgical patients were willing to pay up to $100, at 
their own expense, for an antiemetic that would abolish their symptoms o f PONV.5 In 
addition, patient preference for the avoidance o f  specific side effects from anaesthesia may 
be different from that o f anaesthesia care providers. In one survey, anaesthesiologists
14
responded that incision-site pain was patients’ most undesirable outcome, when in reality, 
the patients' chief concern was postoperative vomiting.4
PONV can have economic consequences. Previous studies have demonstrated that 
PONV can prolong post-anaesthesia care unit (PACU) stay and unanticipated admissions 
following ambulatory surgery, therefore increasing medical costs.6 It was estimated that 
each vomiting episode delays discharge from the recovery room by about 20 m inutes.7 
Although PONV is almost always self-limiting and non-fatal, it can cause significant 
morbidity, including dehydration, electrolyte imbalance, suture tension and dehiscence, 
venous hypertension and bleeding, subcutaneous emphysema, oesophageal rupture, and life- 
threatening airway compromise8’910, albeit the more severe complications are rare1112.
Definition and Classification of PONV
PONV encompasses three main symptoms that may occur separately or in 
combination after surgery. Nausea  is the subjective sensation o f an urge to vomit, in the 
absence o f expulsive muscular movements; when severe, it is associated with increased 
salivary secretion, vasomotor disturbances, and sweating. Vomiting or emesis is the forcible 
expulsion through the mouth o f the gastric contents. Vomiting results from coordinated 
activity o f the abdominal, intercostal, laryngeal and pharyngeal muscles, including 
retrograde giant contraction o f the intestines, relaxation o f the gastric fundus, closure o f the 
glottis and elevation o f the soft palate.11 This activity is associated with increased heart rate
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and breathing and with sweating.13 Retching  is an unproductive effort to vom it.11 Retching 
and vomiting are collectively termed emetic episodes.
PONV may take place in single or multiple episodes, which may last minutes, hours, 
or even days. It is classified as early, occurring up to 2 to 6 hours after surgery, or late, 
occurring up to 24 or 48 hours after surgery, with the exact cut-off times depending upon the 
individual investigator's definition.11 As may be inferred from this lack o f a standard cut-off 
time, the delineation is somewhat arbitrary and related to the patient’s location at the time o f 
evaluation for the symptoms, e.g., the post anaesthesia care unit (PACU), surgical or other 
ward, or home. However, there are suggestions that early and late PONV may differ at least 
somewhat in their pathogenesis. The use o f volatile anaesthetics may be a main cause o f 
early PO N V 11 12. Opioid-induced symptoms and motion sickness caused by transportation 
from the PACU to the ward or from the hospital to the home may account for much o f late 
PO N V .141x16 However, for the most part, PONV research has focused on identifying risk 
factors themselves rather than their time o f activity.
Mechanism of Vomiting and Nausea
Vomiting is elicited through a complex series o f autonomic changes that interact in 
the hindbrain at the level o f the medulla oblongata, located between the level o f the obex 
(opening o f the central canal into the fourth ventricle) to the level o f the rostral portion 
(compact /one) o f the nucleus am biguous.13 Vomiting may be triggered through a variety o f 
different input mechanisms, including PONV, pregnancy sickness, radiation-induced emesis.
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cancer chemotherapy-induced emesis, food poisoning, psychogenic vomiting, motion 
sickness, and blood poisoning.13 Afferent sources o f emetic input include the abdominal 
viscera, heart, vestibular system, brain stem area postrema chem oreceptor trigger zone 
(CTZ), and higher brain centres.13
There are a series o f events associated with the act o f vomiting. Motor changes 
during vomiting occur in both gastroesophageal and respiratory muscles. Gastrointestinal 
changes include reductions in gastric tone and mobility, changes in gastric myoelectric 
activity, and a large retrograde contraction that, prior to expulsion, serves to push the 
contents o f the small intestine back into the stom ach.lj The oesophagus longitudinally 
contracts, pulling open the gastroesophageal junction so that there is an open funnel 
sufficiently wide to allow for retrograde contraction o f the cervical oesophagus. Respiratory 
muscles, especially the diaphragm and abdominal muscles, contract, thereby providing the 
muscular impetus for retching and expulsion while the glottis remains closed.13
Signals from the peripheral afferent input may also trigger vomiting. For PONV, 
enterochromaffin cells in the gastrointestinal (GI) tract release serotonin, which binds to 
visceral receptors (5-hydroxytryptamine type 3 [5 -HT3]), causing stimulation o f vagal 
afferents in the GI tract to conduct impulses that reach the CTZ, also known as the area 
postrem a  (Figure 1 '
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Figure 1. Neuroanatomical areas associated with postoperative nausea and vomiting 
w ith peripheral input from the gastrointestinal enterochromaffin cells, medulla and 
dorsal vagal complex (DVC). NTS = nucleus tractus solitarius.
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Pivotal in the central mechanism o f vomiting is the area postrema, located on the 
dorsal surface o f the medulla oblongata at the caudal end o f  the fourth ventricle.17,18 Lacking 
a blood-brain barrier, it is capable o f detecting emetic agents in both blood and cerebrospinal 
fluid and is more sensitive to toxic stimuli than motion sickness, which is associated with 
labyrinthine end organs).13 The electrical stimulation for vomiting may originate in the 
cerebral cortex (for psychogenic and conditioned vomiting), amygdala, olfactory tubercle, 
septum fornix, ventral anterior thalamic nucleus, and supraoptic area o f the 
hypothalam us.1319 Centrally, within the region that coordinates vomiting in the brain stem 
(between the obex and retrofacial nucleus), the nucleus tractus solitarius (NTS) receives 
these convergent impulses from the vagus nerve, area postrema, and vestibular and limbic 
systems. The region o f the brain that includes the area postrema, NTS, fourth ventricle, 
dorsal motor neuron, and hypoglossal nucleus is called the dorsal vagal complex. The NTS 
consists o f the subnucleus gelatinosus (related to gastric sensation), the subnucleus centralis 
(related to swallowing), the intermediate and interstitial NTS (related to laryngeal and 
pharyngeal sensation), the medial NTS (related to baroreceptor function), and the 
ventrolateral NTS (related to respiration).lj 19
Gastrointestinal vagal afferents terminate primarily in the subnucleus gelatinosus.20 
Efferent neurons from the NTS reach the central pattern generator, which coordinates motor 
activities for vomiting, and the ventral medulla and hypothalam us.13 The areas o f the 
hindbrain medulla involved in emesis that may receive input from the NTS include the 
rostral nucleus, ambiguous/retro facial nucleus (which controls the larynx and pharynx), the 
Botzinger/ventral respiratory group (which controls respiratory behaviour), and the dorsal
19
motor nucleus o f the vagus (which controls motor function o f the lower oesophageal 
sphincter and stomach). The sites involved in emesis therefore are scattered throughout the 
m edulla oblongata and are activated in a sequence o f events described as a “central pattern 
generator” (rather than a “vomiting centre”). The NTS also may send afferents to the 
magnocellular hypothalamic neurons, leading to increases in plasma vasopressin and arterial
13.17pressure.
These signals are mediated primarily through 5 major neurotransmitter receptor 
systems, including serotonergic, dopaminergic, histaminergic, cholinergic, and neurokinin.
2122 Antiemetics for prophylaxis and/or treatment o f PONV act by blocking one or more o f 
these major receptors: type 3 serotonin receptor (5 -HT3), type 2 dopamine receptor (D 2), 
type 1 histamine receptor (Hi), muscarinic cholinergic receptor, and type 1 neurokinin 
receptor (NKi) (Figure 2).21-22,23
20
Figure 2. Receptors involved in postoperative nausea and vomiting in the 
chemoreceptor trigger zone and the vomiting centre.
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5 -H T 3 =  5-hydroxytryptam ine type 3 ; NK-1 = neurokin in-1 ; H 2 = histam ine type 2; A ch = 
acetylcholine; D 2 = dopam ine type 2; RA = receptor antagonist.
O pioids, although not neurotransm itters, m ay have a significant effect on PO N V , 
exerting  both excitatory  and inhibitory effects on the GI system  (e.g., inhibition o f  GI 
m otility). E xogenous opioid  agonists (e.g.. m orphine) affect intestinal m otility  by 
m odulating cholinergic transm ission. W hen adm inistered peripherally , exogenous opioid  
agonists decrease GI m otility  and delay gastric em pty ing  by inhibiting  central p -recep to rs.24 
E xogenous opioid agonists m ay also m odulate cholinergic transm ission  via the K -receptor,
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which may be more potent.25 Opioid receptor antagonists that act centrally, such as naloxone,
0 1
may counteract the inhibitory effect on gastric motility f
Influence of genetics in PONV
The recent advance in genomics helps further understanding o f the mechanism o f 
nausea and vomiting. In addition to receptor pharmacology, genetics also may play a 
significant role in antiemetic therapy. For example, nearly all 5-111^ receptor antagonists (5- 
HT3 RAs) (e.g., ondansetron, dolasetron, palonosetron), with the exception o f granisetron, 
are metabolized by the cytochrome P-450 system enzyme 2D6 (CYP2D6 ) . 26 Different 
alleles o f the CYP2D6 enzyme, resulting from single-nucleotide polymorphisms (SNPs), 
may create ultrametabolizers (UM), which rapidly metabolize the 5 -HT3 RA, leading to 
diminished duration o f efficacy against PONV, or poor metabolises, which inefficiently 
metabolize the 5 -HT3 RA, leading to inadequate formation o f the active metabolite and 
diminished efficacy.26 Patients with three or more copies o f  the CYP2D6 gene and/or UM 
genotypes are more likely to develop postoperative vomiting, despite prophylaxis with 
ondansetron.27
Pharmacology of Antiemetics
There are a variety o f different pharmacological agents, acting on one or more o f the 
five major neurotransmitter categories (i.e., serotonin [5-hydroxy-tryptamine], dopamine,
22
2 |  -> o  • • ■*histamine, muscarinic cholinergic, neurokinin). These antiemetics are used for the
prophylaxis and/or treatment o f PONV. (Table 1)
Table 1. Antiemetic choices for prophylaxis and/or treatment of PONV
Class Agent Receptor site affinity Formulations
Generic Trade Primary Secondary
Anticholinergics
(muscarinic)
S co p o la m in e S c o p a ce ,
T ransderm
S co p
M uscarin ic
ch o lin erg ic
O ral,
transderm al
D im enhcdrinate D im entabs.
D inate,
D ram am ine,
D ram anate.
C a lm -X ,
T riptone
H istam ineHistamine 
antagonists 
(H, RA)
(Antihistamines)
M uscarin ic
ch o lin erg ic
O ral, in jectab le
P rom ethazine A nergan,
M epergan,
P entazine,
P henazin e,
P henergan
H istam in e M uscarin ic
ch o lin erg ic
D op am in e
O ral, in jectab le , 
rectal
Dopamine 
antagonists 
(D2 RA)
•  P hen oth iaz in es P rochlorperazine C om p azin e ,
C om pro
D op am in e H istam ine
M uscarin ic
ch o lin erg ic
O ral, in jectab le , 
rectal
•  B en za m id es M etoclop ram id e C lopra. E m ex, 
M axeran, 
O ctam ide, 
R eglan
D op am in e Serotonin O ral, in jectab le
•  B utyrop h en on es D roperidol Inapsine.
D roleptan
D op am in e — O ral, in jectab le
H alop eridol H ald ol, N o v o -
Peridol,
Peridol
D op am in e O ral, in jectab le
Serotonin 
antagonists 
(5-HT3 RA)
G ranisetron Kytril Seroton in — O ral, in jectab le
O ndansetron Z ofran Serotonin — O ral, in jectab le
D olasetron A n zem et Seroton in — O ral, in jectab le
T ropisetron N avob an Serotonin — O ral, in jectab le
Neurokinin
antagonists
A prepitant E m end N eurok in in — Oral
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Class Agent Receptor site affinity Formulations
Generic Trade Primary Secondary
(NK, RAs) G R 2 0 5 1 7 1 N eu rok in in — —
C P -1 2 2 ,7 2 1 ' N eu rok in in — —
D ata from  Scud eri, " D iem u n sch  et a l.,'  G esz te s i et a l., and G an et al.
1 G R  205171  and CP 122721 are not being studied further.
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Acetylcholine Receptor Antagonists
Anticholinergics, among the oldest antiemetic agents, block muscarinic cholinergic 
CNS emetic receptors in the cerebral cortex and pons. Scopolamine has been thought to 
block cholinergic transmission from the vestibular nuclei to higher centres in the CNS and 
from the reticular formation to the central pattern generator (vomiting centre). “ Common 
adverse events (AE) associated with anticholinergics include dry mouth and drowsiness; rare 
AEs include disorientation, memory disturbances, dizziness, and hallucinations.32
A meta-analysis o f 23 random ized controlled trials (RCT), which included 1963 
patients (979 scopolamine, 984 placebo/control), compared transdermal scopolamine with 
placebo or inactive controls for prophylaxis o f PONV. Scopolamine was significantly 
superior to placebo or controls for prevention o f vomiting and/or nausea and use o f  rescue 
medication. The number needed to treat (NNT), defined as the number o f patients who need 
to be treated to prevent one adverse outcome, ranged from 5 to 8 (always rounded to higher 
integer) for nausea and/or vomiting, and 8 for use o f rescue medication.33
Histamine Receptor Antagonists
H] receptors exert peripheral effects, including contraction o f smooth muscle and 
dilation and increased permeability o f capillaries, as well as induction o f nausea and 
vomiting via the NTS. Antihistamines, i.e., H| receptor blockers, block acetylcholine in the 
vestibular apparatus and Hi receptors in the NTS.21 Because antihistamines can effectively
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treat motion sickness and nausea or vomiting after middle ear surgery, they are thought to 
act on the central pattern generator and vestibular system.21 Antihistamines used to treat 
emesis include cyclizine, dimenhydrinate, diphenhydramine, hydroxyzine, meclizine, and 
promethazine. More frequent AEs include sedation, dry mouth, and constipation; less 
frequent AEs include confusion, blurred vision, and urinary retention. The com bination o f 
promethazine and opioid in the postoperative period may cause significant sedation and 
respiratory depression.21
A meta-analysis 18 RCTs comparing dimenhydrinate (n = 1387 patients) with 
placebo (n = 1658) for prophylaxis o f PONV found that dimenhydrinate was significantly 
superior to placebo for absence o f nausea and/or vomiting. During the early postoperative 
period (defined by study authors as 0 to 6 hours), the NNT ranged from 8 to 9, whereas 
overall (0 to 24 hours), the NNT ranged from 5 to 6.
Dopaminergic Receptor Antagonists
Dopaminergic receptors may be inhibited by D: receptor antagonists (D 2 RAs) acting 
at the CTZ. D2 RAs include the phenothiazines (e.g., chlorpromazine, fluphenazine, 
prochlorperazine), benzamides (e.g., domperidone, metoclopramide), and butyrophenones
t  '■y
(droperidol, haloperidol). “ Although the phenothiazines chlorpromazine and promethazine 
have been used historically to treat PONV, AEs frequently associated with their use (e.g., 
sedation, lethargy, and skin sensitization) have limited their usefulness. Common AEs 
associated with benzamides include sedation, restlessness, diarrhoea, agitation, and central
26
nervous system (CNS) depression. Less common AEs include extrapyramidal effects, 
hypotension, neuroleptic syndrome, and supraventricular tachycardia. Phenothiazines, 
particularly droperidol, have been commonly used in the past, either as a single agent or in 
combination with 5-HTi RAs. In a dose o f 1.25 mg. it was more cost-effective than 
ondansetron 4 mg and was recommended as a first line agent for PONV prophylaxis (IA).3r> 
In children, the recommended dose is 50-75 mcg/kg (IIA).36 The recent Society o f 
Ambulatory Anesthesia (SAMBA) PONV consensus group recommends even lower doses 
at 10-15 mcg/kg.2 Droperidol received a “black box” warning from the US Food and Drug 
Administration in December 2001 because o f an association with fatal cardiac arrhythmias 
o f the torsades de pointe variety.37 However, recent studies have shown no significant 
increase in the incidence o f QTc prolongation among patients undergoing prophylaxis for 
PONV with low-dose droperidol com pared with placebo or ondansetron , adding to the 
controversy o f this ruling.40 Recent debate on this topic weighed the rationale for the Food 
and Drug Administration (FDA) action and the pros and cons o f the implications o f the 
“black box” warning.4142
Several meta-analyses have assessed the efficacy o f  dopamine receptor antagonists 
for prevention o f PONV.43,44,45 Henzi et al. assessed 66 RCTs comparing 18 different 
regimens o f metoclopramide (n = 3260), at doses including 10 or 20 mg intravenous (IV), 10 
mg intramuscular (IM), and 10, 20 or 30 mg orally (PO), with placebo or no treatment (n = 
3006) during early (0 to 6 hours postoperative) and late (0 to 48 hours postoperative) 
periods.44 During the early period, the 10 mg IV and 10 mg IM doses o f metoclopramide 
significantly reduced the incidence o f nausea and/or vomiting compared to placebo. During
27
the late period, the 10 mg IV also significantly reduced the incidence o f nausea and/or 
vomiting, whereas the 10 mg PO significantly reduced the incidence o f nausea or vomiting, 
but not nausea or vomiting alone. None o f the other metoclopramide regimens significantly 
differed from placebo. Hirayama et al.4? found similar results in a smaller meta-analysis o f 5 
RCTs comparing metoclopramide (n = 153) with placebo (n = 165) from 24 to 36 hours 
postoperatively. In the same meta-analysis, 11 RCTs comparing another dopaminergic 
receptor antagonist, droperidol (n = 525), yielded a significantly less PONV from 24 to 36 
hours postoperatively than placebo (n = 518). Domino et a l . ,43 as part o f a meta-analysis that 
included ondansetron, directly com pared droperidol with metoclopramide in 15 studies for 
prevention o f nausea (n = 1021) and in 20 studies for prevention o f vomiting (n = 1374). In 
both analyses, droperidol was superior to metoclopramide.
5-Hydroxytryptamine Receptor Antagonists
With noxious or mechanical stimuli, the neurotransmitter serotonin (5- 
hydroxytryptamine [5-HT]), found in high concentrations peripherally in the 
enterochromaffin cells o f the gastrointestinal tract (and also in the central nervous system), 
may be released, stimulating vagal afferent neurons, which in turn activate the vomiting 
centre or directly activate the CTZ by binding to receptor sites. " Serotonin has many 
different receptors, but the most important receptor for nausea and vomiting is subtype 3 (5- 
HT3). The greatest intensity o f 5 -HT3 receptors is in the NTS and CTZ. 5-HT3 RAs block 
the nausea and vomiting cascade mediated by serotonin. As a class, 5 -HT3 RAs are 
considered the most potent antiemetic agents and are effective both for prophylaxis and
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treatment o f PONV.46 However, their action occurs primarily during the early phase o f 
PONV. They are less efficacious during the delayed phase o f PONV. 5 -HT3 RAs are highly 
specific for the 5 -HT3 receptor, having little to no affinity for dopamine, muscarinic 
cholinergic, or histamine receptor sites. These drugs include dolasetron, granisetron, 
ondansetron, ramosetron, and tropisetron (not available in the United States); all are 
metabolized by the CYP450 system in the liver. Granisetron, unlike ondansetron or 
dolasetron, is not metabolized by the CYP2D6 isoform, which may be associated with 
adverse drug interactions, poor metabolism in patients with CYP2D6 deficiency (leading to 
significant accumulation o f drug), or ultrametabolism in patients with increased CYP2D6 
(leading to rapid metabolism o f drug).26 Frequently observed adverse effects (AEs) with 5- 
HT3 RAs include headache and asymptomatic prolongation o f the QTc interval.32 Less 
common AEs include constipation, asthenia, somnolence, diarrhoea, ataxia, lightheadedness, 
dizziness, and muscle pain.
Many published meta-analyses for treatment and/or prophylaxis o f PONV have 
centred on the use o f serotonin antagonists (5 -HT3RAS), most often involving 
ondansetron.43 47 48,49 50,5152 Tramer et al.53 assessed early and late periods for further 
prevention o f PONV (defined as “success”) in 4 RCTs (n = 1043) in patients who had 
already experience nausea and/or vomiting. When at least 2 studies provided data, patients 
treated with ondansetron 1, 4, and 8 mg IV achieved significantly greater success rates than 
those receiving placebo. There was no evidence o f a clinically relevant dose response 
between ondansetron 1 and 8 mg IV. However, during the early period, the success rates did 
not significantly differ between ondansetron and droperidol. Similarly, Figueredo et al.54
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evaluated different schedules o f ondansetron compared to placebo during the early and late 
periods from data obtained from 48 RCTs (n = 12,078 patients). During the early period, 
patients treated with ondansetron 4 mg or 8 mg IV experienced less vomiting than those 
administered placebo. During the late period, patients treated with ondansetron 1, 4, or 8 mg 
IV, or with 4, 8, or 16 mg PO had significantly less vomiting than those who received 
placebo. There was no evidence o f increased efficacy with ondansetron at doses greater than 
4 mg, and the 1 mg dose was barely more effective than placebo. Subsequently, a m eta­
analysis, by the same authors,53 o f 21 RCTs (ondansetron: n = 2446; placebo: n = 1538) 
evaluated the effect o f previous history o f PONV on prophylaxis o f PONV. Treatment with 
ondansetron 4 or 8 mg IV prevented a significantly greater proportion o f patients from 
vomiting postoperatively than placebo, regardless o f patient history o f prior PONV. There 
was no significant difference in absence o f vomiting between patients who had a prior 
history o f PONV and those who did not, nor were there any significant differences between 
ondansetron dose levels. However, a more recent, but smaller meta-analysis,45 which pooled 
results from 5 RCTs comparing ondansetron with placebo (n = 149 each) for prevention o f 
nausea and vomiting induced by morphine for postoperative pain, reported that ondansetron 
was not significantly superior to placebo. Another meta-analysis evaluated the relative 
efficacy o f ondansetron to the dopamine receptor antagonists metoclopramide [N (number o f 
studies) = 19 RCTs; n = 2502 patients] and droperidol (N = 22; n = 1584).43 Ondansetron 
was significantly superior to both metoclopramide and droperidol for prevention o f vomiting, 
but did not significantly differ from either dopamine receptor antagonist for prevention o f 
nausea.
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5 -HT3RAS other than ondansetron have been evaluated in meta-analyses. A pooled 
analysis o f three RCTs with patients treated with dolasetron (n = 1527) or placebo (n = 419) 
evaluated complete response rate (defined as the proportion o f absence o f vomiting and o f 
need for rescue medication) and absence o f  nausea rate.56 Dolasetron 12.5, 25, 50, and 100 
mg IV doses had significantly greater complete response rates than placebo, and dolasetron 
12.5, 25, and 100 mg IV doses had significantly greater absence o f nausea rates.
There is no evidence that there is any difference in efficacy or side-effect profile 
between the various 5 -HT3 receptor antagonists, when appropriate doses are used for the 
management o f PONV. In patients undergoing laparoscopic cholecystectomy, there was no 
difference in antiemetic efficacy between ondansetron 4mg, tropisetron 5mg and granisetron 
3mg given before induction o f anaesthesia.57
Dolasetron 12.5mg was also found to have similar efficacy to ondansetron 4mg with 
a similar side effect profile for the prevention o f PONV.58 39 In an earlier study, dolasetron 
50 mg had similar efficacy to ondansetron 4 mg.60 Similarly, in a multicentre trial, it was 
demonstrated that 2 mg tropisetron intravenously had similar efficacy and side effect 
profiles to those o f ondansetron 4 mg.61 This was confirmed in another two trials comparing 
intravenous tropisetron 5 mg with ondansetron 4 mg and oral tropisetron 5 mg with
z "I
ondansetron 16 mg. ’
Fujii and colleagues compared the antiemetic efficacy o f granisetron 2.5-3 mg and 
ramosetron 0.3 mg in three studies. There was no difference between the two agents in
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achieving a complete response (no PONV and no antiemetic rescue) during the first 24 
hours postoperatively. Between 24 and 48 hours, however, ramosetron provided better 
prophylaxis.64,65,66,67
Several meta-analyses have examined 5 -HT3RAS in combination with droperidol (5- 
HTiRA/droperidol) and with dexamethasone (5-HT3RA/dexamethasone) for prevention o f 
PONV. During both the early period and overall, Eberhart et al.68 (N = 8; n = 881) observed 
no significant difference in vomiting or nausea rates between 5-HT3RA/droperidol 
compared to 5 -HT3RAS or droperidol monotherapies. On the other hand, Habib et al.69 (N = 
33; n = 3447) observed significantly greater prevention o f vomiting with 5- 
HTsRA/droperidol compared to droperidol monotherapy during the early period and overall, 
and significantly greater prevention o f  nausea overall. The same study69 also observed that 
combination therapies o f 5-HT3RA/dexamethasone had greater prevention o f nausea and 
vomiting during both the early period and overall. A more recent meta-analysis by Kovac70 
(N = 49; n = 12,752) evaluated the need for rescue medication with 5- 
HT3RA/dexamethasone compared to placebo, and to 5 -HT3RA and dexamethasone 
monotherapies. For each comparison, a significantly smaller proportion o f patients treated 
with combination 5-HT3RA/dexamethasone required rescue medication.
Leslie et al.52 conducted a meta-analysis (N = 28; n = 3440) that exam ined the safety 
o f 5 -HT3RA combination therapies. The proportion o f patients experiencing headaches was 
significantly smaller with 5-HT3RA/droperidol combination therapy than droperidol 
monotherapy. Where calculable, the drowsiness, dizziness, or any AE rates o f 5-
32
HT^RA/droperidol did not significantly differ from 5 -HT3RA or droperidol monotherapies.
As for combination 5-HT3RA/dexamethasone therapy, the proportions o f patients with 
headaches, dizziness, drowsiness, abdominal pain, or any AE did not significantly differ 
from 5 -HT3RA monotherapy, and was only greater than dexamethasone com bination 
therapy for the proportion o f patients with headaches.
However, the efficacy o f 5 -HT3RAS, as monotherapy or in combination with 
dexamethasone or droperidol, occurs primarily during the early postoperative period and 
overall; little efficacy has been reported during the late postoperative period.13 Delayed 
emesis remains a problem. This has led to significant interest in the use o f neurokinin 
receptor antagonists, which appear to show efficacy during both the early and delayed
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chemotherapy-induced nausea and vomiting.
Neurokinin Receptor Antagonists
Substance P, a member o f the tachykinin family o f neuropeptides, is an ubiquitous 
and important neurotransmitter in afferent pathways o f the em esis.28 Substance P may be 
released from enterochromaffin cells in the stomach and intestine {e.g., postoperative trauma) 
or from sensory neurons {e.g., radiation, chemotherapeutic agents).28 Tachykinin peptide 
activity is tied to at least three G -protein-coupled receptor subtype found in the peripheral or 
central nervous tissue: neurokinin receptor subtype 1 (NKi), subtype 2 (NK 2), and subtype 3 
(NK3 ). The NK| receptors are located in the area postrema and are thought to play a 
particularly important role in emesis. However, N K| receptor antagonists (NKi RAs) are
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thought to exert their mechanism o f action on neurons in the “afferent relay station” situated 
between the medial NTS and the central pattern generator for vomiting, although this has not 
been definitively isolated for humans. The potential NKi receptor blocking activity located 
deeper in the brain stem is thought to prevent both acute and delayed emesis, whereas 5 -HT3
■y o
RAs are largely effective only against acute em esis ." This has led to considerable recent 
interest in the use o f NKi RAs for prophylaxis o f PONV.
Only a few RCTs have been published in this expanding area o f research. In a 
double-blind randomized controlled trial (RCT), Diemunsch et al. 29 treated 36 patients who 
experienced PONV following hysterectomy or ovariectomy with GR205171 (NKi RA) 25 
mg IV or placebo. Patients in the GR205171 group exhibited significantly fewer emetic 
episodes by 2 hours postoperative (P = 0.006) and less severe nausea at all times (P  < 0.025.
TOexact W ilcoxon rank-sum test). Gesztesi et al. reported on two double-blind RCTs 
involving another NKi RA, C P-122,721. In the first part o f the study, 86 patients were 
treated with oral C P-122,721 at 100 or 200 mg or placebo 60 to 90 minutes before induction 
o f general anaesthesia. Patients who received C P -122,721 200 mg had a significant delay in 
time to emesis compared with those receiving placebo (P < 0.01), and a significantly lower 
proportion o f patients exhibited emesis (P < 0.01). In the second part o f the study, 157 
patients were randomized to receive treatment with oral C P -122,721 200 mg, ondansetron 4 
mg IV, or a combination o f the two agents. A significantly lower proportion o f patients 
exhibited emesis within 24 hours postoperative with C P -122,721 or combination therapy 
than with ondansetron alone (6% vs. 4% vs. 24%, P < 0.05). The median emesis-free time 
for 75% of patients was significantly less with combination therapy than ondansetron alone
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(362 vs. 82 minutes, P < 0.05). Gan et al.31 recently reported on a multi-centre, phase III 
RCT in which 805 inpatients undergoing abdominal surgery received oral aprepitant (a NKi 
RA) at 125 or 40 mg or ondansetron 4 mg IV preoperatively. The proportion o f complete 
responders (no vomiting or use o f rescue medication) did not significantly differ among the 
treatment groups from 0 to 24 hours. More importantly, however, 95% o f patients treated 
with aprepitant 125 mg and 90% o f patients treated with aprepitant 40 mg experienced no 
vomiting compared with 74% o f patients treated with ondansetron (P < 0.001 for both). A 
significantly greater proportion o f patients treated with aprepitant 125 and 40 mg also had 
no vomiting from 0 to 48 hours (93% and 85%, respectively) compared with those receiving 
ondansetron (67%, P < 0.001 for both). The long-term safety o f  NKi RAs is under 
investigation.31
Other anti-emetics
Steroids
Following the successful use o f  dexamethasone in the prevention and treatment o f 
chemotherapy induced emesis; this agent has been evaluated and found to be effective for 
the management o f PONV.72 73 The recommended dose is 5-10 mg in adults74 75,76 and 150 
mcg/kg in children.75 More recently, smaller doses (2.5 -  5 mg) have been found to be 
effective.74 77 Dexamethasone appears to be most effective when administered prior to 
induction o f anaesthesia rather than at the end in preventing early PONV ( 0 - 2  hours).77
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There are no reports o f dexamethasone related adverse effects in the doses used for the 
management o f PONV.75
Benzodiazepines
Benzodiazepines were found to be effective for the prophylaxis o f PONV.67 78,79 The 
successful use o f midazolam in cases o f persistent PONV and following failure o f  other 
antiemetics has also been described.80,8182
Ephedrine
Intramuscular ephedrine (0.5 mg/kg) has been shown to be effective for PONV
O S O 1 o  ^
prophylaxis especially in the early postoperative period ( 0 - 3  hours).
0 .2 adrenergic agonists
ct2 adrenergic agonists also significantly reduced the incidence o f PONV in both
86 87children and adults. It has been suggested that the antiemetic effect o f clonidine might be 
secondary to a reduction in the use o f  volatile agents and opioids, or a reduction in 
sympathetic tone.86
High concentration o f  oxygen
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Oxygen supplementation (80 %) intraoperatively or both intraoperatively and for two 
hours postoperatively have been shown to be effective in reducing the incidence o f PONV
OO O Q
compared to patients receiving 30 % oxygen. ’ These findings were not confirmed in a 
more recent study in females undergoing ambulatory gynaecologic surgery. In this study, 80 
% oxygen was given intraoperatively and for up to one hour postoperatively.90 A recent 
meta-analysis concluded that 80% Fi0 2  should no longer be considered an effective or 
reliable method to reduce overall PONV.91 This was adopted by the recent PONV consensus 
statement.
Fluid Administration
Adequate hydration is associated with a significant reduction in the incidence o f
O')
PONV. " Liberal fluid regimen (median vol = 4.2 L) is associated with a lower incidence o f 
vomiting and improved pulmonary function in patients undergoing knee arthroplasty
q -i
compared with restricted fluid regimen (median vol = 1.7 L). In a more recent study, a 
combination o f colloid and crystalloid fluid resuscitation was associated with less PONV 
and less use o f rescue antiemetics, compared with the administration o f crystalloids alone in 
patients undergoing major abdominal procedures.94
Non-Pharmacological Methods
Acupuncture
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Several investigators have show n a useful effect o f  acupuncture in the m anagem ent 
o f  PONV . A cupuncture at the 6th acupoin t along the pericardial m eridian, trad itionally  
know n as P6 or “neiguam ’ (F igure 3) has been show n to be effective in chem otherapy , 
pregnancy induced as w ell as PONV.
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Pericardial
m eridian
Figure 3. Pericardial 6, an acupuncture point commonly used for the prevention of PONV. 
Lu 5 and Lu 9 are acupuncture points along the lung meridian.
Lee and D one perform ed a system atic review  o f  24 random ized trials o f  acupuncture, 
electroacupuncture, transcutaneous electrical nerve stim ulation, acupoint stim ulation  and 
acupressure. They found that there w as a significant reduction in early  PO N V  (0 -  6h) in 
adults treated w ith acupuncture com pared w ith placebo and that antiem etics 
(m etoclopram ide, cyclizine, droperidol, prochlorperazine) versus acupuncture techniques 
w ere com parable in preventing early  and late (0-48h) PO N V  in adults. These techniques 
w ere m ore effective for contro lling  nausea than vom iting. In children, how ever, no benefit
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was found.95 More recently, in a randomized placebo controlled study in patients undergoing 
breast surgery, Gan and colleagues reported similar efficacy o f electroacupuncture at the P6 
point and prophylactic ondansetron. O f interest electroacupuncture patients reported less 
pain compared with the other groups.96 The comparable efficacy o f acupoint electrical 
stimulation to ondansetron for both the prophylaxis and treatment o f PONV was also 
confirmed in two recent studies. When used for prophylaxis, the combination o f ondansetron 
and acupoint electrical stimulation was associated with lower incidence o f PONV, less need 
for rescue antiemetics as well as improved quality o f recovery and patient satisfaction, 
compared to ondansetron alone.97 98
Other non-pharmacological methods
Hypnosis has also been found effective when compared with placebo.99 Although 
some earlier reports suggested that ginger root might have a beneficial effect for PONV 
prophylaxis, this has not been confirmed in a recent m eta-analysis.100
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CHAPTER 2
Risk Factors for PONV
Administering prophylactic antiemetics to all patients may expose them to 
unnecessary risks due to side effects o f the drugs and may not be cost-effective. Hence, it is 
important to recognize the various risk factors which increase the risk for developing PONV 
and hence target a subgroup o f patients for prophylactic management. PONV risk factors 
have been described in the literature since the late 1800s101. Traditionally, investigation 
focused on a single potential factor at a time, with little to no attempt to control for other 
variables.
The modem era in PONV risk factor research began in the early 1990s, with 
publication o f the first studies that attempted to simultaneously identify multiple risk factors 
and, in so doing, used regression models to control for a wide variety o f variables.1 102 
Nearly all these studies were prospective and relied on logistic regression analysis.103 
Logistic regression analysis uses modelling in which a binary or dichotomous dependent 
variable, that is, an outcome comprising two possible categories (e.g., PONV: yes or no), is 
described as a function o f one or more independent variables. Logistic regression analyses 
generate an odds ratio (OR) for each factor examined. The OR is the ratio o f the likelihood 
o f an outcome in a group with the given risk factor to the likelihood o f the outcome in a 
group lacking that factor. The statistical significance o f each OR also is assessed. In 
addition, the 95% confidence interval (Cl) o f  the OR, i.e., that is, the range o f  values that is
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95% likely to include the true OR in the study population, is calculated. When the lower 
limit o f the 95% Cl o f its OR exceeds 1.00, it is likely that a given factor increases PONV 
risk.
The potential risk factors studied thus far (Table 2) may be classified as patient-, 
surgery- or anaesthesia-related.16102104 Most patient and surgical technique-related factors 
are fixed; some other surgery-related factors and some anaesthesia-related factors are 
variable.
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Main Risk Factors for PONV
Table 2 classifies risk factors as well-established or possible as well as by 
relationship to the patient, surgery, or anaesthesia.
Table 2. PONV risk factors.
W ell-Established Risk Factors Possible Risk Factors
Patient Related
Female gender from
puberty*1'14-15,102-105-106,107,108,109,110,111,112,113-
114
Better ASA physical status1 14
N onsm oking status
1.14.15.102.105.106.107.108.109.110,1 1 1.112.1 13 1 14 115.1 16
History o f  migraine [nausea o n ly ]14115
History o f  PONV or motion
sickness114'15'102'105’106107'108’109'110111,112-113'
114.117,118
History o f  PO N V  or motion sickness in a 
parent or sibling (children o n ly )112
Childhood after infancy and younger
adulthood1'14'15'102'105'106'107'108'10911011'''1211
3,1 14,117,118,1 19
Preoperative anx iety114
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W ell-Established Risk Factors Possible Risk Factors
Ethnicity (Dutch/English versus 
Scandinavian)120
Surgery Related
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W ell-Established Risk Factors Possible Risk Factors
Increasing duration o f surgical Certain surgery types:
procedures14’15'108-"0-"7! .in traabdom inal,-,4-,5-l02-'05-,06-'07-,08-'09-"°-1
11,112,113,114
• hernia repair [children]121
• laparoscopic1,14,15’104,105’107’108,109’113,118,1
21,122,123,124,125
•  orthopaedic1’14’15’104’105’107’108’109’113,118,12
1,122,123,124,125
•  major gynaecological
(G YN )1’14’15’104,105’107,108,109’113’118’121,122’
123,124,125
• ENT [including adenotonsillectomy in
children]1’14’15’104’105’107’108’109’11311812112
2,123,124,125
• strabismus [children]
1 ,14 ,15 ,104,105,107,108,109,113,118,121,122,123,124,12
5
•  neurosurgery109,121,126
• breast
surgery1 ,l4,15’104,105’107,108,109,113,1,8’121’122’
123,124,125
plastic
surgery
123,124,125
1 ,14 ,15 ,104,105,107.108,109,113,118,121,122,
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W ell-Established Risk Factors Possible Risk Factors
Anaesthesia Related
Less pre- or intraoperative fluid 
adm inistration128129
Intraoperative crystalloid versus colloid 
adm inistration94
Volatile anaesthetics21 ’1 u 114’130 Increasing duration o f
anaesthesia1,15,21,107,117,130
Nitrous oxide108,110,114,1'30,1'31 General versus other forms of 
anaesthesia15,113,132
Balanced versus total IV 
anaesthesia21,110130,133
Use o f longer- versus shorter-acting opioids134
Large-dose (>2.5 mg) neostigmine ~3
Intraoperative opioids110136
Postoperative
opioids1'14102107,108,111-113,137138,139
Patient-Related Factors
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Probably the strongest risk factor identified is female gender from puberty on: all 
adult studies listed in Table 2 1 14■s . ' « . i o 5 . , o 7 . , o « . , w . h o . i „  .ii4.i39.t4am i  concurred in identifying
female gender as a risk factor, and no study has contradicted this finding. All adult risk 
scoring systems include this factor. In most studies, ORs for this predictor have ranged from 
2.0-4.0, reflecting a two-fold to four-fold increased PONV risk for adolescent and adult
females ( e . g . ; ' . ' - * . i 5 . i 0 2 . 10 5 . i 0 7 . l 08.i0<), i i 0 j n . i i 4 , i 3 9 . l 4 0 . i 4 i )  T h a t  p r e . p u b e s c e m  g i r l s  a p p a r e n t l y
lack increased likelihood o f PO N V 117,119 could imply that the risk relates to hormonal factors. 
However, although early studies142,143 reported increased susceptibility to PONV during the 
first week o f the menstrual cycle, early stage o f the menstrual cycle has been disproved as a
144 145risk factor by a subsequent study , and in a systematic review.
Nonsmoking status has been identified as an independent PONV risk factor in 
numerous adult studies1 141x107110113140 146 as has history o f either or both PONV or motion 
sickness1,14,15,107,110,112,1 lj,l39140,14f); intriguingly, a recent study in children also found history 
o f PONV in a parent or sibling to be a risk factor.117 There have been few contradictory 
reports.102111 139 Nonsmoking status is included in all but one adult risk scoring system, and 
history o f PONV or motion sickness in all risk scoring systems. Most studies have found 
ORs o f -1 .5-2.5 for nonsmoking status and o f -1.8-3.1 for history o f PONV, motion 
sickness, or both.
A number o f investigators also have identified childhood after infancy and younger 
adulthood as independent PONV risk factors1 1 ^ 10:' 1 °7,1 °8'1 w 110111119 For example, 2 reports 
noted a >10% decreased risk for every decade o f age in adults.1 x 1,1 A study in children age
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<14 years found a sharp increase in PONV risk around age 3, with a 0.2%-0.8% per year 
increase in risk thereafter, depending on the presence o f other risk
factors1'1' 10' ' 107108109110 111119 However, age is included in only a minority o f risk scoring 
systems (Table 3).
Possible PONV risk factors include better ASA physical status14147 and a history o f 
migraine (post-operative nausea only).14113 A recent adult study found higher scores on the 
Spielberger State-Trait Anxiety Inventory anxiety scale or on the Amsterdam Preoperative 
Anxiety and Information Scale anxiety section to be weak PONV risk factors (OR 1.01,
95% Cl, 1.00-1.02, P = 0.04 and OR 1.04, 95% Cl, 1.02-1.05, P = 0.02, respectively); their 
inclusion in the investigators’ risk scoring system did not improve its discriminating
114power. In contrast, a paediatric study found preoperative anxiety not to be a significant 
PONV risk factor.77 A meta-analysis o f PONV after gynaecological surgery120 and studies in
1 48the laboratory-induced motion sickness setting suggest that ethnicity (Dutch or English 
versus Scandinavian and Chinese or Asian-American versus Caucasian- or African- 
American, respectively) could be a PONV risk factor. However, two studies using 
multivariable analyses do not support a role for this characteristic.114’139
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Table 3. Overview of risk factors use in risk scoring systems
R isk Factor* A d ults, sim p lified  or se m isim p lif ie d  sy stem s A d ults, n o n sim p lified  sy stem s
F em ale  
H istory o f  
P O N V  or 
m otion  
sick n ess  
N on sm ok er  
A g e
D uration o f  
surgery  
T ype o f  
surgery
A p fel et al. K oivuranta et V an den A p fel et al. K oivuranta et P a lazzo  and S in cla ir  et al. 
14 B o sc h  et al. 150 al. 14 E vans 102
149
al.
X
X
X
X
P a tien t-re la ted  
X X
X X
X
S u rg ery -re la ted
X
X
X
X
X
X
C hildren, 
sim p lified  
system  
Eberhart et
a l .118
X
X
X
X
N um ber o f  
sy stem s in 
w h ich  risk  
factor is used
7/8
8/8
6/8
3/8
4 /8
3 /8
Risk Factor* A d ults, sim p lified  or se m isim p lif ie d  sy stem s
A p fel et al. K oivuranta et 
al. 14
D uration o f  
anaesth esia  
A n aesthetic  
tech nique  
P ostoperative  
o p io id s  
N um ber o f  
each type o f  
risk factors  
N um ber o f  
risk factors
X
3 PR, 1 A R
4
4 PR, 1 SR
5
V an den  
B o sc h  et al.
149
X
4 PR, 1 SR , 1 
A R
6
48
A d ults, n o n sim p lified  sy stem s C hildren,
sim p lified
sy stem
A p fel et al. K oivuranta et P a lazzo  and S in cla ir  et al. 151 Eberhart et
1,0 al. 14 E vans 102 a l .118
A n aesthesia -re lated
X
X
X
4 PR, 1 A R  4 PR, 1 SR  3 PR, 1 A R  3 PR, 8 SR , 1 2 PR, 2 SR
A R
5 5 4 12 4
N um ber o f  
system s in 
w h ich  risk  
factor is used
1 8  
2 8 
2 8
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AR, anaesthesia-related; D&C, dilatation and curettage; ENT, ear nose and throat; GYN, gynaecologic; OPHTH, ophthalmologic; 
ORTHO, orthopaedic; PONV. postoperative nausea and vomiting; PR, patient-related; SR, surgery-related, X, used in the 
particular risk scoring system
Besides early stage o f the menstrual cycle, obesity has been disproved as a patient- 
related PONV risk factor.152 Interestingly, the systematic review that did so found that the 
belief in increased body mass index as a risk factor apparently largely stemmed from a 
“chain reaction” o f 14 review articles misquoting or misinterpreting 4 original studies.
Surgery-Related Factors
Increasing duration o f surgery has been shown to be an independent PONV risk 
factor by a few well-conducted studies in adults1415’108,110 or children.117 An outpatient study 
found that each 30 min increase in surgery duration increased baseline PONV risk by 60% .15 
However, while type o f surgery has been identified as a risk factor in numerous 
reports1’11’14’15’104105’107’109’113’121, its status as such is still somewhat controversial, since the 
specific procedures implicated as particularly emetogenic sometimes vary among studies. 
Types o f procedures that may be viewed as possible risk factors include intra­
abdom inal1’11’14'15’104’105’107’109’113’121, laparoscopic, orthopaedic, major gynaecological, ear, 
nose and throat, thyroid, breast and plastic surgery 1J 1141x104 10x1071091 lj 121 as w ep as 
neurosurgery1’11105107 l09 l231“6. and. in children, hernia repair121, adenotonsillectom y121, 
strabismus or penile surgery, and orchiopexy.121 Half o f risk scoring systems include 
duration o f surgery, and several incorporate one or more types o f surgery (Table 3). Other 
possible surgery-related PONV risk factors include less pre- or intraoperative fluid
p g  ] 29 • • 94administration “ or intraoperative colloid versus crystalloid administration , when a 
large volume o f crystalloid in a prolonged surgery may result in gastrointestinal tissue 
oedema leading to an increased incidence o f PONV.
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Anaesthesia-Related Factors
Numerous anaesthesia-related variables have been well established as PONV risk 
factors, including use o f volatile anaesthetics21 110130141, nitrous oxide110'114’130'131, balanced 
inhalational versus total IV anaesthesia110130 13U33, and large-dose (> 2.5 mg) 
neostigmine.135 The choice o f volatile anaesthetic, e.g., isoflurane versus sevoflurane versus 
enflurane, appears not to affect the risk o f  PONV130141. Use o f intra-110,136 or 
postoperative1’14’102’107,111’113,137,138’139 opioids and larger peri and postoperative doses o f these 
drugs also have been implicated as associated with PO N V .153’154,155,156 However, some 
contradictory findings have been reported with respect to post-operative opioid use in 
adults114, intra- or post-operative opioid use in children117 or intra-operative opioid use in a
i i \ n
mixed adult and paediatric population. Interestingly, despite the relatively large number o f 
anaesthesia-related variables identified as risk factors, most risk scoring systems do not 
include any, while the remainder o f the systems includes only a few (Table 3).
Administration o f a long- rather than a short-acting opioid is, at best, a possible 
PONV risk factor. Although a small recent study observed an association between use o f 
fentanyl versus remifentanil as an adjunct to propofol m aintenance134 and PONV, another 
similarly sized study found no association o f alfentanil versus remifentanil use and 
PON V .157 Moreover, a 5199-patient multi-national multifactorial designed study o f anti- 
PONV interventions130 failed to find fentanyl versus remifentanil as a PONV risk factor.
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Far more likely, but not yet well established, anaesthesia-related PONV risk factors 
include longer duration o f anaesthesia1’15,105,107’117 or general versus other forms o f 
anaesthesia, e.g., regional or sedation.15,113132 Together with postoperative opioid or 
isoflurane use, they comprise the anaesthesia-related risk factors used by current risk scoring 
systems (Table 3). Use o f standard (30%) rather than supplemental (50% or 80%) oxygen 
seems to have been disproved as a risk factor90,130,158,1 >9, despite early evidence o f its validity
i 88,89as such.
Risk Factors in Paediatric Patients
In the paediatric population, only vomiting is reported due to difficulties in eliciting 
nausea in the young age group. The incidence o f PONV increases after the age o f 3 years 
with a peak incidence o f about 40 % in the 1 1 -1 4  year age group.15,104,119 Prior to puberty, 
gender differences for postoperative vomiting have not been identified.7 Operations 
associated with a high incidence o f postoperative vomiting in children include strabismus, 
adenotonsillectomy, hernia repair, orchidopexy and penile surgery.104
PO N V Risk Scoring in Adult Patients
A number o f PONV risk scoring systems have been developed. In 1993, Palazzo and 
Evans prospectively studied 147 patients undergoing minor orthopaedic surgery. Using 
logistic regression analysis, they concluded that the probability o f postoperative sickness in 
the first 24 hours after surgery can be estimated using the following equation: logit
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postoperative sickness = -5.03 + 2.24 (postoperative opioids) + 3.97 (previous sickness 
history) + 2.4 (gender) + 0.78 (history o f motion sickness) -  3.2 (gender x  previous sickness 
history).102 This equation has not been validated further.
Subsequently, Koivuranta studied 1107 in-patients and used a logistic regression 
model to generate a score based on the strongest five predictors for PONV: score=0.93 (if 
female) + 0.82 (if  previous PONV) + 0.75 (if duration o f surgery over 60min) + 0.61 (if 
nonsmoker) + 0.59 (if history o f motion sickness).14
More recently, in a study o f 2,722 patients, Apfel et al developed a simplified risk 
score consisting o f four predictors: female gender, history o f motion sickness or PONV, 
non-smoking status and the use o f  opioids for postoperative analgesia. If none, one, two, 
three or four o f  these risk factors were present, the incidences o f PONV were 10, 21, 39, 61 
and 79 % respectively.108
Knowledge o f independent PONV risk factors is crucial for the optimal use o f 
antiemetic prophylaxis and multimodal management strategies. M odem multivariable 
studies, meta-analyses, and systematic reviews have greatly increased such knowledge. 
Independent risk factors identified by modem research, such as female gender from puberty, 
nonsmoking status, history o f PONV or motion sickness, childhood after infancy or younger 
adulthood, lengthy or emetogenic surgery, or administration o f nitrous oxide, volatile 
anaesthetics, or postoperative opioids, may be used in combination to predict, with moderate 
accuracy, the likelihood o f PONV in a given patient. Additional PONV research examining
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patient genetic characteristics and under-investigated potential clinical risk factors, and 
involving outpatients and children should lead to predictive systems with improved 
discriminating power and applicability. This development, in turn, will enable 
anaesthesiologists to better identify at-risk patients, further reduce the incidence o f PONV 
and increase the safety and cost-effectiveness o f  PONV prophylaxis.
Strategies for the Management of PONV
None o f the available anti-emetics is entirely effective for preventing PONV, 
especially in high-risk patients. Since at least 4 major receptor systems (serotonergic, 
cholinergic, histaminergic and dopaminergic) are involved in the aetiology o f PONV, a 
better prophylaxis might be achieved by using a combination o f agents acting at different 
receptor sites. This approach, introduced first in chemotherapy induced nausea and vomiting, 
is gaining more popularity for PONV prophylaxis. More than forty randomized controlled 
trials have been published comparing combination versus single agent for PONV 
prophylaxis. Most o f these studies demonstrated improved prophylaxis using a combination 
o f two or more agents acting at different receptor sites.160 This has also been confirmed in 
systematic reviews.75160 Table 4 and Table 5, respectively, demonstrate the number needed- 
to-treat (NNT) for the common antiemetics as well as the side effects profile, or number 
needed-to-harm (NNH) for these drugs. In clinical practice, an NNT o f >10 is considered as 
lack o f efficacy that is o f clinical significance and an NNT o f < 5 is considered as strong 
clinical efficacy and its used is advised.
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Table 4: NNT (95 % Cl) of antiemetics studied in systematic reviews
Early
Nausea
Late nausea Early
vomiting
Late
vomiting
Anticholinergics
Transdermal
scopolamine33
5 (3.2 to 11.1) 5.9 (4.2 to 
11.1)
Antihistamines
Dimenhydrinate34 8 (3 to 20) 6 (3 to 33) 7 (4 to 50) 5 (3 to 8)
Butyrophenones
Droperidol 0.5-0.75
mg36
4.8 
(3.0 to 12)
11
(6.9 to 25)
10
(4.6 to 51)
3.4 
(2.4 to 5.7)
Droperidol 1 -1 .2 5  
mg
6.1
(4.5 to 9.4)
6.8 
(5.2 to 9.7)
7.6 
(5.8 to 11)
8.2 
(5.6 to 15)
Droperidol 1.5 -  2.5
mg36
5.9 
(3.8 to 13)
5.8 
(3.8 to 12)
6.9 
(4.7 to 13)
7.1 
(4.2 to 23)
Droperidol 5 - 2 0  meg 
/kg
7.3 
(4.5 to 20)
Droperidol 50 meg / kg
36
7.4 
(3.9 to 58)
4.4
(2.5 to 17)
Droperidol 75 meg / kg
36
4.2 
(3.3 to 5.9)
3.8 
(2.8 to 5.2)
Droperidol in PCA 
m orphine161
5.1 
(3.1 to 15)
3.1
(2.3 to 4.8)
5 -HT3 receptor antagonists
Ondansetron*5 161
O ndansetron 1 m g 21 (9 to 00) 9 (5.3 to 30) 15(8 to 210)
Ondansetron 4 mg 5.6 
(4 to 9)
4.6 
(4 to 5.5)
5.5 
(4.4 to 7.5)
6.4 
(5.3 to 7.9)
Ondansetron 8 mg 11
(4.2 to 00)
6.4 
(4.6 to 10)
6.4 
(4.7 to 10)
5.0 
(4.0 to 6.7)
Ondansetron 100 
meg/kg
5
(3.7 to 7.6)
2.7 
(2 to 4.2)
Ondansetron 150 
meg/kg
2.5 
(1.9 to 3.6)
2.7 
(1.7 to 7.6)
Ondansetron in PCA 
morphine
-67 
(-5.8 to a)
5.1
(2.8 to 23)
Tropisetron
Tropisetron 2 -  5 mg " 6.7
(4.8 to 11.1)
5
(3.6 to 8.3)
Benzamides
Metoclopramide 10 
44mg
16
(7.5 to -210)
12
(6 t o -1587)
9.1
(5.5 to 27)
1 0
(6 to 41)
Propofol
Propofol induction163 9.3 50.1 13.7 14.9
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(6.1 to 19.4) (7.6 to oo) (8.1 to 45.4) (6 to oo)
Propofol maintenance 8
(6.4 to 10.8)
5.8 
(4.2 to 9.4)
9.2
(7.6 to 11.7)
10.1 
(6.2 to 28.8)
Steroids
Dexamethasone 8 m g/5 5
(2.2 t o -21)
4.3 
(2.3 to 26)
3.6 
(2.3 to 8)
4.3 
(2.6 to 12)
Other interventions
Omitting nitrous 
oxide131
30
(13.5 to oo)
36.9 
(11.8 to go)
11.8 
(8.5 to 19.4)
13.8 
(8.8 to 31.6)
Omitting reversal o f IOC
neuromuscular block
-636 14 417 23
Non-pharmacological 
techniques (0 -  48 h)95
4
(3 to 6)
5
(4 to 8)
14
(6 to go)
NNT = Number needed to trea r
Although data from systematic reviews provide us with an indicator o f the relative efficacy 
and side effects o f the various antiemetics it is important to note that there are limitations to 
the interpretation o f these data. The studies analyzed are often heterogeneous with varied 
study designs. The outcome variables may not have been the same between studies and the 
duration o f data collection may be variable. Allocation concealment tends to be dissimilar 
between studies and the definition o f nausea and vomiting may not be standardized.
" T he c o n fid en ce  in tervals o f  the N N T  and N N H  va lu es straddled b etw een  p o s it iv e  to n eg a tiv e  num bers and at 
t im es infib ity . T his is because the N N T  is a recip rocal fun ction , or the inverse  o f  a b so lu te  risk red uction  (A R R ). 
1 his function is not co n tin u ou s. A s the A R R  cro sses  the “ line o f  no e ffe c t” from  p o s it iv e  to n eg a tiv e , the N N T  
c ro sses from  p lus in fin ity  to m inus in fin ity . W hen the A R R  is n o n -sig n ifica n t, by  d efin ition  its co n fid e n c e  
interval in c lu d es or to u ch es zero . T he c o n fid e n c e  interval for the corresp on d in g  N N T  w ill straddle from  plus to 
m inus infin ity .
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Table 5: NNH (95 % Cl) of antiemetics studied in systematic reviews
Scopolamine 44Metoclopramide Ondansetr
on53
Droperidol36
Extrapyramidal 
symptoms (adults and 
children)
556 
(72 to -98)
408 
(171 t o -  
1061)
Extrapyramidal 
symptoms (children)
91 (38 to - 
241)
Restlessness or 
abnormal movements 
(adults)
245 
(42 to -65)
39
(18 to -263)
Dizziness (adults) 50 10  mg iv :
-42 (-14 to 44) 
20 mg iv:
3.3 (1.9 to 12) 
All doses 
combined: 
-3862 (-30 to 31)
142 
(26 to -41)
Headache (adults) -45 
(-18 to 90)
1 mg: 54 
4 mg: 30 
8 mg : 42 
16- 
48mg: 38 
All doses: 
36 
(22 -  89)
-25
(-14 t o -137)
Sedation and 
drowsiness (Adults)
10 mg :
20
(8.7 to -65) 
0.2 mg/kg:
3.9
(1.6 to -7.7) 
All doses (iv and 
im) combined: 
58
(16 to -36)
0 .2 5 -6 .2 5  
mg :
-57 
(52 t o -18) 
1.25 mg: 
24
(13 to 139) 
2.5 mg: 
7.8 
(4.9 to 20)
Sedation and 
drowsiness (Children)
-9316 
(-35 to 35)
24
(13 to 139)
Elevated liver 
enzymes
31
Hypotension 4 mg : 12
Constipation 23
Visual disturbances 5.6
Dry mouth 12.5
Agitation 100
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NNH = Number Needed to Harm
When no dose is indicated, the NNH is for all the doses tested combined.
The most commonly studied combinations have included a 5 -HT3 receptor 
antagonist with either droperidol or dexamethasone. Both combination regimens appear to 
be equally efficacious .6 9 164
In addition to using a com bination o f anti-emetics acting at different receptor sites, 
the multifactorial aetiology o f PONV might be better addressed by the adoption o f a 
multimodal approach. This is especially important in patients at high risk for PONV. Table 6  
summarizes different strategies for keeping the baseline risk o f PONV low.
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Table 6: Strategies to keep the baseline risk of PONV low
A) Use o f  regional anaesthesia15
B) Avoid emetogenic stimuli:
Nitrous oxide108'131 
Inhalational agents141 
Etomidate and ketam ine163
C) Minimize the following:
Intraoperative and postoperative opioids.107’136,137’138’146 Adequate 
analgesia should, however, be achieved by incorporating local 
anaesthetics, NSAIDS, and opioids as required)
The dose o f neostigm ine.133 Consider limiting the dose to a maximum 
of 2.5 mg in adults.
D) Multimodal therapy:
Total intravenous anaesthesia (TIVA) with propofol133163
Adequate hydration92, especially with
colloids94
Anxiolytics, e.g. benzodiazepines67 78 79 
Non-pharmacological techniques e.g. acupuncture93
OZ 0*7
a 2-adrenergic agonists e.g. clonidine ’
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For instance, there is an 11 fold increased risk for PONV in patients receiving 
general anaesthesia compared to those receiving a regional anaesthetic.15 TIVA with 
propofol has been shown to reduce the incidence o f PONV, especially in the early 
postoperative period.163 However, the dose response relationship o f propofol for its 
antiemetic effects is unclear (see Chapter 5). Avoidance o f nitrous oxide (which increases 
postoperative vomiting) and volatile agents (which cause PONV for up to two hours 
postoperatively), and minimizing intraoperative and postoperative opioids, also reduce the 
incidence o f poN V .107’108’131’136’137’138 The use o f large doses o f  neostigmine (>2.5 mg) 
increases the risk o f PONV.135 Other strategies that might reduce the incidence o f PONV 
adequate hydration especially using colloids,92'94 anxiolysis with benzodiazepines, 79 166
oz 07
and the use o f a 2-agonists. ’
Scuderi et al tested a multimodal approach to the management o f PONV in females 
undergoing outpatient laparoscopy. Their multimodal critical care algorithm consisted o f 
total intravenous anaesthesia with propofol and remifentanil, no nitrous oxide, no 
neuromuscular blockade, aggressive intravenous hydration (25 ml/kg), triple prophylactic 
antiemetics (ondansetron 1 mg, droperidol 0.625 mg and dexamethasone 10 mg), and 
ketorolac 30 mg. Control groups included standard balanced outpatient anaesthetic with or 
without 4 mg ondansetron prophylaxis. Multimodal management resulted in a 98% complete 
response rate (no PONV and no antiemetic rescue) in PACU. No patient in this group 
vomited before discharge, compared with 7 % o f patients in ondansetron group (p=0.07) and 
22 % of patients in the placebo group (p=0.0003).167 Subsequently, more studies confirmed 
the efficacy o f a multimodal approach, especially in high-risk patients.168169
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Recommended strategy for PONV prophylaxis
Figure 4. illustrates a suggested algorithm for PONV prophylaxis. The risk o f PONV 
should be estimated for each patient. No prophylaxis is recommended for patients at low risk 
for PONV except if  they are at risk for medical consequences from vomiting e.g. patients 
with wired jaws. For patients at moderate to high risk for PONV, regional anaesthesia 
should be considered. If this is not possible or contraindicated and a general anaesthetic is 
used, a multimodal approach to the management o f PONV should be adopted to keep the 
baseline risk o f PONV low (Table 6). Combination antiemetic therapy is superior to 
monotherapy for PONV prophylaxis.160 However, the best available combination and the 
optimum doses o f antiemetic agents when used in combination are yet to be established.
Figure 4. Strategies for the management of PONV.
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A
History o f PONV
PONV 
Reduction 
Strategy
B
Female gender 
Postoperative opioid 
History o f motion sickness 
Emetogenic surgery 
Non-smoker
Consider
f
A on one occasion 
OR > 2 factors 
from B
• Regional anaesthesia
• Adequate hydration
• Avoid nitrous oxide
• Avoid high dose neostigmine
A on one occasion 
PLUS > 1 factor from B 
OR > 3 factors from B
1
A on more than one occasions 
PLUS > 1 factor from B
Single Agent Combination o f 2 Agents Multimodal
5 -HT3 antagonist
Dexamethasone
Scopolamine
Promethazine
Acupuncture
5 -HT3 antagonist 
&
Dexamethasone
OR
5 -HT3 antagonist 
& Acupuncture
> 2 antiemetics
PLUS
TIVA with Propofol
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Recommendations for the treatment of established PONV:
There is a paucity o f data on the use o f antiemetics for the treatment o f PONV in 
patients who failed prophylaxis or did not receive prophylaxis. This is due to the difficulty 
in performing such studies since a large number o f patients would need to be recruited in 
order to obtain the required target o f patients who eventually experience PONV.
The 5 -HT3 receptor antagonists were the most commonly tested drugs in rescue trials. 
Similar to their use in PONV prophylaxis, the anti-vomiting efficacy o f the 5 -HT3 receptor 
antagonists is more pronounced than their anti-nausea efficacy. There is no evidence o f 
dose-responsiveness for these agents when used for rescue. Therefore, small doses o f these 
agents have been recommended for treatment: ondansetron 1 mg, dolasetron 12.5 mg,
1 7 0granisetron 0.1 mg and tropisetron 0.5 mg. The NNTs for the different doses o f the 5 -HT3 
receptor antagonists when used for treatment are shown in Table 4.
In patients who fail ondansetron prophylaxis, there is evidence to suggest that the use 
o f ondansetron for rescue is no more effective than placebo.51 A drug acting at a different 
receptor might be more effective in this case.35 There are some data from chemotherapy 
induced nausea and vomiting to suggest that granisetron might be efficacious for treating 
patients who fail ondansetron prophylaxis.171172 Such evidence is lacking in the PONV 
literature. There is also a striking lack o f evidence on the therapeutic efficacy o f older 
generation antiemetics in the treatment o f established PONV. Droperidol was not different 
from ondansetron when used for the treatment o f established PONV.53 On the other hand,
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ondansetron 4 mg was more effective than metoclopramide 10 mg in the treatment o f 
established PO N V .138173
When evaluating PONV following surgery, the role o f medication and mechanical 
factors should be considered first. Such contributing factors might include opioids, blood 
draining down the throat, or bowel obstruction. Then rescue therapy can be initiated. If 
PONV occurs within 6 hours postoperatively, patients should not receive a repeat dose o f 
the prophylactic antiemetic; a drug from a different class should be used for rescue. Beyond 
6 hours, PONV can be treated with any o f the agents used for prophylaxis except 
dexamethasone and scopolamine, which are longer acting.
Summary
Identification o f patients at increased risk for PONV allows targeting antiemetic 
prophylaxis to those who will benefit most from it. No prophylaxis is warranted for patients 
at low risk for PONV unless there is risk o f medical sequelae from vomiting. The first step 
in reducing PONV risk is to reduce baseline risk factors. For patients at moderate to high 
risk, antiemetics should be used either as monotherapy or in combination for PONV 
prophylaxis. There is increasing evidence that a better prophylaxis might be achieved by 
using a combination o f agents acting at different receptors. The adoption o f a multimodal 
approach to the management o f PONV should be considered in patients at high risk for 
PONV. In patients who develop PONV despite receiving prophylaxis, an antiemetic acting 
at a different receptor should be used for rescue within the first 6 hours following surgery.
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After 6 hours, PONV can be treated with any o f the drugs used for prophylaxis except 
dexamethasone and scopolamine.
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C H A PTER  3 
Propofol
Propofol is a sedative-hypnotic that was introduced in 1986 in the UK as the first in a 
new class o f agents known as the alkylphenols. Its distinctive pharmacokinetic and 
pharmacodynamic properties make it useful for a wide range o f clinical uses. The injectable 
emulsion is indicated for induction and maintenance o f general anaesthesia and monitored 
anaesthesia care with local or regional anaesthesia. Because it is characterized by a rapid 
onset o f action, easy dose titration, and rapid recovery, propofol is frequently used for 
sedation in the intensive care unit and during office-based procedures such as colonoscopy. 
This chapter will discuss the pharmacokinetic and pharmacodynamic properties o f propofol 
as well as its clinical uses and adverse effects.
Physical and Chemical Characteristics
Chemically, propofol is 2,6-diisopropylphenol (Figure 5). It has a molecular weight 
o f 178.27. 174. Propofol has only slight solubility in water and is formulated in an oil-in- 
water emulsion consisting o f 10% soybean oil, 2.25% glycerol, 1.2% egg phosphatide, and 
disodium edetate (EDTA). 175 Propofol is isotonic with a neutral pH o f 6 to 8.5, and a pKa 
in water o f 11,174 175
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Figure 5. Propofol chemical structure.
CHCH OH
Pharmacokinetics
Propofol provides a rapid induction to anaesthesia, acting within 40 seconds o f 
initiation o f intravenous injection to induce hypnosis.174 Propofol crosses the blood-brain 
barrier and is rapidly absorbed and extensively distributed. A 10-day infusion is associated
17*1 •with a volume o f distribution o f approximately 60 L/kg. Propofol's initial distribution 
half-life is between 2-8 minutes, its slow distribution half-life is 30 to 70 minutes, and its 
terminal elimination half-life is 4-24 hours. Propofol’s duration o f action can vary based on 
the age o f the patient, their medical status, and whether propofol is given as infusion or 
bolus dosing, as well as the duration o f infusion.175
After the initial infusion, plasm a levels decline rapidly as propofol is redistributed 
from the brain and other well-perfused sites into muscle, fat and other poorly-perfused tissue.
176 . . .  .The initial distribution clearance o f  propofol is close to that o f thiopental (3 to 4
176L/kg/min). However, propofol has a rapid metabolic clearance rate (nearly 10 times faster
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than thiopental) and hence the recovery from its clinical effects is rapid.17x177 As a result, 
propofol concentrations decline rapidly in peripheral sites allowing for clinical recovery 
from sedation and hypnosis while concentrations in the central compartment decline slowly 
having little effect on the patient’s clinical state. 176 The “context-sensitive half-tim e”, which 
is the time needed to reduce propofol concentrations in the central compartment by 50%, is 
less than 25 minutes for infusions lasting up to three hours. 176 Recovery is even more rapid 
when propofol infusion is titrated to effect, i.e. when plasma propofol levels are kept close 
to the desired effect to ensure that a reduction o f 10% to 20% will lead to awakening. 176
Elimination, distribution clearance, and volume o f  central compartment are 
decreased among elderly patients and are increased when normalized to body weight in 
paediatric patients. Thus, compared w ith adults, proportionally higher doses o f  propofol 
are required to induce and maintain sedation in children and proportionally lower doses are 
required for the elderly.179 Propofol administration is typically titrated to effect in all 
patients, however no extreme adjustments are necessary for patients who are obese or who 
have moderate hepatic or renal dysfunction.179
Propofol is primarily metabolized in the liver through the cytochrome P450 system 
and through glucuronidation.180 One half to two thirds o f propofol is excreted as propofol 
glucuronide.175 The primary catalysts for propofol glucuronidation are uridine diphosphate 
glucuronosyltransferase I (UGT) family enzymes. The P450 isoforms that catalyze propofol 
oxidation include CYP 2B6, 2C9, 1A2. 2A6, 2C8, 2C18. and 2C19 (2K1 and 3A4 are not 
involved).17:1 However, Oda and colleagues demonstrated that CYP2B6 is the predominant
69
181CYP isoform involved in the oxidation o f propofol by human liver microsomes.
Propofol’s metabolic clearance rate exceeds hepatic blood flow, which indicates the 
drug is also being metabolized in extrahepatic sites. 182 Hiraoka et al found that nearly one
183third o f propofol clearance is renal.
Pharmacodynamics
Mechanism o f  Action
Propofol’s mechanism o f action stems primarily from its effects on presynaptic and 
postsynaptic gamma-aminobutyric acid type A (GABA(A)) receptors which are found 
throughout the central nervous system and are associated with fast neuronal inhibition.175 
Propofol acts postsynaptically by enhancing the activity o f the inhibitory neurotransmitter 
GABA at the GABAa receptor. When propofol is administered in clinically-relevant 
concentrations, chloride conductance increases and the postsynaptic membrane becomes 
hyperpolarized, which results in an anaesthetic effect. Studies evaluating the binding sites 
on the GABAa receptor indicate that propofol acts at a separate site o f the GABA a receptor 
than benzodiazepines, barbiturates, or steroids.175 Propofol’s presynaptic effects occur 
through inhibition o f GABA uptake and consequent accumulation o f GABA in the 
synapse.175 Propofol also interacts with different neurotransmitter receptors such as glycine, 
glutamate, and neuronal nicotinic ACh receptors.175
70
CNS Effects
Administration o f propofol causes a generalized reduction in functional activity of
I O 4
the central nervous system, including sensory, motor, and limbic activity. Propofol 
decreases cerebral blood flow and the cerebral metabolic rate in a dose-dependent
185manner. When used during treatm ent o f brain injury, propofol administration leads to a 
decline in regional cerebral blood flow, cerebral perfusion pressure, and intracranial pressure 
without causing changes in cerebrovascular resistance and cerebral arteriovenous oxygen 
content difference.186
Cardiovascular Effects
Propofol causes some cardiovascular depression during clinical use. Its 
cardiovascular effects include a decrease in mean arterial pressure and a reduced end-
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systolic quotient, most likely due to diminished afterload. Global and segmental 
ventricular function appear to be unaffected by propofol. The cardiovascular depression 
associated with propofol appears to be due to decreased sympathetic tone with reduced 
vascular resistance.175 It has been suggested that propofol-induced hypotension is related to 
its inhibitory effects on the sympathetic nervous system, impairment o f the baroflex 
regulatory mechanisms, and reduced Ca~ influx into arteries.188 In an open-chested dog 
model, Puttick et al, found that propofol reduced left ventricular preload and contractility, as 
indicated by reductions in end-diastolic pressure and length. High infusion rates also
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impaired relaxation. Reductions in preload and contractility contributed to the propofol-
189induced hypotension. However, regulation o f coronary blood flow was not disrupted.
Propofol has cardioprotective effects during myocardial surgery. It is believed to 
protect the heart from ischemia-reperfusion injury by preventing changes in adenine 
nucleotides, lactate, and amino acids during ischemia and by reducing cardiac troponin I 
release during reperfusion.175 Propofol has antioxidant and free radical scavenging 
properties that promote further myocardial protection.190 Another mechanism that adds to 
propofol’s cardioprotective effect is its inhibition o f the mitochondrial permeability 
transition pore (M PTP).191 Opening the MPTP causes interference with ATP synthesis and 
other mitochondrial functions, which are a principle cause o f reperfusion injury.
Respiratory System Effects
When propofol is administered for sedation it has a negative impact on ventilation. 
Propofol depresses ventilatory control causing depression o f the ventilatory response to 
hypercapnia and the ventilatory adaptation to hypoxia.192193 This response is mediated 
through the central chemoreflex loop at the central chemoreceptors. Research shows 
propofol reduces central carbon dioxide sensitivity which has an effect on the control o f 
breathing. GABA a receptors appear to play a role in the hypoxic ventilatory decline by 
inhibiting ventilation during sustained hypoxia.194 Propofol may also cause airway 
obstruction by decreasing rib cage contribution to tidal volume and causing a decline in 
arterial oxygen tensions.195
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Hepatic and Renal System Effects
Propofol sedation does not adversely affect renal or portal venous blood flow and it 
appears to increase hepatic arterial blood flow in a dose-dependent m anner.196 No 
impairment o f proteinuria and glucosuria or protein/creatinine ratio were noted in the 
postoperative period following propofol anaesthesia.197 After propofol administration, uric 
acid concentrations in urine are increased, causing the appearance o f cloudy urine.175
Immuomodulatory effects
Propofol has several immunomodulatory effects. It decreases secretion o f 
proinflammatory cytokines, changes nitric oxide expression, and impairs monocyte and 
neutrophil functions.175 Propofol also has antioxidant radical scavenging activity that is
1QXsimilar to the actions o f endogenous vitamin E. This effect is dose dependent and is seen 
at doses significantly higher than those used for anaesthesia. However it has been suggested 
that propofol’s antioxidant and anti-inflammatory effects may be beneficial in patients with 
sepsis and systemic inflammatory response from non-infective causes and in patients with 
ischemia-reperfusion injury. Propofol’s neuroprotective effect may also be related to the 
antioxidant properties o f its phenol ring structure.175
Clinical Uses
73
General Anaesthesia
For induction o f general anaesthesia, adult patients typically receive 1.5 to 2.5 mg/kg 
of propofol whether unpremedicated or premedicated with benzodiazepines or opioids.174 
Propofol should be titrated upward by approximately 20-40 mg every 10 seconds until 
anaesthesia is achieved. Immediately after induction, anaesthesia can be maintained either 
by infusion or intermittent IV bolus injection. When delivered as a continuous infusion, 
from 100 to 200 mcg/kg/min is administered in a variable rate infusion with 60% to 70% 
nitrous oxide and oxygen. Typically, maintenance is initiated at 150 to 200 mcg/kg/min for 
the first 10 to 15 minutes, then decreased 30% to 50% during the first half-hour o f 
maintenance. An overall rate o f 50 to 100 mcg/kg/min should be achieved during 
maintenance. When delivered as an incremental bolus, 25 mg (2.5 mL) to 50 mg (5 mL) o f 
propofol is given whenever alterations in vital signs suggest that the patient is responding to 
either surgical stimulation or light anaesthesia.
In clinical trials, propofol proved similar efficacy when used for induction o f general 
anaesthesia as thiopental, methohexital or etomidate.199 Compared with the other 
anaesthetics, propofol had a lower incidence o f excitatory effects than methohexital, but was 
more likely to cause apnoea on induction than the other drugs. Due to its favourable 
pharmacological properties, propofol has replaced most other intravenous induction agents, 
such as thiopental and methohexital. It is also increasingly being used as maintenance agent 
during surgery instead o f the inhalational agents.
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Propofol is also commonly used for induction o f general anaesthesia in paediatric 
patients aged 3 years and older.174 A dose o f 2.5 to 3.5 mg/kg is typically administered over 
20 to 30 seconds when patients are not premedicated or are lightly premedicated with 
benzodiazepines or opioids. However the younger patients may need a higher induction 
dosage. Patients classified as American Society o f Anaesthesiologists Physical Status III or 
IV require a lower dosage. Maintenance doses o f propofol are given as a variable rate 
infusion in conjunction with or without nitrous oxide. The maintenance therapy in children 
with propofol is usually achieved at a rate o f 200 to 300 mcg/kg/min immediately after the 
induction dose. After the first half-hour o f infusion, the rate can be lowered to 125 to 150 
mcg/kg/min.
Induction o f general anaesthesia with propofol in elderly, debilitated, or ASA-PS III 
or IV patients should not be given as a rapid bolus due to an increased risk for 
cardiorespiratory depression primarily due to vasodilatation.174 Instead, such patients should 
receive 1 to 1.5 mg/kg (approximately 20 mg every 10 seconds) until anaesthesia is achieved. 
For maintenance o f general anaesthesia, propofol should be administered at a rate o f 50 to 
100 mcg/kg/min.
Propofol has been widely used for induction o f cardiac anaesthesia, especially 
among patients with intact left ventricular function undergoing elective coronary artery 
bypass grafting. Its use is more controversial in patients with impaired left ventricular 
function due to its known risk for hypotension.179 The recommended approach to 
administration o f propofol for induction o f cardiac surgery is to avoid a rapid bolus and
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174administer boluses o f 20 mg every 10 seconds to achieve a dose o f 0.5 to 1.5 mg/kg.
Among patients with impaired ventricular function, propofol is more frequently used for 
maintenance rather than induction o f cardiac anaesthesia. For maintenance o f cardiac 
anaesthesia, primary propofol (100 to 150 mcg/kg/min) is recommended with secondary 
opioid therapy. Alternatively, a primary opioid can be given with secondary low-dose 
propofol (50 to 100 mcg/kg/min).
Due to its capacity to elicit rapid recovery from sedation, propofol makes a valuable 
tool for neuroanaesthesia. It allows for immediate post-operative assessment o f CNS 
function. Unlike volatile anaesthetic agents, propofol does not increase intracranial pressure 
through cerebrovascular dilatation. Instead, it reduces intracranial pressure and intraocular 
pressure, decreases cerebral metabolic requirement for O:, and appears to provide cerebral 
protection.179 However, propofol should be given cautiously to patients with reduced 
intracranial compliance and those receiving diuretic therapy to avoid acute haemodynamic 
changes.179 When administered for induction o f neuroanaesthesia, propofol should be 
administered at a rate o f 20 mg every 10 seconds until induction onset (1 to 2 m g/kg).174 For 
maintenance, patients should receive 100 to 200 mcg/kg/min. Propofol has been the 
anaesthetic drug o f choice in awake craniotomy.
In a clinical trial, a propofol/fentanyl combination had fewer side effects and proved 
as effective as two different volatile anaesthetic regimens in patients undergoing elective 
craniotomy for supratentorial mass lesions.~(,<) In the first study group, propofol 1 to 2 mg/kg 
was given, followed by propofol 50 to 300 mcg/kg/min infusions and fentanyl 0.03 to 0.05
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mcg/kg/min. The second study group received thiopental 4 to 6 mg/kg followed by 
isoflurane-N20 anaesthesia. The third study group received thiopental followed by fentanyl- 
N 2O anaesthesia with supplemental isoflurane to maintain haemodynamic stability as 
needed. The group receiving isoflurane- N 2O had higher heart rate during induction and 
lower mean arterial pressures during maintenance than the other groups and had the slowest 
emergence rates. The fentanyl- N 2O group had the fastest emergence rates but also the 
highest rate o f vomiting (17%) compared with a rate o f 2.5% in the propofol-fentanyl group. 
No significant differences in neurologic outcome were found between the three groups.
The potential for seizure-like activity is a concern when propofol is used in 
neurosurgery since propofol can induce dose-dependent changes in EEG.179 While propofol 
appears safe in patients with no history o f epilepsy, its use is controversial in patients who 
do have a history o f epilepsy. There have been reports that propofol causes convulsions and
9 0 1involuntary movements in such patients. However, these seizure-like activities may be 
opisthotonos and subcortical depression and do not appear to cause seizure-like activity on
909EEG. " In other studies, propofol has been associated with anticonvulsant activity. It 
decreases the duration o f seizures in patients receiving electroconvulsive therapy.203
Sedation in the Intensive Care Unit (ICU)
Sedation in the ICU is primarily administered to reduce patient anxiety, facilitate 
mechanical ventilation, and promote sleep. One o f the primary attributes o f a sedative used 
in the ICU is rapid clinical recovery. When propofol 30 mcg/kg/min was compared with
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midazolam 1.7 mcg/kg/min for sedation o f 101 critically ill patients, recovery was more 
rapid with propofo l.204 Patients were also discontinued from ventilatory support in a mean 
o f 5 minutes in the propofol-sedated group versus a mean o f 148 minutes in the midazolam 
group. In other studies, no clinical differences were found between propofol and
174benzodiazepine infusion or bolus in the medical and post-surgical ICU.
After cardiac surgery, propofol is often used for sedation in the ICU. A study 
comparing midazolam (0.1 to 0.5 mg/kg/hr) with propofol (1 to 6 mg/kg/hr) found a 
significantly shorter weaning time with propofol compared with midazolam.205 Time from 
midazolam discontinuation to extubation was 97.9 +/- 54.6 hrs (48.9 +/- 47.2 hrs to the first 
disconnection, and 49.0 +/- 23.7 hrs to extubation). With propofol, time from 
discontinuation to extubation was 34.8 +/- 29.4 hrs (4.0 +/- 3.9 hrs to the first disconnection, 
and 30.8 +/- 29.2 hrs to extubation) (p < .0001).
However, concerns about cardiovascular stability with propofol remain. Several 
studies reported a reduction in mean arterial pressure o f 15% to 20% when a loading dose o f 
propofol (0.24 to 1.0 mg/kg) was administered following cardiac surgery.206,207 Although the 
mean arterial pressure remained low throughout the duration o f one o f the studies (10 hours), 
Roekaerts et al. found the level acceptable in this population (patients with an ejection
• ->()7fraction > 40% prior to surgery)."
The use o f propofol for sedation o f paediatric patients in the ICU remains 
controversial due to reports o f neurologic sequelae following withdrawal o f propofol and the
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occurrence o f metabolic acidosis following propofol infusions in patients with upper 
respiratory tract infections.179
Sedation in Monitored Anaesthetic Care
Several sedative regimens have been used as supplements to local or regional 
anaesthesia in monitored anaesthesia care but most have limitations. Benzodiazepines are 
effective for sedation but their effects are often long-lasting and delay recovery. Opioid 
analgesia has been combined with midazolam for monitored anaesthetic care, but this
*)AO
combination can cause respiratory depression." Propofol is a reliable alternative as a 
supplement to monitored anaesthetic care sedation. Its ability to produce euphoria-like
179mood alterations make it useful for procedures that require conscious sedation. To achieve 
monitored anaesthetic care, propofol can be used alone or in combination with low-dose
179midazolam (2 to 3 mg) and fentanyl (50 to 75 meg) or alfentanil (0.5 to 1 mg).
A comparison between propofol and midazolam during monitored anaesthetic care 
showed that propofol was associated with a lower incidence o f ongoing sedation, drowsiness, 
confusion, clumsiness, and amnesia than midazolam.209 Although it was noted that 
midazolam provided a greater degree o f intraoperative amnesia, residual am nesia continued 
for > 60 minutes postoperatively. Another study compared remifentanil. (0.5 mcg/kg 
followed by 0.05 mcg/kg/min) with propofol (0.5 mg/kg followed by 50 mcg/kg/m in).210 
Mean arterial pressure, heart rate and end-tidal C 02  remained stable in both groups. 
Respiratory rate and oxygen saturation values were lower in the remifentanil group than in
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the group receiving propofol and one patient in the remifentanil group required airway 
support. Patients receiving propofol had higher sedation levels, better amnesia and less 
frequent nausea and vomiting during the recovery phase while those in the remifentanil 
group had better pain and discomfort scores. Discharge times were similar in the two groups.
Propofol sedation has been given as an adjunct to local infiltration in a variety o f
9 11 919procedures including oral surgery, venous catheter placement, and breast biopsy. ’ " 
Propofol has also been used for upper gastrointestinal endoscopy. Compared with 
midazolam, propofol had a more rapid recovery time and fewer symptoms o f ongoing 
sedation and grogginess following surgery.213
For initiation o f monitored anaesthetic care, propofol should be administered either 
as an infusion or using a slow injection method. During initiation o f monitored anaesthetic 
care, cardiorespiratory function should be closely monitored. When propofol is 
administered as an infusion, the recommended rate is 100 to 150 mcg/kg/min for 3 to 5 
minutes then it is titrated to the desired clinical effect.174 Administration o f propofol via the 
slow injection method requires approximately 0.5 mg/kg administered over 3 to 5 minutes 
and titrated to clinical responses. Rapid bolus dosing should not be used in the elderly, 
debilitated, or ASA III or IV patients.
For maintenance o f monitored anaesthetic care, it is preferable to use a variable rate 
infusion method instead o f intermittent bolus doses.174 Maintenance rates o f 25 to 75 
mcg/kg/min during the first 10 to 15 minutes o f sedation are recommended and infusion
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rates should be decreased over time to 25 to 50 mcg/kg/min and adjusted to clinical 
responses. Alternatively, incremental bolus doses o f 10 mg or 20 mg can be used. In the 
elderly, debilitated, or ASA-PS III or IV patients, the rate o f administration should be over 3 
to 5 minutes and 80% o f the adult dose should be used.
Office-Based Sedation
Propofol is frequently used for office-based sedation because recovery is predictable 
and rapid after a single bolus dose as well as after continuous infusion. Clarke et al. studied 
the safety o f propofol for office-based sedation over a five year period in two endoscopy 
centres performing gastroscopy and/or colonoscopy.214 O f the 28,472 procedures performed, 
there were 185 sedation-related adverse events (6.5 per every 1000 procedures; 95% 
confidence interval (Cl): 5.6-7.4): 107 for airway or ventilation problems (3.8 per every 
1000 procedures; 95% Cl: 3.1-4.5) and 77 hypotensive episodes (2.7 per every 1000 
procedures; 95% Cl: 2.1-3.3). Four patients required transfer or admission to hospital, 
however there were no patients who required endotracheal intubation and no deaths. The 
authors concluded that general practitioners can safely use propofol for in-office sedation.
Another study evaluated the use o f propofol for office-based plastic surgery in 4.778 
outpatient plastic surgery procedures.215 The anaesthesia protocol included sedation with 
midazolam, propofol, and a narcotic. The average duration o f the procedures was 111 
minutes. No deaths, ventilator requirements, deep venous thromboses, or pulmonary emboli 
occurred. Dyspnoea occurred in 0.05 percent (n = 2) o f patients, protracted nausea and
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vomiting occurred in 0.2 percent (n = 6) o f patients, and unplanned hospital admission 
occurred in 0.05 percent (n = 2) o f patients.
Although office-based sedation is increasingly popular in the US, it is not practised 
in the United Kingdom. Most o f the procdures requiring minor sedation are performed in a 
hospital or an ambulatory facility.
Adverse Effects
Pain on Injection
One o f the most common problems with propofol sedation is the occurrence o f pain
^16 ^17 218on injection, which has been reported in about 70% o f patients." " The sensation o f 
pain is thought to be due to activation o f the kinin cascade system caused by propofol.219 
Several approaches have been used to reduce pain on injection. Local analgesics have been 
administered at the injection site including lidocaine 40 mg, metoclopramide 10 mg, and 
flurbiprofen axetil 50 mg. When preceded by venous occlusion for 2 minutes, these drugs 
proved comparable for reducing pain during the injection o f p ropofo l.220 In another study, 
investigators compared premixture with lidocaine, premedication with remifentanil, and a 
combination o f the two.221 The incidence o f pain on injection in the group receiving 2% 
lidocaine premixed with propofol (40 mg lignocaine in 180 mg propofol) was 35%. 
Pretreatment with remifentanil 2 mcg/kg IV over 30 seconds had a pain incidence o f  36%. 
In contrast, the combination o f lignocaine and remifentanil abolished moderate and severe
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pain on propofol injection and reduced the incidence o f pain to 10% (P = 0.003). Another 
approach is to administer a propofol formulation with a 10% emulsion o f long- and medium- 
chain triglycerides (LCT/MCT), however this approach appears to be less effective than 
propofol 1% with IV lignocaine pretreatment.216
Hypotension
Between 3% to 10% o f adults experience hypotension during monitored anaesthetic 
care with propofol.174 The incidence increases to 17% in paediatric patients.
The rate is higher during ICU sedation with propofol. In that setting 26% o f adults 
experience hypotension. During induction of anaesthesia, arterial hypotension can result 
from administration o f propofol if spontaneous ventilation is maintained, however this is 
typically not associated with a change in heart rate and minimal decrease in cardiac 
output.174 With positive pressure ventilation, cardiac output may become depressed, 
especially if an opioid is added as premedication, which can cause a further decline in 
cardiac output and respiratory drive. Patients who are at increased risk for hypotension 
during propofol sedation include those with compromised myocardial function, intravascular
17*1volume depletion, or abnormally low vascular tone (e.g., sepsis). Other factors that 
increase risk for hypotension include administration techniques. A rapid bolus injection o f 
propofol can result in undesirable cardiorespiratory depression. Similarly, if  an infusion rate 
o f 50 mcg/kg/min or higher is required to achieve adequate sedation in medical ICU patients 
or patients who have recovered from the effects o f general anaesthesia or deep sedation, this 
may also increase the likelihood o f hypotension. To minimize hypotension in intubated.
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mechanically ventilated adult patients, ICU sedation should be initiated slowly with a 
continuous infusion so propofol can be titrated to desired clinical effect without increasing 
the risk for hypotension.
Respiratory Depression
Both adults and paediatric patients are at increased risk for apnoea when propofol is 
used for induction o f anaesthesia. In clinical trials, 7% o f adult patients receiving propofol 
(2 to 2.5 mg/kg) on induction had apnoea lasting less than 30 seconds, 24% had apnoea 
lasting between 30 and 60 seconds, and 12% had apnoea lasting longer than 60 seconds.174 
When propofol was administered to paediatric patients for induction o f anaesthesia, 12% of 
patients who received bolus doses o f propofol (1 to 3.6 mg/kg) had apnoea lasting less than 
30 seconds, 10% had apnoea lasting between 30 and 60 seconds, and 5% had apnoea lasting 
more than 60 seconds.
If propofol is given as a rapid bolus injection during monitored anaesthetic care, 
cardiorespiratory depression can occur including hypotension, apnoea, airway obstruction,
1IXand oxygen desaturation. Elderly, debilitated, and ASA III or IV patients are at increased 
risk for respiratory depression as they may have exaggerated haemodynamic and respiratory 
responses to rapid bolus doses. The risk o f cardiorespiratory depression with propofol is 
also greater when infusion rates are rapidly increased. Thus, it is recommended that slow 
infusion or injection techniques are used during initiation o f monitored anaesthetic care and 
variable rate infusion is used during maintenance o f monitored anaesthetic care. This is
84
especially true for elderly or debilitated patients. When administered during maintenance o f 
general anaesthesia, propofol can reduce spontaneous minute ventilation and increase carbon 
dioxide tension.174 This effect can become more pronounced during rapid injection of 
propofol or when it is administered in conjunction with opioids or other sedatives.
Propofol Infusion Syndrome
In rare instances, prolonged propofol administration (>48 hours) at high doses (>4 
mg/kg/h) may cause a fatal complication called propofol infusion syndrome.222 This 
syndrome is associated with onset o f  metabolic acidosis, rhabdomyolysis o f skeletal and 
cardiac muscle, and arrhythmias that can manifest as bradycardia, atrial fibrillation, 
ventricular and supraventricular tachycardia, bundle branch block and asystole.222 223 In most 
cases, myocardial failure, renal failure, hepatomegaly, and death occur. In one recent report,
propofol infusion syndrome occurred at a low infusion rate (1.9-2.6 mg/kg/h) and proved
221
fatal. " Characteristic findings for propofol infusion syndrome include myoglobinuria, 
downsloping ST-segment elevation, an increase in plasma creatine kinase, troponin I, 
potassium, creatinine, azotaemia, malonylcamitine and C5-acylcamitine. If  these 
characteristic findings are observed, propofol should be immediately stopped and 
cardiocirculatory stabilization should be initiated along with corrections o f metabolic 
acidosis. When treating critically ill children and adults, propofol should not be 
administered for an extended period time (>48 hours) and doses should not exceed 4 to 5 
mg/kg/h.222
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C H A PTER  4
The use of propofol for its antiemetic effect: a survey of clinical practice in 
the United States.
Abstract
Introduction
Propofol is widely used for induction and maintenance o f anaesthesia. The choice for 
the selection o f propofol over other induction and maintenance agents depends on a number 
o f factors. This project investigates the use o f propofol by anaesthesiologists for its 
antiemetic effect, and to compare this with published evidence.
Methods
This survey was conducted with a random group o f  anaesthesiologists at the 1995 
American Society o f Anaesthesiologists annual meeting. One hundred and fifty 
anaesthesiologists were surveyed on how they use propofol to achieve an antiemetic effect.
Results
A large majority (84%) o f the anaesthesiologists surveyed use propofol for its 
antiemetic effect: 63% of these use propofol for induction only for cases > 1 hour to achieve 
an antiemetic effect. In addition 37% use a ‘sandwich’ technique, utilizing propofol at the 
beginning and end o f a case for a similar purpose. Simulation data demonstrate that
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following propofol 2 mg/kg its concentration will drop below 350 ng/ml at 32 minutes. 
Following 2 mg/kg and 20 mg within 10 minutes o f the end surgery, its concentration will 
drop below 350 ng/ml by 7 minutes after the 20mg bolus dose. This suggests that the plasma 
concentrations o f propofol when used in these cases may be below the effective range o f 
antiemetic effect.
Conclusions
Many anaesthesiologists use propofol for its antiemetic effect. However, 
pharmacokinetic data suggest that the use o f propofol purely for induction o f anaesthesia, or 
as part o f a “sandwich’ technique is unlikely to confer an antiemetic benefit. However, there 
is strong evidence for its antiemetic efficacy following anaesthesia maintained by a propofol 
infusion, and also for its use in the post-anaesthesia care unit (PACU).
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Introduction
Total intravenous anaesthesia before the introduction o f propofol was not widely 
practiced and was associated with prolonged recovery with many side effects. This was 
primarily due to the long duration o f action o f the older intravenous sedatives as well as 
older generation o f opioids. Since the introduction o f propofol into clinical practice in the 
eighties, practitioners have embraced it enthusiastically due to its many favourable 
properties which are associated with rapid and better quality o f  recovery from general 
anaesthesia. Not only was wakeup more rapid and predictable, patients also achieved
176recovery milestones much more rapidly, with more clear headedness and less drowsiness.
Another phenomenon that was noted with propofol maintained anaesthetic was the 
lower incidence o f PONV. A meta-analysis of studies involving propofol found a significant 
reduction in the incidence o f PONV when compared with inhalational agent maintained
133anaesthetic. Thus practitioners have been increasingly using propofol either at induction 
o f anaesthesia224'225, during maintenance o f anaesthesia226’227’228, or as a 'sandw ich' 
technique (at induction and again towards the end o f anaesthesia) I24-2295 with the hope o f 
achieving an antiemetic effect. There was a widespread belief that propofol use, regardless 
o f duration confers an antiemetic benefit. Hence, the purpose o f this questionnaire survey 
was to investigate how practitioners use propofol for its antiemetic effect and if  the 
perception o f antiemetic properties o f propofol when used in different settings is evidence 
based.
Method
We surveyed practising anaesthesiologists at random, attending the American 
Society o f Anaesthesiologists (ASA) annual meeting. One hundred and fifty questionnaires 
were handed out to anaesthesiologists standing in line to register at the meeting over a three- 
day period. Completed surveys were collected after registration. The survey was anonymous. 
Questions were asked concerning the use o f propofol specifically to reduce PONV.
(Appendix 1) The respondents were asked to check all boxes, which apply to their practice.
Plasma concentrations o f propofol were simulated based on a practice regimen using
'J
pharmacokinetic simulation software for a) an induction dose o f 2 mg/kg, and b) an 
induction dose o f 2 mg/kg, and a bolus o f 20 mg one hour later or 2 hours later. The second 
simulation represents two examples o f a simple ‘sandwich' technique. The simulation was 
based on the pharmacokinetic parameters for propofol reported by Gepts and colleagues.2'10 
Descriptive statistics were used to describe the data from the questionnaire.
Results
A total o f one hundred and fifty questionnaires were returned, which included 72 
respondents working in an academic institution and 78 working in private (i.e. non-academic) 
practice.
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The antiemetic potential o f propofol is a commonly cited reason for its use for 
induction and maintenance o f anaesthesia. In our survey, 84% of respondents used propofol 
for this reason. O f these, 75% used propofol for induction only, and 37% for induction and 
emergence. Total intravenous anaesthesia with propofol is practiced by up to 61% o f this 
group for at least a proportion o f their anaesthetics. The numbers do not add up to 100% 
because more than one response was allowed (i.e. an anaesthesiologist may use propofol for 
induction o f anaesthesia for some patients, but may also use the ‘sandwich’ technique on 
occasion for others). The results are shown in Table 7.
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Table 7. The use of propofol during anaesthesia, in expectation of an antiemetic effect.
Methods of propofol use % propofol users
Induction only : cases less than 60 min 75
: cases greater than 60 min 63
Induction/emergence cases less than 60 min 37
(i/e ‘‘sandwich” ) : cases greater than 60 min 36
Propofol-based : cases less than 60 min 61
: cases greater than 60 min 47
Tables 8 and 9 show the dose, frequency, and the time before the end o f the case that 
propofol was administered by those using a sandwich technique. A majority (75%) uses a 
small dose (10-20 mg), and start using propofol within 10 minutes o f the end o f the 
anaesthetic. Many anaesthetists in this group (40%) use only a single dose o f propofol at the 
end o f the case.
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Table 8. Propofol dose per bolus given towards the end of the case, and the frequency 
of dosing.
Bolus doses % Dose Frequency %
lOmg 29 once 40
20mg 45 1-4 min 35
30mg 10 5-10 min 14
40mg 5 11-15 min 6
>40mg 11 >15 min 5
Table 9. Of those administering bolus doses of propofol towards the end of the case, the 
time before the end that the bolus is administered.
Time to end case: %
1-5 min 27
6-10 min 40
11-15 min 17
16-30 min 12
31-45 min 4
Fifty-eight percent o f the respondents combined an additional antiemetic to enhance 
efficacy. Table 10 lists the various antiemetics and how often they were used. O f this group,
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65% administer the additional antiemetic at the beginning o f  the case, and 35% towards the 
end.
Table 10. Additional antiemetics given.
Antiemetic %
Droperidol 29
Ondansetron 30
Metoclopramide 27
Promethazine 3
Prochlorperazine 0
Other 1
Simulation o f propofol plasma and effect site concentration over time following a 2 
mg/kg bolus and 20 mg at 1 hour is illustrated in Figure 6. Propofol concentrations fall 
below 350 ng/ml within 32 minutes o f the initial bolus and by 7 minutes following the 
second 20 mg. bolus. An initial bolus o f either 20 or 40 mg o f propofol followed by an 
infusion of 1 mg/kg/hr will maintain a propofol plasma concentration between 350 and 500 
ng/ml.
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Figure 6. Simulated plasma propofol concentration (ng/ml) following an intravenous 
(IV) induction dose of 2 mg/kg, with a further bolus of 20 mg iv given at 60 minutes. 
The therapeutic plasma concentration (dotted line) is shown at 350 ng/ml.
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Discussion
This survey dem onstrated that 84% o f anaesthesiologists use propofol in the 
intraoperative period with the hope that it wall reduce PONV. Propofol was used as either a 
single induction dose (63-75% ), as a ‘sandwich technique’ (36-37% ), or as a continuous 
infusion (47-61%). The percentages represent the response for longer cases and shorter cases 
respectively. The most com m on dose o f  propofol used in the sandwich technique was 20 mg. 
Simulations o f  propofol disposition indicate that following an induction dose o f  2 mg/kg the
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propofol concentration at 32 minutes will fall below its anti-emetic therapeutic concentration, 
or by 7 minutes after a second dose o f 20 mg administered at 1 hour following induction 
(Figure 6).
A lower incidence o f PONV following propofol anaesthetic was claimed early 
following its introduction.231'232'233 A direct anti-emetic effect of propofol was first 
demonstrated by Borgeat234 23x236 and subsequently substantiated by several other authors.
Propofol-based anaesthetics (propofol induction and maintenance) have been 
associated with a low incidence o f PO N V .133’239,240 This is true when compared with 
anaesthetics maintained with volatile agents such as halothane,239,241 enflurane,240,242,243,244 
isoflurane,227,245,246,247 desflurane,248,249'250,251,252,253 or sevoflurane.254,255,256,257,258,259,260
Studies confirming the efficacy o f propofol as an antiemetic have almost invariably 
involved the use o f a propofol infusion, or an intermittent bolus technique for maintenance 
o f anaesthesia.163 245,261,262 This survey found that a large majority o f practising 
anaesthesiologists use propofol at induction for long and short cases, with the hope of 
achieving an antiemetic effect. However the scientific evidence for this is lacking. The lack 
o f efficacy o f a single dose o f propofol has been shown in many studies.241,242,2:*0,263 Indeed, 
some studies suggest that even a short intermittent bolus technique with propofol may not be 
superior to other intravenous induction agents, following cases with a relatively low emetic 
potential such as therapeutic termination o f pregnancy.224,264 A few studies show a trend for 
a reduction in PONV when patients were given propofol for induction o f anaesthesia only. 
The duration o f procedure in these studies were all relatively short (less than 30 minutes).
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Moreover this apparent trend failed to reach statistical significance in most o f the 
studies.245,265,266,267,268 There are exceptions, however. Rutter et al found, in patients 
undergoing minor gynaecological procedures, a significant reduction in PONV following 
incremental propofol, compared with incremental methohexital.^ Mirakhur et al 
demonstrated a significant reduction in early nausea, but not vomiting, following minor 
surgical procedures in children.269 Myles et al in a retrospective study found a modest
7  7 0reduction in PONV following propofol induction. These conflicting findings may be due 
in part to the relative emetogenic potential o f the operative procedure, individual differences 
in pharmacodynamic and the duration o f the cases. There is evidence that the antiemetic 
efficacy o f propofol is associated with a defined plasma concentration range.263 We 
demonstrated (see chapter 5) that plasm a propofol concentration for a 50% reduction in 
nausea scores is 343 ng/ml (10-90% Cl, plasma propofol concentration 200-600 ng/ml).271
Interestingly 63% of respondents admitted to using propofol as an induction agent 
for longer cases primarily with the expectation of an antiemetic effect. In addition 
approximately one-third o f respondents utilized a 'sandw ich' technique with the same 
expectation. O f those using this technique a majority used a low dose o f propofol (10-20 mg) 
and a significant number (40%) used only a single dose o f propofol. Figure 6 demonstrates 
the serum propofol level following a bolus o f propofol 2 mg/kg (a standard induction dose) 
declines rapidly and falls below 350 ng/ml after 32 minutes.271 A single bolus o f 20 mg 
propofol at 60 minutes leads the plasma level to rise into the therapeutic range for only 7 
minutes (Figure 6), which simulates the situation if a ‘sandwich’ technique is employed. In 
another study (see chapter 7) where we compared the use o f intraoperative propofol at
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different times during surgery with ondansetron administered at the beginning o f an 
isoflurane maintained anaesthetic, we found that a ‘sandwich’ technique did not confer any 
advantage with respect to PONV or more rapid recovery124 The group that had propofol at 
induction as well as maintenance had significantly greater efficacy compared with the 
ondansetron group. The incidence o f emesis and rescue antiemetic use was lower in the 
propofol group compared to the ondansetron group. However the group where propofol was 
administered at induction and towards the end o f surgery (sandwich technique) did not show 
a reduction in PONV compared with propofol used as the induction and throughout surgery. 
Simulations o f plasma propofol concentrations suggested that this group had a 
subtherapeutic level. Campbell and Thomas studied the efficacy o f a bolus dose o f propofol 
0.3 mg/kg given at the completion o f  surgery in a group o f patients having gynaecological
272laparoscopy, following thiopental induction and volatile maintenance o f anaesthesia. Not 
surprisingly, in light of our simulation data, no benefit was found, probably because an 
insufficient serum propofol concentration was achieved. Hence, it appears that propofol has 
a concentration response relationship for the prevention o f PONV.
In contrast to the findings above, Song et al have demonstrated a significant 
reduction in early (but not late) PONV using a ‘sandwich’ technique with sevoflurane 
anaesthesia, following laparoscopic cholecystectomy.273 This may be due to the shorter 
duration o f surgery in this study. If the anti-emetic effect o f propofol is related to its plasma 
concentration, our simulations indicate that any possible benefit o f a single dose either at 
induction or near the end o f surgery would disappear fairly rapidly. To achieve a therapeutic 
concentration post-operatively, a bolus o f 20-40 mg propofol followed by an infusion o f 1 -2
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mg/kg/hr must be used. Another alternative is to administer propofol 20 mg intermittently
74via a patient controlled device with a lock out interval o f 5 minutes.- (see chapter 6)
It is interesting to note that 58% o f respondents routinely add another antiemetic to 
their anaesthetic. Table 10 indicates that droperidol, metoclopramide, and ondansetron are 
given with approximately equal frequency. A majority (65%) gives the additional antiemetic 
at the beginning o f the case. Combining an additional antiemetic increases efficacy 
especially in high risk patients, as combinations o f a variety o f antiemetics have been shown
* 160 275 276 277 278 279to be more efficacious than using a single agent alone. ’ ’ ’ ’ ’ More recently,
Apfel and colleagues demonstrated an additive effect o f the various antiemetics, including 
propofol when used throughout the surgical procedure. Each antiemetic reduces the risk for 
developing PONV by about 25% .130
A limitation o f the study is the applicability o f the findings from this relatively small 
sample to a wider anaesthesiologist cohort. It is possible that anaesthesiologists attending an 
anaesthesiology meeting may have been better informed about the antiemetic effects o f 
propofol. Previous meetings have shown roughly equal attendance o f participants from 
academic and private practice background and hence strengthen the validity o f our results.
In conclusion, this study demonstrates that many anaesthesiologists use a single dose o f 
propofol to induce anaesthesia in expectation o f an antiemetic effect, even though scientific 
evidence supporting this is lacking. The lack o f efficacy o f a single induction dose o f propofol
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may be explained by the subtherapeutic concentration o f propofol. To achieve, and sustain a 
therapeutic antiemetic level, especially for longer cases (>1 hour), a propofol infusion at 
concentration levels used to maintain anaesthesia should be used.
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CH A PTER  5
Determination of Effective Plasma Concentrations of Propofol for 
The Treatment of Postoperative Nausea and Vomiting
Abstract
Background
Propofol is widely used as the anaesthetic maintenance agent and is associated with a 
lower incidence o f PONV. Small doses o f propofol appear to possess direct antiemetic 
properties. The doses used were arbitrary and not based on dose response analysis. We 
sought to determine the plasma concentrations o f propofol as an antiemetic for the effective 
treatment o f postoperative nausea and vomiting.
Methods
Adult patients with ASA physical status 1 or 2, who had surgery under general 
anaesthesia were approached to take part in the study. Only patients who had nausea with a 
verbal rating score (VRS) >5, retching or vomiting in the Post Anaesthetic Care Unit (PACU) 
participated in the study. Propofol was administered to target plasma concentrations o f 100, 
200, 400 and 800 ng/ml by a computer assisted continuous infusion (CACI) device. If the 
preceding concentration o f propofol did not adequately relieve symptoms, then the next step 
in incremental plasma concentration was taken. Treatment success was defined as having a 
50% or more reduction o f symptoms on the VRS. Fifteen minutes after achieving each target
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concentration, the patient was assessed on a VRS for nausea and an arterial blood sample 
was obtained. The measured plasma propofol concentrations were used for analysis o f data. 
Blood pressure, heart and respiratory rates, arterial blood saturation and sedation score were 
recorded. An overall satisfaction o f treatment was assessed.
Results
O f the total o f 89 patients consented for the study, 15 patients (17%) met entry 
criteria and were enrolled into the study. Five o f these patients also experienced 
retching/vomiting at the entry o f the study. Fourteen patients responded successfully to 
treatment. One patient did not achieve the required response at target plasma concentration 
o f 800 ng/ml. Hence, the success rate for the treatment o f PONV was 93%. The median 
plasma concentration that was associated with antiemetic response was 343 ng/ml. There 
was no difference in sedation scores from baseline and no episode o f desaturation. 
Haemodynamic parameters were stable during the study period.
Conclusions
Propofol is efficacious for the treatment o f postoperative nausea and vomiting at 
plasma concentrations that do not appear to produce increased sedation. Propofol is 
associated with minimal side effects and a great degree o f patient satisfaction. Simulations 
indicate that to achieve plasma propofol concentration o f 343 ng/ml, a bolus dose o f 10 mg 
followed by 10 pg.kg’1.m in'1 would be necessary.
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Introduction
Intraoperative maintenance o f anaesthesia with propofol is widely practiced and is 
associated with a lower incidence o f PONV compared to inhalational agent maintained 
anaesthetic.228'242'267'280,281 More recently, propofol in smaller doses had been used with 
success for the treatment o f chemotherapy-induced emesis234 as well as PONV.235 In the 
PONV study, Borgeat and colleagues randomized patients who developed PONV in the 
recovery room into either receiving propofol 10 mg i.v. or placebo (intralipid) bolus.
Patients who received propofol had a significant greater success rate (81% vs. 35%, p<0.05) 
when compared with placebo, but this response is short-lived. The doses that have been 
employed in these studies234,235 were chosen empirically and not based on any systematic 
dose response analysis. It was further demonstrated that the antiemetic action o f propofol 
was not due to the intralipid emulsion in the formulation and propofol has a direct antiemetic 
effect.282 Schulman et al in a case report, determined the plasm a concentration o f propofol
787for the successful treatment of nausea in a postoperative patient to be 197 ng/ml.
Given that propofol possesses antiemetic properties and studies to date have not 
systematically define the dose response relationship o f propofol for its antiemetic effect, this 
study’s aim was to determine the effective plasma concentration o f propofol when used as 
treatment for postoperative nausea, retching and/or vomiting using a Computer Assisted 
Continuous Infusion (CACI) device. The primary objective was to determine the 50th 
percentile o f the plasma propofol concentrations for the reduction o f nausea score o f at least 
50%.
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Methods
After Institutional Review Board approval, ASA physical status 1 or 2 male or non 
pregnant female patients between the ages o f 18 and 70 who were scheduled to have 
surgeries under general anaesthesia were approached to participate in this study. Patients 
who had received drugs with an antiemetic effect within 24 h prior to initiation o f 
anaesthesia, had previous allergy to propofol, had received an investigational drug within 
the past 30 days, had vomited or retched within the preceding 24 h, were twice their ideal 
body weight, or have significant organ dysfunction were excluded from the study. As this 
was a treatment study, we obtained informed consent from all potential study subjects in the 
preoperative screening clinic. Patients were provided with detailed explanation on the study 
protocol. Only subjects who met inclusion criteria as defined below were enrolled.
Patients were given a standardized general anaesthetic regimen. Fentanyl up to 100 
meg and midazolam up to 2 mg was used as premedication. Thiopental or propofol was used 
for induction o f anaesthesia. General anaesthesia was maintained with fentanyl up to 5 
mcg/kg/h, with nitrous oxide, oxygen and isoflurane to maintain haemodynamic variables 
within 20% o f baseline. The choice o f neuromuscular blocking drugs and reversal of 
neuromuscular blockade were left to the discretion o f the anaesthesia care providers.
Patients were extubated at the end o f the surgery and transferred to the PACU when awake, 
obey commands and met clinical criteria for extubation.
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A research personnel was with the patients at all time during their stay in the PACU. 
While in the PACU, patients were assessed on their presence o f nausea and vomiting 
symptoms. Those patients who developed symptoms o f severe nausea as judged by the 
Verbal Rating Score (VRS) score >5 retching or vomiting and requesting an antiemetic were 
formally studied.
A CACI device was used to deliver the propofol. CACI device is an infusion pump
284programmed with a pharmacokinetic model for the drug being infused. A pump control 
algorithm used a simulation o f the model, computed at frequent intervals, to determine the 
infusion rates required to theoretically achieve and maintain the specified plasm a drug
? o r
concentration and the pharmacokinetic data set used (Appendix 2) in this study was based 
on that by Gepts et al.230
Plasma concentration o f propofol or intralipid was achieved in an incremental step- 
up fashion, with the first target plasma concentration o f propofol at 100 ng/ml, followed by 
200, 400 and 800 ng/ml if  the preceding concentrations o f propofol did not adequately 
relieve symptoms. (Figure 7) Each target concentration was maintained for a minimum o f 15 
minutes. Patients were assessed on their nausea scores every 15 min during the study period.
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Figure 7. Study design. Targeted plasma propofol concentrations (ng/mL). Each 
plasma concentration was held for 15 min.
800
400
200
100
0
When the patients consented for the study, they were told that they would first 
receive propofol if they had symptoms o f nausea, retching and/or vomiting in the recovery 
period and would like to have an antiemetic to relieve or treat their symptoms. However, 
they could request for rescue antiemetic at any time during the study period. The 11 point 
VRS, 0-10 whole number linear scale to assess their severity o f symptoms, was also 
explained to them. Zero (0) described “no nausea' and 10 described ‘nausea as bad as it 
could be'.
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Prior to the commencement o f the propofol infusion, a baseline VRS for nausea was 
assessed. A separate intravenous cannula was established to deliver the study medication. A 
radial arterial cannula was inserted if  it had not already been placed for surgical indications. 
An arterial blood sample was taken to determine the baseline plasma propofol concentration. 
The propofol infusion was set at a target plasma concentration o f 100 ng/ml. Fifteen minutes 
after achieving each target concentration, the patient was assessed on a VRS for nausea and 
further arterial blood samples were obtained. Episodes o f retching and vomiting were 
recorded. Treatment was considered successful if  there was a 50% reduction o f symptoms or 
greater on the VRS. Otherwise, the next higher plasma concentration was targeted until 800 
ng/ml was reached. Successfully treated patients had the infusion continued at that target 
concentration for a further 2 hours. If the patients' VRS scores increased during the study 
period, the next higher target propofol concentration was delivered up to a maximum of 800 
ng/ml.
Blood pressure, heart and respiratory rates, arterial blood saturation with the use o f a 
pulse oximeter and observer assessment o f sedation score (Table 11) were recorded prior to 
the commencement o f the study, 15 minutes after each target plasma concentration and half 
hourly during the study period. An overall satisfaction o f treatment was assessed at 24 h 
after the study period.
Blood samples and assays for propofol concentrations
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Arterial samples were collected for whole blood propofol in heparinised tubes amd 
placed on ice. They were refrigerated at -4°C and the concentrations were measured by high- 
performance liquid chromatography (see appendix 3).
Table 11. Sedation scores
0 
1 
2
3
4
Statistical Analysis
Steady state plasma concentrations were correlated with nausea scores for each 
individual at the various time points. These data were then examined for plasma 
concentrations that bracketed the transition from “no response” to “response”. The mean o f 
resulting two plasma concentrations was computed for each individual. The median and 
percentiles of the individual means were taken to represent the study population. All 
calculations were performed with an Excel spreadsheet (Excel 7.0. Microsoft Corporation, 
Redmond WA. 1995).
completely awake 
awake but drowsy
asleep but responds to verbal commands 
asleep but responds to physical stimulus 
unarousable
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Results
A total o f 89 patients consented for the study. Fifteen patients (17% o f total) met 
entry criteria and were enrolled into the study. Fourteen patients completed the study. One 
patient did not achieve the required response at a target level o f 800 ng/ml and was not 
included in the analysis. Hence, the success rate was 93%. Five o f these patients also 
experienced retching/vomiting at the entry of the study and no patient had retching/vomiting 
at the end o f the study period. There were 2 male and 12 female patients. The Mean ± SD 
for age was 41.2 ± 12, for weight was 78.8 ± 15.4 kg and intraoperative fentanyl use was 
454 ± 187 pg. Nine patients received propofol intraoperatively for induction only.
The median (interquartile range) plasma concentration that was associated with 
antiemetic response was 343 (246-507) ng/ml. Other concentrations and associated study 
population percentiles are given in Table 12.
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Table 12. Plasma propofol concentrations associated with a successful treatment 
response in various percentiles of population.
Percentile o f population Propofol plasma concentrations 
(ng/ml)
10 71
25 246
50 325
75 507
90 578
The targeted and measured propofol plasma concentrations were close and there was 
no overlap between the different target and measured propofol concentrations (Figure 8).
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Data on measured plasm a propofol concentrations that bracketed the transition from 
“no response” and “response” vs. VRS for nausea are shown in figure 9. Nausea VRS at 
various time periods and plasma propofol concentrations immediately before response, at 
response and their arithmetic means for each subject are shown in table 13.
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Figure 9. Raw nausea score vs. measured plasma propofol concentrations that 
bracketed the transition from “no response” to “response” for each patient. Below: 
Plasma propofol concentrations and probability of response.
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There was no request for rescue antiemetic during the study period and no patient 
had a sedation score o f > 2 or an episode o f desaturation. There were no significant changes 
with respect to time in sedation score (Table 14), neither were there changes in haemoglobin 
oxygen saturation, systolic and diastolic blood pressures and heart rate during the study.
Raw data on individual propofol concentrations are shown in figure 10. Only one 
patient had breakthrough nausea after initial control at plasma propofol concentration o f 200 
ng/ml but symptoms were controlled when the next higher plasma concentration (400 ng/nL)
I l l
was achieved. Thirteen out o f 14 patients rated the treatment as satisfactory or very 
satisfactory. One patient rated it as not satisfactory.
Figure 10. Individual plasm a propofol concentrations at various nausea scores.
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Table 13. Individual data on baseline VRS, VRS at treatment response and at the end of study period, measured plasma 
propofol concentrations at bracketed transition from “no response” to “treatment response” and the arithmetic means of 
the two propofol concentrations.
Patient
No.
Baseline
VRS
Treatment
Response
VRS
Final VRS 
(2 h)
[propofol] 
No response
[propofol]
Treatm ent Response
Arithmetic Mean
1 6 0 0 280 430 355
2 7 0 0 270 320 295
3 6 1 0 420 550 485
4 10 3 0 0 170 85
5 6 2 2 210 300 255
6 6 0 0 100 310 205
7 7 2 2 200 300 250
8 7 0 0 200 660 330
9 10 0 0 220 420 320
10 10 5 4 260 510 385
11 7 0 0 520 870 595
12 8 1 2 430 620 525
13 10 2 2 240 790 585
14 6 0 2 510 710 610
[propofol]: Plasma propofol concentration in ng/ml
Table 14. Sedation scores at the various target plasm a concentrations.
Target Plasm a Propofol N o . o f M edian 25 -  75' Percentile
C oncentrations (ng/m l) Patients Sedation Scores Sedation Scores
0 15 1 0-2
100 15 1 0-1
200 15 1 0-1
400 10 1 0-1
800 5 1 0-1
End o f  Study 15 0 0-1
D iscussions
The median (10th-90th percentile) concentration o f propofol for an antiemetic effect is 
325 (71-578) ng/mL. Propofol when administered in these concentration ranges did not 
result in significant sedation or change in haemodynamics and was well tolerated.
Propofol has been widely used for the maintenance o f anaesthesia. More recently, 
propofol has been used as an antiemetic for treatment o f both PONV23^  as well as
3^*4chemotherapy-induced- nausea and vomiting. Borgeat and colleagues used 17 pg/kg/min 
o f propofol infusion in a group o f patients receiving cisplatinum chemotherapy that had 
previously failed ondansetron and steroid during their initial chemotherapeutic treatment 
cycle. They found an incidence o f 89% success in this group o f patients. In the PONV 
settings, the same group of investigators reported the efficacy o f propofol 10 mg (1 mL) vs.
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intralipid for the treatment o f established PONV. They found a high success rate o f 81% in 
the propofol group (versus 35% in the intralipid group). However, the effect was relatively 
short lasting and 28% and 22% o f the propofol and intralipid patients, respectively, had 
relapse within 30 min following treatment. We demonstrated that the antiemetic effects o f 
propofol could be maintained if  the plasma concentration was within the therapeutic range. 
These results suggest that propofol efficacy is likely to be related to its plasma 
concentrations.
We performed a simulation based on Borgeat et a l’s235 propofol dosing regimen of 
17 pg/kg/min which resulted in a high degree o f efficacy in chemotherapy patients. The 
plasma concentrations o f propofol were between 300-500 ng/ml for most o f the 24 hour 
period. This is very similar to the median concentrations associated with successful PONV 
relief found in the present study. The 25%-75% plasma propofol concentrations for this 
study were between 246 and 507 ng/mL.
In a recent study, Pavlin et al investigated the clinical effects o f the sedative 
doses o f propofol and alfentanil, alone and in combination. Interestingly, no subject 
experienced nausea or vomiting during the study period in the propofol and the 
propofol/alfentanil groups. However, there was an incidence o f nausea o f 50% in the 
alfentanil only group. The plasma propofol concentrations in their subjects ranged 150—
600 ng/ml. The propofol concentrations in that study were almost identical to our results o f 
the 90% confidence level o f the anti-emetic action o f propofol.
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One o f the concerns o f using propofol in this setting is its sedative effects. However, 
the range o f the propofol concentrations associated with antiemetic effects (10th to 90th 
percentile concentrations are 71-578 ng/mL) appear to be much lower than the propofol
'JQf. ,
concentrations needed for sedation (1500-2000 ng/ml) and maintenance o f general 
anaesthesia (3000-10,000 ng/m l).176,287 None o f the patients in this study demonstrated 
sedation. Hence, although propofol has the potential to provide sedation the concentrations 
required for the treatment o f PONV are well below these values and thus can be used in 
appropriately monitored settings.
There is much evidence in the literature that appropriate plasma concentrations of
272propofol are essential to demonstrate an antiemetic effect. Campbell et al administered 
propofol 0.3 mg/kg at the completion o f surgery and found that it had no effect in 
preventing PONV. Borgeat at al235 found that the patient successfully treated with 10 mg 
bolus o f propofol had relapse within 30 min after therapy. Simulation o f 10 and 20 mg 
bolus dose o f propofol revealed that the plasma concentration only remain above 300-500 
ng/ml for 5-8 min after administration. However, a propofol loading dose o f 10 mg 
followed by a continuous infusion o f 10 pg/kg/min provides an immediate achievement 
and subsequent maintenance o f an effective plasma concentration for the treatment of 
PONV. One patient in the present study did not achieve the required response and was 
considered treatment failure. This patient’s highest plasma propofol concentration was 830 
ng/ml. Hence it is important to note that high concentrations o f propofol may not be 
effective in some patients in the treatment o f PONV.
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General anaesthetics maintained with propofol are associated with a lower 
incidence o f PONV compared to enflurane240,242,243, isoflurane288 or desflurane249,250 based 
anaesthetics. These findings only hold true when propofol is used throughout the procedure. 
The protective effect o f propofol against PONV seems to disappear when it is used as an 
induction drug only. Although none o f these studies measured the plasma concentrations o f 
propofol during the recovery period, the findings may not be surprising when one 
considers that there is a therapeutic range o f propofol to successfully prevent PONV.
The mechanism of action o f propofol as an antiemetic is not known. It has been
289postulated that propofol may act via an antidopaminergic pathway. However, two recent 
studies have not been able to substantiate this claim. Appadu and colleagues290 showed that
291propofol did not interact strongly with D2 dopamine receptors. Hvarfner and associates, 
on the other hand, investigated subhypnotic doses of propofol infusion in healthy volunteers 
after they were given apomorphine (acting on dopamine D2 receptors in the chemoreceptor 
trigger zone) to induce vomiting. They concluded that propofol given in a nonsedative dose 
has no effect on apomorphine-induced vomiting. However, the total amount o f apomorphine 
given to induce vomiting was significantly larger during propofol sedation than during 
saline infusion. They also did not measure blood concentrations o f propofol. Several 
mechanisms may be possible for propofol's antiemetic action. Propofol may have a direct 
depressant effect on the chemoreceptor trigger zone, the vagal nuclei, and other centres 
implicated in nausea and vomiting. Propofol also has been shown to decrease synaptic 
transmission in the olfactory cortex, suggesting a decrease in the release o f excitatory amino 
acids such as glutamate and aspartate, which may be related to its antiemetic activity.292
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Recently researchers showed that prolonged infusions o f propofol (20 to 25 mg/kg/h for 6 h) 
cause decreased concentrations o f serotonin in the area postrema,293 and this may be 
mediated through gamma-aminobutyric acidA receptor mechanisms.294
One o f the limitations o f the study is the lack o f a control group. The original plan 
was to include one. However, the institutional review board was adamant that it was 
unethical to include a placebo group as it was a PONV treatment study. Hence, the relief of 
PONV symptoms could have been due to some o f the risk factors, e.g. inhalational agents 
and opioid’s concentrations dissipating.
In summary we have defined the 50th percentiles for the plasma concentration of 
propofol associated with 50% reduction in nausea scores to be 343 ng/ml and the 10th to 
90th percentile for similar outcome to be between 71 to 592 ng/ml. Based on simulation, 
the 50th percentile concentration can be achieved by a bolus dose o f 10 mg followed by a 
continuous infusion o f 10 pg/kg/min. This dose range does not cause significant sedation. 
Propofol as an antiemetic is associated with minimal side effects and a high degree o f 
patient satisfaction.
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CH A PTER  6
Comparison of Two Doses of Propofol vs. Placebo in Patient Controlled 
Nausea And Vomiting.
Abstract
Background
The role of propofol for the treatment of PONV is not well established. Empirical 
doses have previously been used to test the efficacy o f propofol for treatment o f PONV. We 
determined the plasma concentration o f propofol for the effective treatment o f PONV. Using 
this information, we designed this study to determine the efficacy and safety o f two small 
doses of propofol administered by patient-controlled device for the treatment o f established 
PONV.
Methods
Patients presenting for an ambulatory surgery under general anaesthesia were 
recruited. A standardized general anaesthetic regimen was prescribed. Those who 
experienced significant nausea and/or emesis in the recovery room were randomized to 
receive demand doses o f propofol 20 mg (Group L), propofol 40 mg (Group H) or intralipid
119
(placebo-P). Study medications were prepared in equal volumes and were administered with 
a patient-controlled delivery device for 2 hours. The following parameters: nausea, vomiting, 
rescue antiemetic use, recovery profile, study drug administration history and satisfaction 
with treatment were assessed.
Results
Sixty-nine patients were enrolled in the study. Patient demographics were similar 
between the groups. The nausea score on average for a patient in groups L and H was 25% 
and 29% less than P (p<0.05). This difference was apparent 15 min after initiation o f therapy. 
More placebo patients vomited (L:12%, H:23% and P:56%; p=0.003) and needed rescue 
antiemetics (L:17%, H:23% and P:70%; p=0.001) compared with treatment groups. Placebo 
patients had a 9 and a 4 fold increase in risk o f emesis and a 10 and an 8 fold increase in the 
likelihood o f using a rescue antiemetic compared to groups L and H respectively. Sedation 
scores were similar between groups. Propofol treated patients had shorter PACU stay and 
higher satisfaction with their control o f PONV than placebo (p<0.01). There were 2 episodes 
o f over sedation in the 40 mg propofol group but did not result in any adverse outcome.
Conclusions
Propofol appears to be safe and effective in treating PONV with great degree of 
patient satisfaction. A demand dose of 20 mg is recommended for treating PONV.
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Introduction
The use o f propofol as a maintenance anaesthetic agent intraoperatively is associated 
with a reduced incidence o f PONV.227,237,270 However, the use o f small doses o f propofol as 
a direct antiemetic has produced mixed results. Borgeat et al. demonstrated that propofol 10 
mg were efficacious in treating PONV.235 On the other hand, Zestos et al. found propofol in 
small doses (0.2 mg/kg) were no difference in efficacy for the treatment o f PONV compared 
to placebo.295 The use o f subhypnotic doses o f propofol infusion for the prevention of 
PONV has also not been proven conclusively. Although Ewalenko et al. demonstrated the 
efficacy o f propofol when administered as an infusion postoperatively, other investigators
296 297 298have not been able to produce similar results. ’
Having defined the median concentration of propofol for 50% reduction in the 
nausea scores271, this study was designed to investigate the safety and efficacy o f propofol 
for the treatment o f PONV, and the feasibility o f its delivery by a patient-controlled device.
Methods
After Institutional Review Board approval and written informed patient consent,
ASA physical status I and II adult patients having day surgery with high emetogenic 
potential under general anaesthesia were approached to participate in the study. Patients who 
received an antiemetic on a regular basis or within 3 days o f the study, who had symptoms 
o f nausea or/and vomiting within 24 hours, allergic to propofol, or not able to use a patient-
121
controlled analgesia (PCA) device were excluded from the study. A PCA machine 
(Lifecare™ PCA, Abbott Laboratory, Chicago, IL) was used to deliver the study solution.
All patients were instructed on the use o f the device during the pre-operative period. Patients 
received a standardized general anaesthetic which consisted o f premedication with 
midazolam 1-2 mg, induction with fentanyl 2-3 pg/kg, thiopental 3-5 mg/kg and anaesthesia 
was maintained with fentanyl < 4 pg/kg/h, isoflurane 0.5-1.5%, N 2O 66% in O2. Tracheal 
intubation and subsequent neuromuscular blockade were achieved with rocuronium or 
vecuronium. At the end o f surgery, neuromuscular blockade was antagonized by 
glycopyrrolate 0.01 mg/kg and neostigmine 0.07 mg/kg.
In the postanaesthetic care unit (PACU), patients who experienced significant nausea 
(nausea score >5/10) and/or emesis, and requesting an antiemetic within 1 h o f entry into 
the PACU, were enrolled. They were randomized to receive, in a double-blind fashion, 
propofol 20 mg (Group L), propofol 40 mg (Group H) or placebo (intralipid-Group P). The 
study drugs were prepared by the investigational drug pharmacy department in a 30 ml clear 
glass syringe with equal volume (4 ml) for each patient demand, and a lockout interval o f 5 
min with no maximum dose limit was prescribed. In group L, the volume o f study solution 
was made up to 4 ml with 2 ml o f intralipid and the placebo group received 4 ml o f intralipid, 
to maintain complete blinding o f the study solution. Rescue antiemetic (ondansetron 4mg 
i.v.) was administered when patient had nausea score > 4, two or more episodes o f emesis or 
retching within 30 min or upon patient’s request. The administration o f propofol was 
discontinued after 2 hours. Patients were cared for in the PACU during the duration o f the 
study.
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The following variables were assessed prior to initiating treatment and at 15 and 30 
min, 1, 1.5 and 2 h thereafter: nausea verbal rating scores (0-10), episodes o f 
vomiting/retching, rescue antiemetic use, sedation scores (Table 15), respiratory rate and 
haemodynamics (heart rate, blood pressure and peripheral arterial oxygenation).
Table 15. Modified Observ er’s Assessment of Alertness/Sedation Scale
Response Score level
Completely awake 5
Awake but lethargic response to name spoken in normal tone 4
Asleep but responds to loud verbal command 3
Asleep but responds to shaking 2
Does not respond to shaking 1
Does not respond to noxious stimulus 0
The time to readiness for PACU discharge was noted. Patients were discharged when 
discharge criteria were met. Satisfaction with treatment (satisfied, neither satisfied nor 
dissatisfied, dissatisfied) were assessed at the end o f the study period. Data on patient's 
study drug met and unmet demands, doses used were retrieved from the PCA machine. 
Propofol utilization information were downloaded and the minimum effective plasma 
propofol concentrations (concentrations at the point when patients self-administered a dose) 
were simulated using a previously published propofol pharmacokinetic data set.230 A 
questionnaire on the incidence o f post-discharge nausea, vomiting and satisfaction with
123
treatment were obtained at 24 h. Patients were asked to send back the questionnaire in a self- 
addressed envelope.
Sample size was estimated based on a two-tailed test o f the difference between 
proportions in independent groups at alpha=0.05.299 As there were no previous data on the 
efficacy o f propofol for the treatment o f PONV using this regimen, we based our power 
calculation on the incidence o f nausea in patients having high risk surgery.124 Considering 
nausea as the primary outcome, with a baseline (control) incidence o f 60%, a sample size of 
20 patients per group was found to provide 80% power to detect a difference o f 30%. 
Mantel-Haenszel test, generalized estimating equations and logistic regression model, were 
used to analyze the data. A p value <0.05 was considered significant.
Results
A total o f 200 patients were consented to participate in the study. Sixty nine patients 
met entry criteria and participated in the study. There were 24, 22 and 23 patients in the low 
dose propofol (Group L), high dose propofol (Group H) and the placebo (Group P) groups 
respectively. There were no significant differences among the groups with respect to age, 
weight, type o f surgery, duration o f  anaesthesia, previous history o f PONV or motion 
sickness, and use o f intraoperative and postoperative fentanyl (Table 16).
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Table 16. Patients’ Demographics
Low Dose High Dose
n=24 n=22
M:F 3:21 5:17
Age 40 ± 13 40 ± 13
Weight (kg) 81.2 ± 17.5 78.8 ± 24.4
Type o f surgery
Gynaecology 7 8
Breast 7 6
ENT 5 5
General 5 3
Surgical duration (h) 2.3 ± 1.4 2.2 ± 1.4
Intraoperative fentanyl use (pg) 429 ± 275 440 ± 379
Postoperative fentanyl use (pg) 17 ± 34 23 ±41
Previous history o f PONV/motion 8/7 10/9
sickness
Values are numbers or mean ± SD
Placebo
n=23
2:21 
43 ± 11 
81.6 ± 20.1
5
4 
9
5
2.2 ± 1.5 
380 ± 250  
29 ± 4 8  
7/7
All three groups demonstrated decreasing severity o f nausea over time (Figure 11). 
Patients in the low dose group had a 25% less likelihood o f being nauseous and patients in 
the high dose group had a 29% less likelihood o f being nauseous compared with the placebo
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group (L vs. P: p=0.03, H vs. P: p=0.006). The difference in nausea scores between 
treatment groups and placebo was apparent at 15 min after initiation of therapy and this 
difference was seen throughout the study period. The complete response rate (no nausea, 
vomiting or rescue antiemetic use) at 2 hours was significantly higher in the propofol treated 
groups than placebo [L: 19/24 (79%), H: 16/22 (73%) and P: 5/23 (22%); p=0.01]. There 
were significantly more patients in the placebo group who experienced vomiting [L:3/24 
(12%), H:5/22 (23%) and P: 13/23 (56%); p=0.003] and the use o f rescue antiemetic [L:4/24 
(17%), H:5/22 (23%) and P: 16/23 (70%); p=0.001] compared with the L and H dose 
propofol groups (Table 17). The odds ratio o f emesis in the low and high dose propofol 
groups were 0.11 (95% Cl 0.02-0.43) and 0.23 (95% Cl 0.06-0.78) compared with placebo 
(The placebo group had a 9 and a 4 fold increase in risk o f emesis compared to the low and 
high dose groups). The odds ratio o f rescue antiemetic use in the low and high dose groups 
were 0.10 (Cl 0.04-0.5) and 0.13 (Cl 0.03-0.46) compared with placebo.
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Figure 11. Nausea scores (VRS) versus time.
Nausea Scores vs. Time
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Values are mean and standard error bars.
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Table 17. Patients’ response, time to readiness for discharge and satisfaction with 
postoperative nausea and vomiting control in post anaesthetic care unit and at 24 hours.
2 hours 24 hours
Low
Dose
n=24
High
Dose
n=22
Placebo
n=23
Low
Dose
n=24
High
Dose
n=22
Placebo
n=23
Complete response* 19(79) 16(73) 5 (2 2 )* 12(50) 12(55) 8(35)
Vomiting 3 (12 ) 5 (23) 13 (56) f 8(33) 8(36) 10(43)
Rescue antiemetic 4 (1 7 ) 5 (23) 16 (7 0 )J
PACU discharge 
readiness (min)
131 ± 3 5 141 ± 3 4 191 ± 9 2  §
Patient Satisfaction
Satisfied 2 3(96) 21 (95) 10(43) 22 (92) 16(76) 12(52)
Neither satisfied nor 1(4) 1(5) 3 (13) 2 (8 ) 2(10) 4(17)
dissatisfied
Dissatisfied 0 0 10(44) 0 3(14) 7(31)
Values are numbers (percentages) or mean ± SD
*p=0.01, tp=0.003, Jp=0.001, §p=0.005; p values indicate placebo vs. propofol low and 
high dose groups.
PACU discharge criteria: haemodynamically stable, protective reflex present, operative pain 
controlled, absence o f severe nausea or active vomiting, skin warm and dry, absence of 
bladder distention, oral temperature >35°C.
^Complete response rate at 24 hours was no nausea and vomiting.
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The time to readiness for PACU discharge was significantly shorter in the low and 
high dose propofol groups compared to the placebo groups. (L: 131 ± 35  min, H: 141 ± 34 
min, P: 191 ± 92 min; p=0.005). Two patients in the placebo group had to be admitted due to 
persistent and uncontrolled nausea and vomiting. There was no difference in sedation scores 
between the groups (Figure 12).
Figure 12. Sedation scores versus time.
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However, 2 patients in the high dose propofol group experienced over-sedation; one 
patient had a sedation score o f 3 (asleep but responds to loud verbal command), and another 
had a brief episode o f  apnoea with a sedation score o f 1 (does not respond to shaking). No 
differences in pain scores, blood pressure, heart rate, respiratory rate, blood oxygen 
saturation were detected between the groups.
The propofol treated patients were also more satisfied with their control o f PONV 
compared to placebo during their recovery room stay as well as at 24 h after discharge , 
p<0.05 (Table 18). Ninety six percent and 95% of the patients in the low and high dose 
propofol groups respectively were satisfied with the treatment compared to 43% in the 
placebo groups, p<0.05. Similar trends were observed at 24 hours.
Total propofol dose and patients’ successful as well as unmet demands are presented 
in Table 18. There was a statistically significant difference in the unmet demands between 
the propofol treatment groups compared with placebo group. Figure 13 represents the 
individual patient data o f the simulated minimum effective plasma propofol concentrations 
(MEC) for the two propofol treatment groups. The simulation was based on the timed doses 
administered by each patient via the patient-controlled device. The median (25-75th 
percentile) o f the simulated MEC o f propofol for the low and high dose groups were 174 
ng/ml (170-297) and 296 ng/ml (240-437), respectively.
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Table 18. The total dose o f propofol administered, the number of successful deliveries and 
unmet patient demands.
Low Dose 
(n=22)
High Dose 
(n=22)
Placebo
(n=23)
p value
Total
Propofol (mg)
100±60 200±80 0
Successful
Deliveries
5 ± 3 
(5, 2-4)
5 ± 2 
(5, 2-4)
8 ± 3 
(7, 2-6)
0.0003
Unmet
Demands
3 ± 4 
(3, 2-6)
2 ± 4 
(2, 1-5)
68 ± 136 
12(5-21)
0.0001
Values are mean ± SD, (median, interquartile range)
Figure 13. Simulated minimum plasma propofol concentrations in the high (40 mg) 
and low (20 mg) dose propofol treatment groups.
8 0 0 1
6 0 0 -
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Discussions
Subhypnotic doses o f propofol are efficacious for the treatment o f PONV and are 
associated with an earlier readiness for PACU discharge and greater degree o f patient 
satisfaction. A patient-controlled device may be used to deliver propofol in small boluses 
(20 mg) for this purpose and is safe in a PACU environment.
A number o f investigators have demonstrated that intraoperative use o f propofol for 
maintenance o f anaesthesia is associated with a lower incidence o f PONV compared to 
patients anaesthetized with inhalational agents.240,242,249 288 More recently, propofol in 
subhypnotic doses have been used with success for the treatment o f chemotherapy-induced 
emesis234 as well as PONV.235,283 The antiemetic action o f propofol is not due to the
9 89intralipid emulsion in the formulation . However, the efficacy o f sub-hypnotic doses of 
propofol as a direct antiemetic has not been proven conclusively. In a relatively small study, 
Zestos et al. found that propofol 0.2 mg/kg was no more effective than placebo when 
administered for the treatment for PONV.295
The use o f subhypnotic doses o f  propofol administered as an infusion for the
9 0 (\ 9 0 7  9 0 8prevention o f PONV have also produced mixed results. ’ ’ Although a number of
studies have demonstrated efficacy when propofol was used as a low dose infusion (1-2 
mg/kg/h) 283 2%9 others have failed to show such results using similar infusion regimen.297,298 
The dosing regimen employed in this study was based on our previous study where we 
defined the plasma concentrations o f propofol for a 50% reduction in nausea scores to be
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343 ng/ml.271 Pharmacokinetic simulation suggested a bolus dose o f 20-40 mg every 10 
minutes would be required to achieve and maintain this concentration range. This study 
confirms that doses able to provide such concentration range are more effective than placebo 
in controlling PONV.
The concept o f patient-controlled analgesia in the post-operative settings has been 
widely accepted and resulted in better pain relief and a great degree o f patient satisfaction. 
3oo,3oi f i r s t  rep0rted study where propofol was used as antiemetic delivered by a
patient-controlled device. Patient-controlled delivery device is a convenient way o f drug 
delivery, without involving the nurses in the recovery room who may have 3-4 patients to 
attend to at anytime. In addition, the pharmacokinetics o f propofol makes it an ideal drug for 
patient-controlled delivery. This study demonstrated that patient-controlled antiemetic drug 
delivery is a feasible and safe technique. However, future studies are needed to compare the 
cost benefit ratio o f this with other methods o f deliveries, such as small dose continuous 
infusion or nurse administered propofol, and the use o f other antiemetics.
Patients who received propofol also resulted in a shorter PACU stay and improved 
patient satisfaction. This may be related to the more rapid and successful control o f PONV. 
Although placebo effect cannot be ruled out completely, however, we believe its effect is 
small and we were able to have effective blinding o f the groups. The placebo group had poor 
control with symptoms o f nausea and vomiting and more patients rated poor satisfaction 
with the treatment. The commonly held notion that nausea and vomiting in the immediate 
postoperative period are usually brief and get better without treatment is also untrue. As
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demonstrated in this study, patients in the placebo group were more likely to have persistent 
nausea and vomiting.
Based on the individual patient’s dose and time o f propofol administration, we 
simulated the minimum effective propofol concentrations, i.e. the concentrations just before 
each dose. This yielded a median simulated minimum effective plasma propofol 
concentrations o f 174 ng/ml (interquartile range 170-297 ng/ml) and 296 ng/ml (interquartile 
range 240-437 ng/ml) for the low and high dose groups respectively. As these are the 
simulated minimum effective concentrations, they are expectedly lower than the 343 ng/ml 
reported for the median plasma propofol concentrations associated with successful control of 
nausea. The simulated narrow interquartile range o f propofol concentrations indicates that 
inter-patient variability o f the m inimum effective antiemetic concentration o f propofol is 
small and well below that needed for sedation (900 -  1300 ng/ml)302 and maintenance of 
general anaesthesia (3000-10,000 ng/m l).176
A previous study compared the use o f intraoperative propofol with ondansetron 
administered at the beginning o f an isoflurane maintained anaesthetic.124 The group that had 
propofol at induction as well as maintenance had significantly greater efficacy compared 
with the ondansetron group. The incidence of emesis and rescue antiemetic use was lower in 
the propofol group. However, the group where propofol was administered at induction and 
towards the end o f surgery (sandwich technique)124 was not as protective against PONV. 
Simulations o f plasma propofol concentrations suggested that this group had subtherapeutic
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drug levels.124 Hence, it appears that propofol has a concentration response relationship for 
the prevention o f PONV.
It was interesting to note that patients in the low dose propofol group had a lower 
risk o f subsequent emesis and likelihood o f using a rescue antiemetic compared with the 
high dose group. It appeared that propofol used as an antiemetic may have a ceiling effect at 
about 20 mg per dose. We do not have specific explanation for this phenomenon. It may be 
that patients in the high dose propofol group were more sedated and less clear headed, which 
could be more susceptible to emesis. Two patients in the high dose group experienced over 
sedation (OAA/S scores o f 3 and 1 respectively). However, their peripheral oxygen 
saturations were above 96%. One o f these patients had surgery lasting 3.5 hours and 
received 980 pg fentanyl intraoperatively. Hence, it is important to realize that high doses of 
propofol in combination with another sedative can result in increased sedation.
Patients’ met and unmet demand data and their satisfaction with treatment provides 
the most compelling evidence that propofol possess antiemetic properties. Patients in the 
placebo group did not receive relief o f their symptoms and hence continue to demand study 
medication during the lock-out intervals. These patients had higher incidence o f vomiting, 
use o f rescue antiemetic and also rated this modality o f treatment poorly.
One o f the limitations o f the study was that we did not compare the propofol groups 
with a standard antiemetic group. Although additional information would have been helpful 
in clinical practice, this study design would also have required much larger sample size.
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However, future studies should com pared propofol used in this manner with another well 
established antiemetic.
In this study, we have dem onstrated that propofol is safe and effective for the 
treatment o f PONV and is associated with a shorter PACU stay and a high degree o f  patient 
satisfaction. The delivery o f propofol by a patient-controlled device is a feasible and safe 
technique. As there was no difference between the low and high dose groups in efficacy and 
the potential o f side effects with the high dose group, a 20 mg demand dose is 
recommended. Further studies are needed to compare the cost effectiv eness o f propofol 
patient-controlled antiemesis to other antiemetics, and the advantage o f this drug delivery 
system over more conventional methods.
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C H A PT E R  7
Double-blind, Randomized Comparison of Ondansetron and Various 
Intraoperative Propofol Regimens for the Prevention of Postoperative 
Nausea and Vomiting
Abstract
Background
Propofol maintained anaesthetic is associated with a reduced incidence o f  PONV. 
Many practitioners utilize propofol in a “sandwich" technique (propofol for induction and 
towards the end o f  surgery) for its antiemetic effects. We therefore com pare the efficacy o f 
ondansetron and intraoperative propofol given in various regimens in a placebo controlled 
study.
Methods
W omen patients scheduled for major breast surgery were approached for this study. 
Patients were randomly assigned to one o f four groups. Group O received 4 mg ondansetron 
in 10 ml 0.9% saline and groups PI, PIP, and PP received 10 ml 0.9% saline before 
anaesthesia induction. Group O received thiopental, isoflurane, nitrous oxide-oxygen, and 
fentanyl for anaesthesia. Group PI received propofol. isoflurane, nitrous oxide-oxygen, and
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fentanyl. Group PIP received propofol, isoflurane, nitrous oxide-oxygen, and fentanyl.
Thirty minutes before expected skin closure, isoflurane was discontinued and 50 to 150 
mcg/kg/min propofol was given intravenously to maintain anaesthesia. Group PP received 
propofol for induction and maintenance o f anaesthesia, nitrous oxide-oxygen, and fentanyl. 
Postoperative pain relief was provided with morphine adm inistered by a patient-controlled 
analgesia device. The incidence o f nausea and vomiting, requests for rescue antiem etic and 
sedation, pain scores, and haem odynam ic data were recorded at various time intervals for 24 
h.
Results
W ithin 6 h o f surgery, groups O and PP had a lower incidence o f nausea com pared 
with groups PI and PIP (P < 0.05). Fewer patients in group PP (19%) vom ited during the 24- 
h period compared with groups O (48%), PI (64%), and PIP (52%) (P < 0.05). The incidence 
o f antiemetic use was also less in group PP (P < 0.05). Patients in group PP had lower 
sedation scores at 30 min and at 1 h (P < 0.05). There were no differences am ong the groups 
in pain scores, blood pressure, heart rate, respiratory rate, and incidence o f pruritus.
Conclusions
Propofol adm inistered to induce and maintain anaesthesia is more effective than 
ondansetron (with thiopental-isoflurane anaesthesia) in preventing PONV and is associated
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with fewer requests for rescue antiemetic and sedation in the early phase o f recovery. It is 
equally effective in preventing postoperative nausea as ondansetron in the first 6 h after 
operation. Propofol used only as an induction agent or for induction and at the end o f 
surgery were not as protective against postoperative nausea and vomiting.
Introduction
-> -> a
Breast surgery is associated with a high incidence o f P O N V ." Propofol as an 
induction and maintenance agent has been associated with a lower incidence o f
->->o o i l  ->4-) ">57 ^gn
P O N V ." “ More recently, propofol in subhypnotic doses has been shown to be
effective against chem otherapy-induced236 nausea and vomiting and PONV.23x283 
Ondansetron is an effective antiemetic when compared with p l a c e b o , 304 
m etoclopram ide,30x306 and droperidol. ’0 308
Many clinicians utilize a propofol administration regimen, where propofol was used 
as an induction agent and the anaesthetic is then maintained with an inhalational agent. 
Towards the end o f the surgery, the inhalational agent is replaced with a propofol infusion 
until wake-up. This is com m only known as the “sandwich" technique. It is generally 
believed that the patients would achieve a faster wake-up with a lower incidence o f  PONV. 
However, no study directly com paring propofol given in this fashion has been reported. We 
therefore conducted a double-blind, randomized study to com pare the efficacy o f  
ondansetron and intraoperative propofol administered in various regimens.
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Methods
We enrolled 89 women classified as American Society o f  A naesthesiologists 
physical status 1 or 2 who were 18 to 70 y old and scheduled for major breast surgery 
(mastectomy, breast reconstruction, and insertion o f breast implants). We obtained 
institutional review board approval and patients gave their informed consent. Patients who 
had received drugs with an antiemetic effect within 24 h before initiation o f anaesthesia, had 
received an investigational drug w ithin the past 30 days, had vomited or retched w ithin the 
preceding 24 h, or were tw ice their ideal body weight were excluded from the study. All 
patients received 1 to 2 mg m idazolam  as premedication. Patients were random ly assigned 
to one o f four groups using com puter-generated random numbers concealed in envelopes. 
Patients in group O received 4 mg ondansetron in 10 ml 0.9% saline, and groups PI. PIP. 
and PP received 10 ml 0.9% saline before induction o f anaesthesia. Group O received 2 to 3 
micro gram/kg fentanyl and 3 to 5 mg/kg thiopental intravenously, followed by 0.5%  to 
1.5% isoflurane and 66% nitrous oxide in oxygen. Group PI received 2 to 3 m icrogram /kg 
fentanyl and 2 mg/kg propofol intravenously, followed by 0.5% to 1.5% isoflurane and 66% 
nitrous oxide in oxygen. Group PIP received 2 to 3 m icrogram/kg fentanyl and 2 mg/kg 
propofol given intravenously, followed by 0.5% to 1.5% isoflurane and 66% nitrous oxide in 
oxygen. Thirty minutes before expected skin closure, isoflurane was discontinued and 
propofol 50 to 150 m icrogram /kg/m in was administered intravenously to m aintain 
anaesthesia until wake-up. Group PP received 2 to 3 micro gram/kg fentanyl and 2 mg/kg 
propofol intravenously, followed by propofol 50 to 150 m icrogram /kg/m in intravenously 
and 66% nitrous oxide in oxygen. All patients received intravenous vecuronium to facilitate
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tracheal intubation and subsequent neurom uscular blockade during surgery. Fentanyl up to a 
maximum intravenous dose o f 5 m icrogram /kg/h was used during the procedure. At the end 
o f  surgery, 40 microgram/kg neostigm ine and 8 microgram/kg glycopyrrolate were used to 
antagonize neuromuscular blockade.
Postoperative pain relief was provided by morphine (1 mg/ml) through the patient- 
controlled analgesia device (L ife-care PCA, Abbott Laboratory, Chicago, IL) with standard 
settings (20 microgram/kg dem and dose, 8-min lock-out intervals with m axim um  dose o f 30 
mg in 4 h). The incidence o f nausea, retching, or vomiting and patient requests for rescue 
antiemetic (promethazine 12.5 mg i.v.) were recorded at 0.5. 1 ,6 . 12. 18. and 24 h by an 
independent observer blinded to the patients' treatment groups. Observer assessm ent o f 
sedation scores309 and patient assessm ent o f pain scores (0 = no pain; 1 = mild pain; 2 = 
moderate pain; 3 = severe pain; 4 = worst pain), incidence o f pruritus and other adverse 
events, blood pressure, and heart and respiratory rates were also recorded at the same time 
periods.
Sample size calculation and statistics
Sample size was estimated based on a two-tailed test o f  the difference between 
proportions in independent groups at alpha 0.05.299 Considering PONV as the primary 
outcome, with a baseline (control) incidence o f about 65%, a sample size o f 22 patients per 
group was found to provide 80% power to detect a difference o f  30%; that is, a reduction
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from 65% to 35% incidence. Based on the literature, a difference at least this large was 
expected between the control group (PI) and the treatm ent groups. Therefore, if  either the 
propofol treatment group or the ondansetron group showed a greater reduction than placebo, 
the study would have at least 80% power to detect this difference. Categorical data were 
analyzed using the chi-squared test, and continuous data were analyzed by one-way analysis 
o f  variance. Post hoc analysis (Bonferroni adjustment) was perform ed to detect intergroup 
differences. A probability value less than 0.05 was declared statistically significant.
Results
A total o f 89 patients com pleted the study. Groups O. PI, PIP, and PP consist o f  21, 
22, 25, and 21 patients, respectively. There were no significant differences am ong the 
groups with respect to age, weight, duration o f anaesthesia, previous history o f  PONV or 
motion sickness, and use o f intraoperative fentanyl and postoperative m orphine (Table 19). 
No patient had a nasogastric tube inserted during the study period.
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Table 19. Patient Demographic Data
Group O  
(n= 21 )
Group PI 
(n=22)
Group PIP 
( n - 2 5 )
Group PP 
( n - 2 1 )
P  Va lue
A g e  (yr) 45  ± 3 46  ± 12.5 46  ±  12.6 48  ±  14.2 N S
Weight  (kg) 70  ±  16 72 ±  19 69  ± 17 70 ±  16 N S
Duration o f  anaesthesia (h) 2 .6  ± 1.2 3.1 ±  1.5 2.8 ±  1.5 2.4 ±  1.3 N S
History o f  PON V/mot ion 5 6 7 5 N S
sickness  (n)
Intraoperative fentanyl (p g ) 305  ± 150 312 ± 200 332  ± 2 1 8 31 0  ± 2 3 9 N S
Postoperat ive (24 h) 1 0 ±  12 7 ± 6 1 0 ±  8 7 ± 8 N S
morphine (m g)
V alu es  are mean ±  SD.
N S  = not statistically signif icant.
The overall incidence o f  PONV was 57%. The incidence o f nausea in groups O and 
PP was less than in groups PI and PIP. This difference was statistically significant at 0.5, 1, 
and 6 h (P < 0.05). The incidence o f  postoperative vomiting and the use o f  rescue 
antiemetics within 24 h were significantly less in group PP com pared with the other three 
groups (P < 0.05). fable 20 summarizes the incidence o f nausea, vomiting, and use o f rescue 
antiemetics am ong the groups.
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T able 20. C u m ulative Incidence o f  P ostop erative  N au sea , V om iting  and 24-H our  
R equest.
Ti me
(h)
Group O  
(n = 21)  (%)
Group PI 
(n = 22) (%)
Group PIP 
(n =  2 5 )  (%)
Group PP 
(n =  2 1)  (%)
P  Value
Na use a 0.5 3 (1 4) 10(45) 9 ( 3 6 ) 1(5) <0 .05
1 4 ( 19 ) 11(50) 9( 3 6 ) 2( 10) <0 .05
6 5(2 4) 13(59) 1 1(44) 4 ( 1 9) <0 .05
12 9 ( 43 ) 13(59) 12(48) 6( 29) N S
18 13(62) 14(64) 14(56) 9( 43 ) N S
24 13(62) 15(68) 14(56) 9( 43 ) N S
V om it in g 0.5 1(5) 3 (14) 1(4) 0 N S
1 2( 10) 5(23) 3 (1 2) 1(5) N S
6 4( 19) 10(45) 8( 32) 2 (1 0) < 0 .0 5
12 8( 38) 13(59) 10(40) 2 (1 0) <0.01
18 8(3 8) 14(64) 12(48) 4 ( 1 9 ) <0 .05
24 10(48) 14(64) 13(52) 4 ( 1 9 ) <0 .05
Request  
for rescue  
antiemetic
24 13(62) 15(68) 15(60) 6 (2 9) <0 .05
Group PP patients consistently had lower sedation scores com pared with the other 
groups (Figure 14). These differences reached statistical significance for group PP versus 
group O at 30 min and for group PP versus group PIP 1 h after the operation (P < 0.05 after
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Bonferroni adjustm ent for post hoc comparison). There were no differences among the 
groups in pain scores, blood pressure, heart and respiratory rates, and incidence o f  pruritus.
Figure 14. Sedation  scores versus tim e (m ean +/- SD ). G roup PP had low er sedation  
scores com pared to the other groups. * (p<0.05 G roup PP vs. the other 3 groups)
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D iscussions
The combined overall incidence o f PONV in this population was 57% and was as 
high as 68% in patients receiving propofol as an induction agent only followed by
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maintenance o f  anaesthesia with isoflurane and nitrous oxide in oxygen. M ajor breast 
surgery is associated with a high incidence o f PONV. A previous study found the incidence 
o f  nausea or vom iting to be as high as 60% and that most o f these symptoms occur after 
patients leave the postoperative care unit.226 Recent reviews on PONV have not included 
major breast surgery as a high-risk procedure,1’16’104 310 311312 probably because sim ilar 
studies in this patient category have been lacking. However, there are many com m on 
denom inators that may account for the very high incidence. W omen have approxim ately two 
to three times the incidence o f  PONV compared with m en,116 311312 313 and the severity o f 
vomiting is also greater in w om en.314 This may be due in part due to the difference between 
men and women in levels o f sex horm ones.313
Ondansetron, a serotonin antagonist, is an effective antiemetic against PONV and 
has minimal side effects30'303'304 compared with other routinely used antiemetics. In 
particular, when com pared with droperidol. it is associated with less postoperative 
drowsiness, restlessness, anxiety, or dizziness.243 Although some data suggest that 
ondansetron is superior to droperidol in the outpatient population,308 the two drugs appear to 
have similar efficacy in inpatient populations.303’307
Propofol was recently found to possess direct antiemetic properties,233 and this
->o->
effect is not due to the intralipid em ulsion in the formulation o f propofol.~ " Propofol-based 
anaesthetics have been associated with a lower incidence o f PONV compared with
146
enflurane,240’242 243 isoflurane.288 or desflurane anaesthesia.249’2?0 These studies found a low 
incidence o f PONV only when propofol was used throughout the procedure. The protective 
effect o f propofol against PONV seemed to disappear when it was used as an induction 
agent only. We found that when propofol was used as an induction agent and anaesthesia 
was maintained with isoflurane, nitrous oxide, and oxygen (group PI), it was not protective 
against PONV. On the other hand, propofol used only as an induction agent has been 
associated with a lower incidence o f  PONV in relatively short surgical procedures (less than 
30 m in).245,266 Thus it is possible that a therapeutic range o f plasm a concentrations o f  
propofol, as has been shown in the previous chapter, is likely related to PONV protection.
We included group PIP (propofol as an induction agent and anaesthesia m aintained 
with isoflurane, nitrous oxide, and oxygen, followed by propofol substituted for isoflurane 
30 min before the expected end o f  surgery) because many believe that propofol used in this 
regimen might be associated with more rapid recovery and provide protection against PONV. 
Our study, however, dem onstrated that this technique, w'hich is popular in clinical practice, 
did not confer any advantage with respect to PONV or more rapid recovery as judged by 
sedation scores. In contrast, the group receiving propofol for m aintenance o f  anaesthesia did.
The plasm a concentration o f propofol for effective treatment o f  nausea was 350 
ng/ml in our previous study.~7I~83 T his was much less than that needed for sedation (1,500 to 
2,000 ng ml) and maintenance o f general anaesthesia (3.000 to 10.000 ng/ml). Borgeat and
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associates236 found an 85% to 90% success rate when propofol 17 microgram /kg/m in was 
used to control chem otherapy-induced nausea and vomiting in a group o f patients who did 
not respond to treatment with ondansetron and steroids during their previous chem otherapy 
cycle. We simulated their dosing regim en and showed that plasma concentrations o f 
propofol lie between 300 and 500 ng/ml for the 24-h period. The simulation was based on 
the pharmacokinetic param eters for propofol reported by Gepts and colleagues.230 
(Appendix 2) In addition, the plasm a concentrations o f propofol associated with at least a 
50% reduction o f postoperative nausea is 405 +/- 59 ng/ml (mean +/- SEM) with 95% 
confidence intervals o f  280 to 530 ng/ml. Using the data on propofol dosing regim ens in 
patients in groups PI, PIP. and PP, we similarly simulated the plasm a concentration o f 
propofol in each o f these patients for 6 h after the induction o f anaesthesia. The results o f the 
simulated data (Figure 15) showed that patients in group PP had higher plasm a 
concentrations o f  propofol com pared with those in groups PI and PIP (P < 0.01; analysis o f 
variance) at all times during the 6-h recovery period. The simulated median plasm a propofol 
concentration 1 h after term ination o f  infusion was 424 ng/ml for group PP, 128 ng/ml for 
group PIP, and 41 ng/ml for group PI. This pharmacokinetic simulation may explain the 
difference in incidence o f  PONV among the three groups. Furthermore, the "sandwich 
technique" may have been protective against PONV for the first hour (36% vs. 50% for 
postoperative nausea and 12% vs. 23% for postoperative vom iting for group PIP vs. control, 
respectively) or after surgery o f shorter duration, when the induction dose would contribute 
to the maintenance o f  therapeutic concentrations o f propofol to prevent nausea and vomiting 
for a longer period.
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Figure 15. Simulated plasma propofol concentrations for groups PI, PIP, and PP 6 h 
after completion of surgery. Bold lines indicate the median concentrations for each 
group. The upper bold line represents the m edian concentrations for G roup PP, m idd le bold 
line represents G roup PIP  and the bottom  bold line represents Group
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In th is study, the antiem etic effects o f  propofol and ondansetron  persisted  through 6
TAD
h. Paxton and cow orkers found that the low er visual analogue score for postoperative 
nausea associated  w ith ondansetron w hen com pared w ith o ther an tiem etics d isappeared  after
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4 h. Ondansetron has a relatively short half-life o f 2.8 +/- 0.6 h after a single 8-mg 
intravenous dose.316 Most o f the parent drug is metabolized by hydroxylation and excreted 
in the urine. Although the metabolites have some 5H T3-antagonist activity, they do not 
contribute significantly to the therapeutic effect. However, the efficacy o f ondansetron317 
and droperidol318 319 have been shown to exceed their elim ination half-lives. This suggests 
that redistribution and termination half-life alone may not have a direct relation with clinical 
efficacy. Factors such as diffusibility and retention o f drug within the site o f action (central 
receptors) may be important. Unfortunately there are no data on the influence o f these 
fac to rs/'18
One o f  the advantages o f ondansetron compared with phenothiazines such as 
droperidol, prochlorperazine, or promethazine is that it lacks the sedative effect commonly 
seen with the latter agent.320 In our study, we noted a significantly lower sedation score in 
the early recovery phase (up to 1 h) when propofol was the induction and the maintenance 
agent com pared with the other groups. The patients who received ondansetron (group O) 
had very similar sedation scores compared with those in the placebo group (PI), indicating 
the lack o f sedative effects o f ondansetron. The absence o f side effects is a particularly 
desirable characteristic o f any drug considered for antiem esis against PONV. Propofol, used 
for induction and maintenance, was effective in preventing PONV. was associated with 
early postoperative patient recovery, and did not cause other side effects.
In summary, propofol (when used to induce and m aintain anaesthesia) and 
ondansetron are equally effective for prophylaxis against postoperative nausea in the first 6
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h. Propofol used in this manner was more effective than ondansetron in decreasing the 
incidence o f  vom iting and the use o f rescue antiemetics and sedation in the early recovery 
period. Propofol used only as an induction agent (group PI) or for induction and at the end 
o f surgery (group PIP) were not as protective against PONY.
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CHAPTER 8
A Randomized Comparison of Propofol versus Inhalational Based 
Anaesthetic Multimodal Management Strategy for the Prevention of 
Postoperative Nausea and Vomiting.
Abstract:
Background
M ultimodal PONV prophylaxis management strategy appears to be superior to single 
agent prophylaxis. Propofol when given as the anaesthetic m aintenance agent has been 
shown to reduce PONV. We tested the hypothesis that a multim odal PONV prophylaxis 
regimen incorporating total intravenous anaesthesia (TIVA) with propofol, and a 
com bination o f ondansetron and droperidol, is more effective than a com bination o f the 
same antiemetics in the presence o f inhalational based anaesthetic or propofol alone.
Methods
Ninety patients undergoing laparoscopic cholecystectom y were randomized to one of 
three groups. G roup 1 (multimodal group) received TIVA with propofol, droperidol and 
ondansetron. Group 2 (combination group) received droperidol and ondansetron with 
isollurane and nitrous oxide for m aintenance o f anaesthesia. Group 3 (TIVA group) received
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propofol for induction and maintenance o f  anaesthesia. PONV outcome variables including 
complete response (no PONV and no rescue antiemetic), incidence o f nausea and vomiting 
and patient satisfaction on PONV control were assessed up to 24 hours.
Results
Complete response at 2 hours postoperatively. was 90 %, 63% and 66% in Groups 1, 
2 and 3, respectively (p<0.05 Group 1 vs. 2). At 24 hours, the com plete response was 80 %, 
63% and 43% in Groups 1, 2 and 3, respectively (p<0.05 Groups 1 vs. 3). Patient 
satisfaction was also greater in the multimodal group compared to the other two groups in 
PACU (p<0.05).
Conclusions
The multimodal m anagement strategy for PONV was associated with a higher 
complete response rate and greater patient satisfaction when com pared to sim ilar antiemetic 
prophylaxis with inhalational based anaesthetic or TIVA with propofol.
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Introduction
Laparoscopic surgery is increasingly replacing open abdominal procedures. 
Postoperative nausea and vomiting (PONV) are common after laparoscopic cholecystectom y 
with a reported incidence from 53-72 o / 0 ^ 7-<>>.32 i . j 22 ^  a e ^ 0 | 0 g y  0 f p o y jy  is often
multifactorial, there has been increasing interest in using a com bination o f antiem etics from 
different classes for PONV prophylaxis for more effective management. Total intravenous 
anaesthesia (TIVA) with propofol has been shown to be associated with less PONV
-> 4 0  249 *>88
compared with inhalational agents, especially in the early postoperative period." ’ The 
use o f  a multimodal approach incorporating both TIVA and a com bination o f antiem etic 
agents was reported to be associated with an incidence o f PONV below 10%. Published 
studies to date investigating a m ultim odal approach for PONV prophylaxis have com pared 
the multimodal regimen to standard balanced anaesthesia using a volatile agent with or 
w ithout a single agent antiemetic prophylaxis.167169 It is unclear if  the com bination o f two 
antiemetics in the presence o f TIVA with propofol is superior to com bination antiemetic 
regimen with volatile anaesthetic.
From our previous work, we demonstrated that propofol adm inistered as the sole 
anaesthetic conferred efficacy in reducing the incidence o f PONV. Therefore this 
prospective double-blind randomized controlled trial was designed to test the hypothesis that 
a multimodal PONV prophylaxis regimen incorporating TIVA with propofol, and a 
com bination o f  ondansetron and droperidol, is more effective than a com bination o f the
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same antiemetics in the presence o f  isoflurane/ nitrous oxide based anaesthetic, or TIVA 
with propofol in ambulatory patients undergoing laparoscopic cholecystectomy.
Methods
Patients scheduled for laparoscopic cholecystectomy were enrolled after obtaining 
IRB approval and written informed patient consent. Exclusion criteria were ASA physical 
status IV or V, antiemetic or glucocortiocosteroids use within 24 hours o f surgery , allergy 
to ondansetron, droperidol or propofol, pregnancy, breast feeding, obesity (BM I>34), mental 
retardation, or psychiatric illness. For women o f childbearing potential, a negative serum P- 
hCG test was confirmed before enrolment.
Anaesthetic technique was standardized. All patients received midazolam up to 2 mg 
IV and fentanyl up to 100 meg as premedication. Patients were randomly assigned to one o f 
three treatment groups. Random ization was achieved using a sealed envelope technique and 
was prepared by an independent personnel not associated with the study. In group 1 
(multimodal group), propofol 1.5-2.5 mg/kg was used for induction and 50-150 m cg/kg/m in 
for maintenance o f anaesthesia with 50 % oxygen in air (no nitrous oxide). Droperidol 0.625 
mg was given intravenously at induction o f anaesthesia and ondansetron 4 mg was given 
intravenously at the end o f  surgery. In group 2 (combination group), propofol 1.5-2.5 mg/kg 
was used for induction o f anaesthesia followed by maintenance with 0.5 -2 .5  % inspired 
isoflurane and 50 % nitrous oxide in oxygen. Droperidol 0.625 mg was given intravenously 
at induction o f anaesthesia and ondansetron 4 mg was given intravenously at the end o f
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surgery. Patients in group 3 (TIVA group) received propofol 1.5-2.5 mg/kg for induction 
and 50-150 m cg/kg/m in for maintenance o f anaesthesia with 50 % oxygen in air (no nitrous 
oxide). The patients' tracheas were intubated using a muscle relaxant o f the anaesthestist's 
choice. An orogastric tube was inserted for suction o f gastric contents following induction o f 
anaesthesia and was removed at the end o f surgery. Intraoperative analgesia was provided 
by fentanyl up to 5 mcg/kg/h. Ketorolac 30 mg i.v. was also given at the end o f  surgery. 
Local infiltration with 10 ml bupivacaine 0.5 % was adm inistered around the trocar incision 
sites. Muscle relaxation was reversed with neostigmine 70 m cg/kg and glycopyrrolate 10 
mcg/kg.
Data were collected by an independent research nurse unaware o f the patients' 
randomization. The duration o f  surgery and anaesthesia, as well as the length o f PACU stay 
were recorded. Postoperative assessm ents were made at 0, 30. 60. 90.120 min in PACU and 
at 24 h by telephone interview with a trained interviewer blinded to the patients' group. 
Nausea, emetic episodes, nausea score (11-point, linear num eric scale 0 -10 , where “0” 
represents no nausea and “ 10” represents worst nausea (the concept was explained to 
patients preoperatively), sedation scores (0-5) (modified observer’s assessm ent o f
777alertness/sedation scale -  Table 15) , and rescue antiemetic use were recorded during these
time intervals. The time to readiness for PACU discharge, when patients were fully awake, 
and oriented, with stable vital signs, minimal pain (<3 on a 0-10 scale) and were able to 
ambulate and not experiencing any side effects, were recorded. Patients rated their 
satisfaction with the control o f PONV using a 5-point scale, ranging from 1 (very satisfied) 
to 5 (very dissatisfied) just before discharge from the hospital and at 24 hours.
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Nausea was defined as a feeling o f the urge to vomit, as solicited by the investigators 
during assessments. Vomiting was defined as expulsion o f  stom ach contents through the 
mouth. Retching was defined as an attempt to vomit, not productive o f stomach contents. An 
emetic episode was defined as a single vomit or retch or any num ber o f  continuous vomits 
or retches. A com plete response was defined as no PONV and no need for rescue 
antiemetics. In the PACU, ondansetron 4 mg was used as the initial rescue medication for 
PONV. This was given if nausea was intractable and lasted for at least 15 minutes, if  three 
emetic episodes occurred within 15 minutes, or at any time at the patient's  request. 
Postoperative pain in the PACU was treated with fentanyl i.v. doses o f 25-50 meg.
Sample size calculation and statistics
Previous studies performed by our group dem onstrated an incidence o f  nausea and or 
vomiting o f 65% in this population under general anaesthesia w ithout a prophylactic 
antiemetic. A sample size o f 30 patients per group was determ ined to be adequate to 
demonstrate a 30% reduction in the incidence o f PONV (from 65% to 35%) with a= 0.05 
and (3= 0.8. Descriptive statistics was used to summarize the dem ographic characteristics of 
patients. Because subjects will be randomly assigned to treatment, no differences in these 
variables are expected across the treatment groups at baseline. F isher's exact test and chi- 
squared procedures for categorical data, and W ilcoxon rank sum test and the Kruskal-W allis 
test for continuous variables were performed for com parisons among the treatment groups.
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Three treatment group comparisons were performed: the multim odal group versus the 
com bination and the TIVA groups. P< 0.05 was accepted as statistically significant.
Results
Ninety patients were enrolled in the study. The three groups were similar with 
respect to age, weight, height, gender, ASA status, race, history o f  PONV or motion 
sickness, duration o f surgery, the am ount o f midazolam used pre-operatively, and the 
amount o f fentanyl used intraoperatively and in PACU (Table 21).
There was a significant difference between the groups in the com plete response rate 
at 2 hours and 24 hours postoperatively (p<0.05). Before discharge from the hospital, there 
was also a significant difference between the groups in the num ber o f patients who were 
very satisfied with PONV management. The complete response rate in the m ultim odal group 
(90 %) was significantly higher com pared to the com bination group (63 %) (p=0.03) but was 
not statistically different com pared to the TIVA group (66 %) (p=0.057). During the first 2-h 
postoperatively. the average nausea score and the need for rescue antiemetic use were 
significantly lower in the m ultim odal group compared with the com bination and the TIVA 
groups (p<0.05). There was no difference in sedation scores, incidence o f vomiting and the 
duration o f  PACU stay (Tables 21 and 22).
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Table 21. Patient demographics
M ultimodal Combination TIVA
Number, n 30 30 30
Age, yr 45 ± 12 42 ± 15 45 ± 15
Weight, kg 81 ± 19 88 ± 2 4 84 ± 13
Height, cm 168 ± 9 162 ± 21 164 ± 20
Sex (male/female), 
n
9/21 3/27 8/22
ASA status (I,II,III), 
n
7/22/1 5/22/3 7/21/2
Race (A/A A/C) 1/4/25 0/5/25 0/6/24
History o f PONV or 
motion sickness 
(yes/no), n
7/23 8/22 5/25
Duration o f surgery, 
min
83 ± 2 3 95 ± 21 94 ± 3 2
M idazolam dose, 
mg
1.87 ± 0 .3 3 1.85 ± 0 .6 7 1.78 ± 0 .0 8
Fentanyl dose, meg 200 ± 76 188 ± 55 187 ± 56
Duration o f PACU 
stay, min
171 ± 81 179 ± 98 181 ± 100
Values are mean ± SD or n.
TIVA= total intravenous anaesthesia. PONV= postoperative nausea and vomiting, PACU= 
post-anaesthesia care unit, A= Asian, AA= African American, C= Caucasian.
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Table 22. Incidence of complete response, nausea, vomiting, degree of nausea, sedation
scores, use of rescue antiemetics, and patients’ satisfaction with PONV management.
Multimodal Combination TIVA P value
Complete 
response (0-2 h)
27 (90) t 19(63) 2 0 (6 6 ) 0.03
Complete 
response (0-24 h)
24 (80) * 19(63) 13(43) 0.02
Average nausea 
score (0-2 h)
0(0-1)*  f 0(0-4) 0 (0 -1 .5 ) 0.057
Average sedation 
score (0-2 h)
4.5 (2.7-5) 4.2 ( 0 .7 - 5 ) 4.4 ( 3 .3 - 5 ) 0.1
Incidence o f 
nausea (0-2 h)
2 (7) * t 9(30) 10(33) 0.02
Incidence o f 
nausea (0-24 h)
6 (20)* 11 (37) 17(57) 0.02
Incidence o f 
emesis (0-2 h)
0 (0 ) 3 (10) 2 (7 ) 0.36
Incidence o f 
emesis (0-24 h)
1(3) 5(17) 6 (2 0 ) 0.13
Need for rescue 
antiemetic 
(0-2 h)
2 (7)* f 9 (30) 10(33) 0.02
Num ber o f very 
satisfied patients 
(2 h)
29 (97)* + 21(70) 21 (70) 0.03
Number o f very 
satisfied patients 
(24 h)
29 (97)* 25 (83) 22 (73) 0.14
Values are median (range), or numbers (%).
* p <0.05 com pared with the TIVA group, 
t  p <0.05 com pared with the com bination group.
At 24 h postoperatively, the number o f patients who experienced a complete 
response was significantly higher in the multimodal group (80 %) com pared with the TIVA 
group (43 %) (p=0.007), but was not different compared to the com bination group (63 %) 
(p=0.25).
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The num ber o f patients who were very satisfied with PONV management before 
discharge from the hospital was significantly higher in the m ultim odal group (97 %) 
compared to both the com bination and the TIVA groups (70 %) (p= 0 .01). At 24 h, the 
number o f patients who were very satisfied with PONV m anagem ent was significantly 
higher in the m ultim odal group (97 %) compared to the TIVA (73 %) (p=0.025) but not to 
the combination group (83 %) (Table 22).
Discussions
We have dem onstrated that a multimodal m anagem ent strategy for the prevention o f 
PONV incorporating TIVA with propofol and a com bination o f  two antiem etics was 
superior to the use o f similar com bination in the presence o f  inhalational anaesthetic or 
TIVA with propofol alone. In patients with high risk for developing PONV, routine 
prophylaxis has been shown to be efficacious in reducing the incidence.3x324 This approach 
has been found to be more cost-effective and associated with a higher degree o f patient 
satisfaction com pared w ith treatm ent o f established sym ptom s.32''' However, the optimal 
prophylactic antiemetic regim en has not yet been established. A com bination o f antiemetic 
agents acting at different receptor sites was found to be more efficacious com pared with
prophylaxis using a single agent.160 The use o f a multim odal approach was also found to
1 “>8have improved efficacy and has been advocated for patients at high risk for PONV. " This 
technique involves a com bination o f antiemetics, use o f less em etogenic anaesthesia 
techniques, adequate intravenous hydration, and effective pain control.326 We have adopted 
this technique in our multimodal group.
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A technique incorporating TIVA with propofol, a com bination o f antiemetics acting 
at different receptors, avoiding nitrous oxide and high-inspired oxygen concentrations was 
described in two previous studies. In the first, Scuderi et al com pared the multimodal 
approach to standard out-patient anaesthesia with or w ithout ondansetron 4 mg in females 
undergoing outpatient laparoscopy. The multimodal group received TIVA with propofol and 
remifentanil, triple antiem etic com bination with droperidol 0.625 mg, dexam ethasone 10 mg 
and ondansetron 1 mg, adequate hydration, no nitrous oxide, 80 % oxygen, and no 
neuromuscular blockade. The other two groups received sevoflurane, nitrous oxide, and 
muscle relaxation with reversal at the end o f the procedure. Patients in one group received 
antiemetic prophylaxis with ondansetron 4 mg while patients in the other group received 
placebo. The multimodal m anagem ent resulted in a com plete response rate o f  98 % in 
PACU, compared to 76 % in the ondansetron group and 59 % in the placebo group.167
In the second study in females undergoing gynaecological and breast surgery, 
Eberhart and colleagues also found that a multimodal approach consisting o f TIVA with 
propofol, no nitrous oxide, 80 % oxygen, dexamethasone 8 mg, haloperidol 10 mcg/kg, and 
tropisetron 2 mg, was associated with a 7 % incidence o f PONV over 24 hours, compared 
with 41 % in the control group (desflurane, nitrous oxide, no antiemetic prophylaxis).169
While these two studies demonstrated the excellent efficacy o f the multimodal 
approach for PONV management, the contribution o f TIVA and avoidance o f volatile agents 
and nitrous oxide to the success o f  the technique could not be evaluated because there was
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no TIVA only group. Furthermore, these studies compared the multimodal approach to an 
inhalational technique with or without antiemetic prophylaxis using a single agent.
Improved PONV prophylaxis using a combination o f different antiemetics compared to
1 9 8prophylaxis using a single agent has previously been shown.
In this study, we found that a multimodal approach consisting o f TIVA with propofol, 
a combination o f  ondansetron and droperidol, and avoiding nitrous oxide, was associated 
with a higher com plete response rate during the first two postoperative hours, compared 
with isoflurane/ nitrous oxide based anaesthetic with similar antiemetic combination. Patient 
satisfaction was also higher in the multimodal group. There was, however, no difference 
between the two groups in the duration o f PACU stay. At 24 hours, there was also no 
difference between these two groups in both the complete response rate and in patients' 
satisfaction. This finding confirm s that the antiemetic effect o f propofol is short lived, since 
the improved PONV prophylaxis in the multimodal group did not extend into the post­
discharge period. The lim itation o f  the antiemetic effect o f propofol to the early 
postoperative period has been shown in previous chapters124 and other study.163
When com pared to the TIVA group, patients in the multimodal group had a 
significantly lower incidence o f nausea, lower nausea scores, required fewer rescues and 
were more satisfied with PONV management during the first 2 hours postoperatively. This 
superiority o f the multimodal group also extended into the post-discharge period with a 
significantly higher com plete response rate and greater patient satisfaction at the 24 hours 
assessment.
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In a meta-analysis, Tram er reported that omitting nitrous oxide from general 
anaesthesia decreases postoperative vomiting significantly if  the baseline risk o f vomiting is 
high.131 In this study, however, there was no difference in the incidence o f  emesis between 
patients who received nitrous oxide (the combination group) and those who did not receive 
nitrous oxide (the multimodal and the TIVA groups). This might be due to the 
administration o f  a com bination o f two antiemetics to patients who are receiving nitrous 
oxide and suggests that omitting nitrous oxide might not confer any additional benefit in 
patients receiving prophylaxis with a combination o f antiemetic agents. However, such 
conclusion cannot be drawn from our study, since there was no control group receiving the 
inhalational technique w ithout nitrous oxide. Apfel and colleagues showed that the 
exclusion o f nitrous oxide only reduce the risk for developing PONV by 12% .130
This study has some limitations. Although it was powered to detect an overall 
difference between the groups in the incidence o f PONV, it was not adequately powered for 
intergroup comparisons. We therefore failed to achieve statistical significance for some o f 
the comparisons. We did not collect data about the smoking status o f the patients. N on­
smoking status is now considered a risk factor for PONV since it was included in A pfefs
1 OX -»simplified risk scoring system. Our study started before the publication ot this scoring 
system, and therefore we did not collect information about the smoking status o f the enrolled 
patients. Another criticism might be the absence o f a placebo group in our study. However, 
since laparoscopic cholecystectom y is associated with a high risk o f PONV in these 
ambulatory patients, we felt that it was ethically inappropriate to include a placebo group.
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Another concern might relate to the Food and Drug Administration “Black Box” warning 
regarding the use o f  droperidol for antiemetic prophylaxis. However, this warning has been 
challenged by many anaesthesiologists.37,40,41 Most experts in the field would agree that low 
dose droperidol has been proven to be a safe and cost-effective antiemetic for over 30
327years.
In summary, we found that, in patients undergoing laparoscopic cholecystectomy, a 
multimodal approach incorporating TIVA with propofol, a combination o f ondansetron and 
droperidol, and omitting nitrous oxide, was associated with a higher complete response rate 
and greater patient satisfaction in the PACU, compared to similar antiemetic prophylaxis 
with isoflurane/nitrous oxide based anaesthetic. The multimodal group also had a 
significantly lower incidence o f  PONV and greater patient satisfaction when compared to 
TIVA group at 24 hours postoperatively.
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C H A P T E R  9
A Randomized Comparison of Propofol and Isoflurane based Anaesthetics 
in Reducing Postoperative Nausea and Vomiting in Children and 
Adolescents
Abstract
Background
In children radiofrequency catheter ablation (RFCA) is typically performed under 
general anaesthesia. With the use o f  volatile agents in these patients postoperative nausea and 
vomiting (PONV) is com m on with an incidence o f emesis as high as 60%, and the 
prophylactic adm inistration o f  antiem etic drugs was reported to be ineffective. We have 
previously dem onstrated the antiem etic effects o f propfol when administered as the sole 
anaesthetic. In this study, we tested the hypothesis that a propofol based anaesthetic would 
have a lower incidence o f  PONV than an isoflurane based anaesthetic in children.
Methods
Children or adolescent were randomly assigned to receive either an isoflurane or 
propofol based anaesthetic. Prophylactic ondansetron was given to all patients and droperidol
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was used as a rescue antiemetic postoperatively while PONV was monitored in the 
postoperative period. Incidence o f  nausea, vomiting, use o f  rescue antiemetic, sedation scores 
were recorded. The costs for the anaesthetic were also calculated.
Results
Fifty-six subjects were included in this study. The cumulative incidence o f  PONV was 
significantly higher in isoflurane group (nausea 63% and emesis 55%) com pared with the 
propofol group (nausea 21%  and em esis 6%). Rescue with droperidol was more effective in 
the propofol group com pared with the isoflurane group. 70% o f patients in the isoflurane 
group developed further vom iting com pared with 0% after rescue with droperidol.
Conclusions
RFCA under isoflurane based anaesthetic was associated with a higher incidence of 
PONV compared with propofol based anaesthetic. Rescue antiemetic with droperidol was 
ineffective following isoflurane based anaesthetic. In contrast a propofol based anaesthesia is 
an effective strategy to prevent PONV in children undergoing RFCA.
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Introduction
In children radiofrequency catheter ablation (RFCA) is a highly effective treatment 
for supraventricular tachycardia (SVT).328 329 General anaesthesia is often required to ensure 
comfort during the prolonged procedure and to assure im mobility in order to facilitate 
accurate mapping and subsequent ablation o f the accessory pathway and/or arrhythmogenic 
focus. However, PONV is a com m on problem in children and adolescents undergoing 
RFCA under volatile anaesthetics; an incidence o f emesis as high as 60% has previously 
been reported.330 M oreover, the intraoperative administration o f prophylactic antiemetics 
(ondansetron, droperidol, and metoclopramide) was reported to be ineffective.330 We 
hypothesize that the adm inistration o f a propofol based anaesthetic could effectively reduce 
PONV in this population as has been previously shown in other adult groups at high risk for 
developing PO N V .124 Therefore, we performed a randomized trial to test the hypothesis that 
a propofol based anaesthetic would have a lower incidence o f  PONV than an isoflurane 
based anaesthetic.
Materials and Methods
After IRB approval and written informed consent from the parent and, when 
appropriate, the participant's assent was also obtained, children from 4 -18  yr admitted to 
undergo RFCA were enrolled in the study. Subjects with contraindications to the use o f 
either propofol or isoflurane were excluded. Patients were randomly allocated to receive
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propofol or isoflurane. Blocked randomization was generated using a computer random 
number. All patients included in the present study were part o f a study evaluating 
electrophysiologic effects o f propofol and isoflurane where sustained SVT was induced 
successful with the initially assigned drug.
Premedication consisted o f  midazolam given either orally (0.5 mg/kg up to a 
maximum o f 10 mg) or intravenously (2 mg) when intravenous access was established prior 
to induction o f anaesthesia. Routine monitoring included electrocardiography, noninvasive 
blood pressure m easurem ent and pulse oximetry. In all patients, anaesthesia was induced by 
inhaling sevoflurane via a face mask. Pancuronium (0.1 mg/kg) was used to facilitate 
endotracheal intubation and fentanyl (2-4 pg/kg) was administered prior to laryngoscopy. 
After tracheal intubation sevoflurane was discontinued. Thereafter, anaesthesia was 
maintained with the assigned study drug, propofol or isoflurane, in a 66% nitrous oxide and 
33% oxygen mixture. Real-tim e bispectral (BIS) data were obtained via 
electroencephalogram electrodes through a fronto-temporal montage (BIS™ sensor, Aspect 
Medical Systems, New ton, M A) and the EEG activity was recorded using an Aspect 1050, 
version 3.3 (Aspect M edical Systems, Newton, MA). Dosage o f the study drugs was 
adjusted to m aintain the BIS within a range o f 50-60. Pancuronium was used as the 
neuromuscular agent during the intraoperative period.
RFCA procedures
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Details o f the electrophysiologic (EP) procedure in these patients have been reported 
elsewhere.331 Briefly, a diagnostic EP study was performed to identify the tachycardia and to 
map the critical substrate. After conclusion o f the diagnostic study, ablation o f the 
pathological substrate(s) was perform ed using radiofrequency energy. Then a final 
diagnostic electrophysiologic study was performed. All patients received isoproterenol 
(0.03-0.07 pg/kg/m in) al least once during the procedure.
Approxim ately 30 min before the conclusion o f the procedure all patients received 
ondansetron (0.1 m g/kg up to 4 mg), ketorolac (0.5 mg/kg up to 30 mg), followed later by 
neostigmine (40 pg/kg) and glycopyrrolate (8 pg/kg) to antagonize neurom uscular blockade. 
Stomach contents were suctioned with an orogastric tube in all patients.
Patients were transferred to the recovery room following awakening from anaesthesia. 
The incidences o f postoperative nausea, and retching or vomiting were recorded by an 
independent observer unaw are o f  the patient’s treatment group at the following time intervals: 
(0 - 0.5, 2, and 18 h). Droperidol (20 pg/kg) was used as rescue anti-emetic in patients who 
vomited, rectched, or at patien t's  request. Elaemodynamic variables (arterial blood pressure,
99 9heart rate, respiratory rate) and observer assessment o f sedation scores (Table 15) were 
recorded at 0. 15, 30. 60, and 90 min after patient admission to the post anaesthesia care unit. 
Patients were ready for discharge from the post anaesthesia care unit when the following 
criteria were met: aerodynam ically stable: protective reflex present: patient fully conscious and 
able to protect own airway; pain adequately controlled; absence o f severe nausea or active
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vomiting; skin warm and dry. All patients were then admitted to the ward and discharged from 
the hospital the next day.
33")Cost were calculated as follows: isoflurane according to the formula by Dion " at a 
price o f $ 19.74 (£ 14) / 100 ml, propofol in 200 mg steps at a price o f $ 10.24 (£6) / 200 mg.
Statistical Analyses
A sample size o f  28 patients in each group would have adequate power o f 85% to 
detect a PONV-risk reduction o f  50% between the two treatments: this would be a reduction 
from 60% (expected in the isoflurane group330) to 30% (expected in the propofol group124). 
Continuous data were analyzed by Student’s /-test and categorical data were analyzed using 
Fisher's exact test. Repeated m easurem ents (haemodynamic parameters and sedation scores 
during the stay in the post anaesthesia unit) were analyzed using mixed models (SAS- 
System 6.12, SAS Institute, Cary, NC, USA). A probability value less than 0.05 was 
considered statistically significant.
Results
Fifty-six subjects were included in the study. Demographic data are shown in Table 
23. The patient characteristics were similar with a predominance o f males in both groups.
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Total anaesthesia time was not different between the two groups (317 ± 88 min. vs. 319 ± 97 
min in the isoflurane and propofol groups, respectively).
Table 23. Demographic data.
Isoflurane Propofol
Age (years) 13.1 (9.5 , 16.3) 12.9(8.1 , 16.3)
Gender (% female / % male) 48 / 52 * 31 / 69 *
Height (cm) 153 (137 . 170) 153 (128 , 176)
Weight (kg) 53(31 ,6 8 ) 56 (34 , 81)
Administered Drugs
Fentanyl (meg) 168 (1 0 0 ,2 5 0 ) 171 (125 ,250)
Pancuronium (mg) 8 .6 (6 ,  10) 10.3 (7 ,  14)
Propofol (mg) 1600 (1088 , 1820)
Isoflurane (MAC h) 3.8 (2 .8 , 4.9)
Values are mean and (25th,75th percentile) or * = %
The incidence o f  postoperative nausea at 0.5, 2, and 18 h and the incidence o f 
vomiting was statistically significantly lower in the propofol group compared with the 
isoflurane group (Tables 24 & 25). The isoflurane patients had an early onset o f PONV 
during the first 2 hours after term ination o f the anaesthesia and no patient suffered from a 
new onset o f PONV after 2 hours. In contrast the onset o f PONV in the propofol group was 
delayed. The use o f a rescue antiemetic drug was significantly greater in isoflurane group 
(Table 25). After the use o f the rescue antiemetic drug in the isoflurane group, 10 o f 14 
patients vs. 0 o f  5 patients in the propofol group had at least one further episode o f vomiting.
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The time until readiness for discharge from the PACU was not different between the groups 
(propofol 106 ± 44 min vs. isoflurane 114 ± 40 min). However, the cost for administered 
propofol ($87 ± 3 8 )  was significantly higher compared with isoflurane ($4 ± 1, p=0.001). 
There were no statistically significant differences among the groups in postoperative 
sedation score (Figure 16).
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Table 24. Incidence of postoperative nausea and vomiting at different time intervals
Interval 
Time (h) ISO
Nausea
PRO p  Value ISO
Vomiting
PRO p  Value
»/~>oio 41% 7% <0.005 26 % 0 % <0.005
n 41% 10% <0.02 41% 0 % <0.001
18 33% 10% <0.05 33 % 6 % <0.02
ISO = isoflurane, PRO = propofol, p value Fisher’s exact test.
Table 25. Cumulative incidence of postoperative nausea, vomiting and use of rescue
antiemetic
Time
(h) ISO
Nausea
PRO p  ISO 
Value
Vomiting
PRO p  Value
Rescue antiemetic 
ISO PRO p  Value
0.5 41% 7% <0.005 26% 0% <0.005 33% 0% <0.001
2 63% 10% <0.001 48% 0% <0.001 55% 14% <0.002
18 63% 21% <0.005 55% 6% <0.001 55% 17% <0.005
ISO = isoflurane, PRO = propofol, p value Fisher’s exact test.
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Figure 16. Sedation scores in post anaesthesia care unit
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Discussions
The results from this study confirm ed that children and adolescents undergoing 
RFCA under anaesthesia with isoflurane are at a high risk for developing PONV. The 
prophylactic use o f ondansetron and the antiemetic therapy with droperidol were not very 
effective in this population undergoing isoflurane based anaesthesia. However, propofol 
based anaesthesia was associated with a lower risk for developing PONV.
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In the present study, the incidence o f PONV in patients receiving isoflurane was 
63% despite prophylaxis with ondansetron 30 min before the end o f anaesthesia. In addition, 
after the use o f  droperidol, when adm inistered as a rescue antiemetic, recurrent vomiting 
was observed in 70% o f  patients receiving isoflurane based anaesthesia, suggesting that 
PONV prophylaxis with ondansetron and PONV treatment with droperidol might not be 
effective in this population. These observations were in line with results previously reported 
in patients undergoing RFCA under volatile anaesthetics; neither the prophylactic use o f 
ondansetron nor droperidol decreased the incidence o f emesis in a placebo controlled 
study.330
Propofol-based anaesthetics have been associated with a lower incidence of
] ^4 *>88 1 °4PONV. “ “ In a pharm acokinetic propofol simulation in the postoperative period ~ , we 
showed that in patients where propofol was used throughout the procedure (duration 2.4 ±
1.3 h), the calculated average concentration was in a range known to reduce PONV
-*) 7 1
effectively up to 6 h r  Thus, the postoperative antiemetic effect lasting up to 18 h in the 
propofol group in the present study might be attributed to the effect o f combination 
antiemetic with ondansetron and propofol enhancing the antiemetic effects.124 In a more 
recent study, Apfel et a l130 dem onstrated an additive effect o f propofol and ondansetron 
when adm inistered in com bination. W hen combining preventive ondansetron with propofol 
in children undergoing tonsillectom y, Barst and coworkers found a very low emesis 
incidence o f 7% in the 24-h period following surgery, which contrasted with an incidence of 
22% when propofol was given alone.333 Nevertheless, whether the similarly low' incidence
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o f PONV achieved in our study in the propofol group was the result o f the combination o f 
these two antiemetic drugs or related to the long lasting adm inistration o f propofol alone is 
less certain. However, there are numerous studies demonstrating increased efficacy for the 
prevention o f PONV when com bination antiemetics versus single agent were used.21
Patients undergoing RFCA under general anaesthesia represent a unique population 
in several perspectives. RFCA is not a painful procedure; in this study fentanyl was given in 
small doses predom inantly at induction o f anaesthesia and NSAIDS were given at the end of 
the procedure and in the postoperative period. Thus opioids did not play a significant role in 
provoking PONV in this setting. All patients included in this study were kept im mobile in 
bed after the procedure until the next morning, reducing the effects o f motion induced 
sickness . Hence, we speculate that the high incidence o f PONV in patients receiving 
isoflurane was primarily related to the long duration combined application o f the volatile 
anaesthetics and nitrous oxide, though the contribution o f nitrous oxide is likely to be 
sm aller.130
The lower incidence o f  PONV with propofol came with an additional costs. Given 
there are no clinically relevant differences regarding the electrophysiolgic properties 
between these drugs in patients undergoing RFCA331, the favourable outcome regarding 
PONV arguably might justify the use o f  propofol. However this cost must be put into 
perspective: first, costs associated with episodes o f emesis were not assessed in this study; 
and second, patients and parents' satisfaction with the perioperative course were not 
assessed. A recent study in adults demonstrated that patients are willing to pay an extra
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median amount o f  US$56-$100 out o f their own expense to avoid PONV.5’334 Another study 
evaluating parents’ w illingness to pay extra for reducing the incidence o f postoperative 
emesis in their children found the median amount to be £50 (US$75) [95% confidence 
interval: £20-80]. 33? At the time this study was conducted, propofol was still under patent.
In today 's generic cost o f propofol, there would be less difference between the propofol and 
isoflurane.
Several limitations must be noted. First, assessment o f nausea is difficult in children. 
Since only one subject was a preschool-aged child we consider the information gathered 
accurately reflect the presence or absence o f nausea. Second, no placebo control is available 
in this study. Therefore, the potential effect o f the prophylactic use o f ondansetron in this 
population remains unknown. Third, an inhalational induction with sevoflurane was used in 
all patients in this study. However, the short lasting use o f this agent at the beginning o f the 
procedure most likely did not confound the findings in our study.
In conclusion, children and adolescents undergoing RFCA under general anaesthesia 
with isoflurane were associated with a high incidence o f  PONV. The use o f propofol based 
anaesthetic reduced the incidence to very low levels, with some increase in costs.
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CHAPTER 10 
Conclusions
In these series o f  clinical investigations we have systematically determined the 
antiemetic effects o f propofol and recommend how propofol should be used in clinical 
practice to have this effect.
Our work has generated the following new scientific knowledge. First, we found a 
high percentage o f  US anaesthesiologists use propofol for its antiemetic effects. We also 
learned the various regim ens that propofol has been used to achieve this beneficial effect. 
Next, we defined the dose response o f propofol which are associated with an antiemetic 
effect. We then utilised this inform ation to provide the explanation for the antiemetic effects 
o f propofol when adm inistered in various regimens and helped determine the appropriate 
dose to be used for the treatm ent o f established PONV. The propofol was delivered using a 
patient-controlled delivery system, which has not been previously described. We found this 
delivery system safe and efficacious in the PACU environment. However, given the practice 
pattern may be different in different hospitals and different countries, caution should be 
exercised when using propofol outside the theatre environment. Continuous monitoring of 
patients should be adopted when propofol is used in this fashion.
We also explored the various regimens o f propofol for prophylactic prevention o f 
PONV and presented evidence why TIVA with propofol was more effective in preventing
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PONV than propofol administered either as an induction agent only or in a “sandwich” 
technique, a regim en com monly practised before these data were published. We 
demonstrated that multim odal management strategy incorporating propofol and other 
combination antiem etic was the most efficacious especially in patients at high risk for 
developing PONV. These findings are in keeping with other work published on the use o f 
combination antiemetic and multim odal approach for the management o f PONV. Indeed 
Apfel et al confirmed that propofol. along with other commonly used antiemetics such as 
ondansetron, droperidol and dexam ethasone has similar degree o f risk reduction and the 
combination o f these drugs appear to be additive in their efficacy. Lastly, we demonstrated 
that propofol anaesthetic is m ore effective in preventing PONV than inhalational anaesthetic 
in children.
The original hypothesis o f  this thesis was that propofol has antiemetic properties and 
this property is concentration dependant. The above studies were conducted between 1994 
and 2000. Since then, num erous studies comparing propofol and inhalational agent based 
anaesthetic have been published and have confirmed our findings, namely propofol based 
anaesthetic is associated with a lower incidence o f PONV compared with inhalational based 
anaesthetic and the use o f propofol as an induction agent only does not confer meaningful 
antiemetic effect. As propofol is no longer patented, the use o f propofol as a continuous 
infusion for m aintenance o f anaesthesia is widespread in the US and even more so in UK 
and Europe. The availability o f  target-controlled infusion (TCI) automated pump has largely 
facilitated its popularity in these countries.
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Retrospectively, some o f the experiments could have been improved with a more 
robust protocol and m ethodology. For example, a larger sample size and a greater variety o f 
background and location among the anaesthesiologists surveyed could have yielded a more 
representative results (Chapter 4); the inclusion o f a placebo group in determining the 
plasma propofol concentrations for its antiemetic effects (Chapter 5); the inclusion o f a 
standard antiemetic regim en group (e.g. ondansetron) would have enabled efficacy 
comparison between propofol and ondansetron for the treatment o f established PONV 
(Chapter 6).
Some exciting new knowledge has em erged since the conduct o f these studies. These new 
information advanced our know ledge on the mechanism o f propofol as an antiemetic. 
Appadu et al290 and Hvarfner et al291 have previously reported that propofol does not possess
294significant antidopaminergic properties. Cechetto et al , in an elegant rat model, 
demonstrated a lower level o f  serotonin and its metabolites, 5-hydroxy indole acetic acid 
(HIAA) in animals that received a propofol infusion compared to controls which received 
intralipid. They concluded that the reduced levels o f serotonin in the area postrema (AP) and 
the CSF could explain the antiem etic property o f propofol. In addition, propofol may also 
directly act on AP neurons via a G A BA a receptor to reduce their activity. More recently, 
Barann and colleagues336 exam ined the kinetics o f the action o f propofol and its lesser 
hydrophobic derivatives 2-isopropylphenol and phenol on human 5-HT3A receptors. They 
found that propofol, as well as its derivatives, appear to have an inhibitory effect on the 
serotonin receptors and the underlying mechanisms appear to involve the phenolic hydroxyl 
group, hydrophobic interactions and steric restrictions. This add further evidence that
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propofol exert its antiemetic properties, at least in part via the serotonergic pathway. 
However, PONV are multifactorial and other receptors, e.g. cholinergic, histaminergic and 
neurokininergic receptors, have been shown to be also important in the mechanism o f 
PONV. Furthermore sedatives such as m idazolam 79’166 and dexmedetomidine337,338 also 
appear to have some antiemetic effect. Hence, the potential o f propofol acting as a sedative 
and other receptor based m echanism s could not be excluded.
These future directions o f  research in this area should focus on other potential 
mechanisms o f propofol induced antiem esis effect and if  the concentrations o f propofol at 
the effect-site are related to the severity o f  nausea and vomiting. In addition, further research 
is needed to develop a practical and safe delivery system for administering propofol as well 
as a user-friendly patient-controlled delivery system.
I believe these series o f  clinical investigations presented in my MD thesis have 
helped us improve the understanding o f propofol for the management o f PONV and provide 
a useful background knowledge for further development o f propofol as an antiemetic.
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Appendix 1
1. Do you use Propofol in an effort to reduce post-operative nausea and vomiting 
(PONV) following general anaesthesia?
O  Yes (Go to # 2 )0  No (Thank you for your time!)
2. How do you use Propofol as described in #1 ? (Please answer all that apply)
Percent o f Use
__________ %At Induction only
__________ %At Induction and Em ergence only (sandwich technique)
__________ % as primarily Propofol based anaesthetic (Induction, Maintenance, and
Emergence)
3. If you use Propofol only at induction, do you: (Check all that apply)
O  Use for cases less than 60 minutes?
O  Use for cases longer than 60 minutes? (Please go to #4 or #7, as applicable)
4. If you use Propofol only at induction and emergence, do you: (Check all that apply)
O  Use for cases less than 60 minutes?
O Use for cases longer than 60 minutes? (Please go to #5 or #7, as applicable)
5.If you use a Propofol based anaesthetic, do you:(Check all that apply)
O  Use for cases less than 60 minutes?
O Use for cases longer than 60 m inutes?
6 . Please explain your dosing technique for a TY PIC A L  patient: (Check all that apply)
A. Maintenance (during a Propofol based anaesthetic):
Boluses ( i f  used): O  10 m gO  20 m gO  30 m gO  40 mgO >40m g
Doses given every: O  O nceO  1-4 M inO  5-10 M inO 11-15 M inO >15M in
Infusion:0  10-40 m cg/kg/m inO  50-90 m cg/kg/m inO 100-150 mcg/kg/min 
O  160-200+mcg/kg/m in
227
B. Emergence:
Boluses {if used): O  10 m gO  20 m gO  30 m gO  40 m gO >40m g 
Doses given every: O  O nceO  1-4 M inO  5-10 M inO  11-15 M inO >15M in
Time before end o f case that you begin Propofol dosing:
O  1-5 M inO 6-10 M inO  11-15 M inO  16-30 M inO  31-45 M inO >45M in
7.Do you usually combine Propofol with:
O  DroperidolO OndansetronO ProchlorperazineO  Promethazine 
O  M etoclopramideO Other_____________ ______________
W hen do you give the above?: O  Near beginning o f caseO  End o f case/ PACU 
O  Other_________________________________________________________________
8.Do you think Propofol has acceptable efficacy in the treatment o f  PONV?
O Y es:0  As the sole anti-emetic agent 
O Only in com bination with drugs in #7 
O Only when used as primarily Propofol based anaesthetic 
O N o
Thank you.
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Appendix 2. Pharmacokinetic variables o f propofol administered as constant rate
176intravenous infusions in humans.
T ab le  2 . P ro p o fo l P h a rm a c o k in e t ic  P a r a m e te r s  D e r iv e d  fro m  C o m p a r tm e n ta l  (c) a n d  fro m  N o n c o m p a r tm e n ta l  (nc) 
D a ta  A n a ly s is
Parameters
Propofol rate (mg-kg '-hr ')
3 (n = 6) 6 (u ■ 6) 9 (n 6) Mean (u - 18)
t, 2w lc) (mm) 3.1 - l . l - 3.2 r 1.1 2.3 £ 1.3 2.8 r 1.2*
t , ( c )  (min) 32.1 £ 15.2 37.5 £ 14.3 24.6 A 14.2 31.4 ♦> 14 7
ti w (c) (min) 402.7 - 254 4 385.5 z 282.2 277.0 Z 138.5 355.0 t 226.6
MKT (nc) (min) 203.6 - 155.4 208.5 ± 199.2 117 2 z 43 4 176.4 - 145.6
C„ (c) (Mg-ml ') 2.060 z 0.432'' 3.573 .* 0.748" 5.885 * 0 762"
(nc) (Mg*ml ') 2.032 £ 0.450*' 3.544 £ 0.756" 6.000 i 0.799*'
V. (c) (L) 21.350 z 9 502 16.408 - 4.350 13.013 a 3.63.3 16.924 £ 6.957
V,. (c) (L) 348.333 1 249.794 .331.500 Z 256.932 181 667 z 73.677 287 167 £ 212.855
(nc) (L) 349.167 z 203.673 348.333 ± 257.970 175.500 z 51.177-
Vd„ (c) (1.) 1007 667 z 451 195 973 333 z 498.481 598 333 * 244 213 859.778 £ 432 314
Clb (c) (L-min ') 1.883 z 0.414 1.864 ± 0.269 1.563 z 0.181 1.770 £ 0.322
(nc) (L-min *') 1.927 - 0.512 1.892 - 0.298 1.532 0.134 1.781 t 0.374
Table 3 . P ro p o fo l T ra n s fe r  R ate  C o n s ta n ts  b e tw e e n  C o m p a r tm e n t s  A s s u m in g  a T h r e e - C o m p a r tm e n t  O p e n  M o d e l w ith  
C e n tr a l  E l im in a tio n
Rate constants
Propofol rate (mg-kg '•hr ')
3 (n = 5) 6 (n 6) II
!
Mean (m = 17)
K„, (min" ’) 0.0966 £ 0.0292“ 0.1212 ± 0.0359 0.1288 £  0.0431 0.1190 £  0.0351
K,= (min •) 0.0961 £  0.0909 0.0696 ±  0.0465 0.1733 £  0.1404 0.1140 ±  0.1051
Ki.i (min ') 0.0380 ± 0.0075 0.0455 £  0.0196 0.0415 £ 0.0177 0.0419 £  0.0155
K:i (min ~ l) 0.0375 ± 0.0257 0.0330 £  0.0216 0 0915 £  0.0806 0.0550 £  0.0558
K,, (min ') 0.0027 ± 0.0012 0.0032 £  0.0012 0.0039 £  0.0014 0.0033 ± 0.0013
Fraction of drug in the central compartment during terminal phase
Fc 0.0189 £  0.0088 0.0190 *. 0.0070 0.0232 £  0.0082 0.0204 r  0.0077
Fraction of drug eliminated during the terminal phase
(n =  6) (n =  6)
F„ 0.297 ‘ 0.069 0 298 t  0 087
(h =  6 )
0.265 - 0 070
(ii  -  1 8 )
0.286 -  0.073
Appendix 3.
Equipment.
Plasma propofol was measured by high-perform ance liquid chromatography with 
fluorescence detection. The separation and quantification procedures were conducted with a 
C-18, 15-cm x 4.6-mm column (Supelcosil LC-18; Supelco, Bellefonte, PA). The excitation 
and em ission wavelengths were 275 and 310 nm, respectively, and both monochromator slit 
widths were 10 nm.
Procedure
Plasma was prepared for chromatography by precipitation o f plasma proteins with 
acetonitrile. Propofol was detected by a fluorescent detector at an excitation wavelength of 
275 nm and an emission wavelength o f 310 nm. The minimum detectable concentration of 
plasm a propofol was estimated as 0.1 pg/mL. The intraassay coefficients o f variation 
determined by replicate analysis o f quality control specimens at three different 
concentrations (0.63, 2.5 and 10 pg/mL) were 2.5%, 2.0%, and 2.0%, respectively. The 
interassay coefficients o f variation for propofol were 3.6% at 0.63 Fg/mL, 3.1% at 2.5 
Fg/mL, and 2.2% at 10 pg/mL.
